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Abstract 
Alcohol is frequently co-administered with other psychotropic 
substances, yet little is known about patterns of alcohol use in a simultaneous 
polysubstance context. In the present dissertation concomitant alcohol-drug 
administration is examined with an emphasis on delineating patterns of alcohol 
use when it is co-administered with psychostimulant drugs known to interact 
with neural mechanisms believed to be involved in mediating alcohol' s 
ascending limb reinforcing effects: midbrain dopamine transmission. 
In two retrospective self-report studies polysubstance users reported on 
their simultaneous use of drugs and a1cohol. Results revealed that alcohol was 
commonly co-administered with various abused substances, particularly with 
psycho stimulant drugs that are known to increase dopamine neurotransmission, 
and there was an identifiable pattern of administration that was characterized 
by initial alcohol consumption preceding repeated intermingled alcohol·· 
psychostimulant administrations which resulted in alcohol dose escalation. 
In a third study, the effects of administering the psycho stimulant drug 
nicotine on a1cohol intake was directly examined using a double-blind placebo 
controlled self-administration procedure. Nicotine was found to significantly 
increase alcohol ingestion. 
In a final study we examined the effect of decreasing dopamine 
neurotransmission on alcohol self-administration by using a dietary 
manipulation that depletes the nutritional precursors to dopamine. This 
procedure was found to decrease alcohol consumption, an effect that was 
l 
especially evident in a subset of drinkers thought to be hypersensitive alcohol's 
ascending limb dopamine effects. Overall findings suggest that alcohol co-
administration with psycho stimulant drugs affects patterns of alcohol intake 
and that this may be the result of an interaction involving dopamine 
neurotransmission. 
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Résumé 
Il est fréquent que l'alcool soit consommé en même temps que d'autres 
substances psychotropes mais on connaît peu de choses sur ces pratiques de 
consommation simultanée d'alcool et de substances multiples. Cet exposé 
s'intéresse à l'administration simultanée d'alcool et d'autres drogues en 
s'appliquant particulièrement à décrire les pratiques de co-consommation 
d'alcool et de psycho stimulants agissant sur les mécanismes neurologiques par 
l'entremise desquels on croit qu'interviennent les effets renforçateurs de la 
phase d'augmentation de la quantité d'alcool dans le sang: il s'agit de la 
transmission de dopamine dans le mésencéphale. 
Dans deux enquêtes réalisées a posteriori, des consommateurs de 
drogues multiples décrivent leurs habitudes de consommation simultanée de 
drogues et d'alcool. Les résultats confirment que l'alcool est couramment 
consommé en même temps que des drogues diverses connues pour augmenter 
la neurotransmission de dopamine. D'autre part, on identifie une pratique de 
consommation consistant en une prise initiale d'alcool suivie de 
consommations alternées et répétées d'alcool et de psycho stimulants dont le 
résultat est une consommation accrue d'alcool. 
Dans une troisième étude, les effets de l'administration d'un 
psychostimulant, la nicotine, sont examinés au moyen d'un protocole d'auto-
administration en double aveugle avec placebo. Il apparaît que la nicotine a 
pour effet d'augmenter la consommation d'alcool. 
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Une dernière étude examine l'effet de la réduction de la 
neurotransmission de dopamine en utilisant un artifice alimentaire qui permet 
de réduire les précurseurs nutritionnels de la dopamine. On observe que cette 
procédure réduit la consommation d'alcool, cet effet étant particulièrement 
manifeste pour un sous-groupe de consommateurs qu'on estime très sensibles à 
la dopamine en phase ascendante de la quantité d'alcool dans le sang. 
Les résultats de manière générale suggèrent que l'administration d'alcool avec 
des psycho stimulants affecte les pratiques de consommation d'alcool et que 
ceci pourrait être le résultat d'une interaction impliquant la neurotransmission 
de dopamine. 
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1. Introduction 
Substance use disorders represent the most prevalent form of adult 
psychopathology (e.g. Somers et al., 2004) and are associated with a variety 
adverse health, economic and social outcomes (e.g. Andin-Sobocki, 2004) . 
Conservative estimates place the annual societal costs associated with alcohol 
and drug use in the hundreds of billions of dollars (e.g. Rice, 1999), yet 
substance use disorders remain relatively poorly understood as weIl as 
notoriously difficult to treat (e.g. McLallan & Meyers, 2004). One issue that 
may confound our understanding of addictive processes is the tendency for 
drug users to administer multiple substances concomitantly, a phenomenon 
known as simultaneous polysubstance use. 
Although evidence suggests that substance users frequently co-
administer multiple substances, most drug-related research tends to focus on 
examining single substances under highly controlled conditions rather than 
delineating the specific ways that drug users typically use their substances. A 
growing body of literature has documented high rates of simultaneous 
polysubstance use across several different drug using populations including 
alcoholics (Staines et al., 2001; Martin et al., 1996a), college students (e.g. 
Webb et al., 1995), rave attendees (e.g. Win stock et al., 2001; Tossmann et al., 
2001) and adolescents (e.g. Martin et al., 1993a; 1996b; Collins et al., 1998), 
as weIl as across users of various substances including alcohol (e.g. Martin et 
al., 1996a; Staines et al., 2001), cannabis (e.g. Earleywine & Newcomb, 1997), 
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cocaine (Leri et al., 2004), heroin (Darke & Ross, 1997), hallucinogens 
(Barrett et al 2000 see Appendix 1), benzodiazepines (Ross & Darke, 2000) 
and 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) (e.g. Tossmann 
et al., 2001). However, to date most studies that have described trends in 
simultaneous polysubstance use have primarily focused on whether or not two 
or more target substances have been used together (e.g. Leri et al., 2004; 
Martin et al., 1996a) and little is known about the order and patterns of 
administration of substances when they are used together or their relative 
doses. Given that many abused substances appear to be routinely co-
administered, delineating the patterns and consequences of concurrent multiple 
substance use may have important implications for understanding addictive 
processes. 
Substances that are frequently co-administered with each other may not 
be haphazardly combined but may rather be co-administered because their 
combination enhances certain desirable effects, diminishes certain undesirable 
effects and/or because they interact with central mechanisms that regulate the 
use of one another (e.g. Leri et al., 2003). If this is the case, then the 
administration pattern of a particular substance might largely depend on what 
other substances are used and a drug's abuse liability may change depending 
on the other substance( s) being administered. Moreover because experimental 
evidence suggests that the way that certain commonly co-administered drugs 
interact may depend on factors such as their relative order (s) of administration 
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(e.g. Perez-Reyes, 1994; Clemens et al., 2005) and doses (e.g. Perez-Reyes et 
al., 1992), it is also possible that polydrug users preferentially co-administer 
sorne substances in a particular order and particular quantities so that they can 
achieve desirable resuIts. 
Most laboratory studies that examine the concurrent use of multiple 
substances tend to compare the effects associated with the solitary 
administration of each of the substances with those of two or more substances 
combined (Earleywine & Newcomb, 1997). In such paradigms many drug-
related factors are usually meticulously controlled for including the timing, 
order and amount of each dose to be administered, and additional assurances 
are made that participants have remained abstinent from aU substances that are 
not under direct investigation (e.g. Hernandez-Lopez et al., 2002; Kouri et al., 
2004). While such efforts to achieve experimental control are laudable, this 
approach may fail to yield ecologically valid results if the administration 
parameters and substances chosen by the experimenter markedly differ from 
those typically used in a more 'natural' setting. 
In the present dissertation patterns of simultaneous polysubstance use 
are examined using a variety of methods with an emphasis on how alcohol is 
used with various commonly abused psychstimulant substances. Alcohol has 
been identified as one of the most frequently co-administered substances with 
various stimulant drugs including tobacco (e.g. Batel et al., 1995), 
amphetamine (e.g. Molina & Jejurika, 1999), co caine (e.g. Pennings et al., 
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2002), and methylphenidate (e.g. Barrett et al., 2005, see Appendix 2) and 
previous research suggests that alcohol co-administration with each of these 
drugs may result in desirable subjective changes (e.g. Perez-Reyes & Jeffcoat, 
1992; Mendleson et al., 1995; Perkins et al., 1995; Barrett & Pihl, 2002, see 
Appendix 3). However little is currently known about the temporal sequence of 
alcohol-stimulant administration, the degree to which concurrent stimulant use 
changes alcohol administration patterns or the degree to which other 
substances are concomitantly used with alcohol-stimulant combinations. 
Because various psycho stimulant substances are known to interact 
with central dopamine (DA) systems (e.g. Wise, 1996) that have been 
implicated in mediating alcohol self-administration (e.g. Leyton et al., 2000a; 
Enggasser & de Wit, 2001; Modell et al., 1993), an evaluation ofhow these 
substances affect alcohol intake may provide additional insight into alcohol's 
reinforcement mechanisms. Moreover because alcohol's neurochemical (e.g. 
Ollat et al. 1988) and subjective (e.g. Martin et al. 1993b) effects are known to 
be biphasic, an examination of the timing of stimulant co-administration may 
provide information about the nature of the interaction and motives of 
simultaneous use. Finally if psychostimulant co-administration does result in 
systematic changes in alcohol intake patterns and these are related to a 
particular neurochemical effeet, then one would expeet manipulations that 
produce opposite neurochemical actions to have opposite effects on alcohol 
ingestion. 
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2. Literature Review 
The focus of this literature review will be research that has examined 
the intake patterns, effects and/or mechanisms associated with the concomitant 
administration of alcohol and various psychostimulant drugs. Because the 
primary goal ofthis dissertation is to better understand how and why humans 
use drugs and alcohol in the ways that they do and each of the studies included 
in this dissertation used human participants, whenever possible an emphasis 
will be placed on reviewing the relevant findings from human studies. 
However, animal studies are also cited in sorne instances especially when the 
findings are seminal to our understanding of a given phenomenon. This is 
particularly true in sections that review the neurochemical effects of the 
substances (Sections 2.33-2.35) and when animal studies are cited this will be 
clearly indicated in the text. 
For the purposes ofthis dissertation the term 'psychostimulant' will be 
used to describe aIl substances whose primary psychoactive effects are to 
stimulate psychological and sensory-motor functioning and that meet the 
Diagnostic and Statistical Manual of Mental Disorders, IVth edition (DSM-
IV), classification criteria for being a drug of abuse and/or dependence. This 
definition includes substances such as tobacco (nicotine), cocaine, 
amphetamine and methylphenidate and the reinforcing properties of each of 
these substances is believed to mediated by a common central DAergic action 
(please see section 2.33 below). Other substances with stimulant properties 
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such as caffeine, that do not meet the DSM IV's classification criteria as a 
substance of abuse or dependence are not included in this operational 
definition and findings from animal studies suggest that such substances are 
often devoid of significant DAergic effects (Cauli & Morelli, 2005). 
2.1 Prevalence & Patterns of Alcohol-Psychostimulant Co-administration 
A growing body of evidence suggests that alcohol is commonly co-
administered with a variety of psycho stimulant drugs and that in sorne cases 
the tendency to co-administer these substances may be especially prominent 
among individuals dependent on one (or more) of the substances (e.g. Dawson 
et al., 2000; Pennings et al., 2002). Previous research detailing the patterns and 
prevalence of alcohol co-administration with specifie psycho stimulant 
substances is outlined below. 
2.11 Alcohol and Tobacco 
Perhaps the most commonly co-administered substance with alcohol is 
tobacco (e.g. Batel et al., 1995; Dierker et al., 2005). The prevalence of 
tobacco smoking among alcoholics is thought to be as high as 90% compared 
to a general population rate of less than 30% (e.g., Sobell et al., 1990; 
\ 
Romberger & Grant, 2004) and it is estimated that smokers are 50% more 
likely to drink regularly than non-smokers (Kozlowski & Ferrence, 1990). In 
addition the strength of the alcohol-tobacco relationship appears to be 
proportional to the extent of use ofeither substance (e.g. Dierker et al., 2005; 
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Bien & Burge, 1990) with binge drinkers being more likely to smoke than non-
binge drinkers (Tucker et al., 2002), heavy smokers reporting greater alcohol 
consumption than occasional smokers (Resnicow et al., 1999) and alcoholics 
smokers using more cigarettes per day than non-alcoholic smokers (Dawson, 
2000). Moreover while smokers appear to be more likely to drink and drinkers 
more likely to smoke evidence suggests that the two behaviours often co-occur 
during the same session. For example, both college students (Dierker et al., 
2005) and adolescents (Duhig et al., 2005) are more likely to drink on days that 
they smoke and to smoke on days that they drink and across tobacco using 
populations, smoking frequently occurs during the course of a drinking session 
(e.g. McKee et al., 2004; Batel et al., 1995). There is also evidence that alcohol 
consumption acutely increases cigarette smoking (e.g. Griffiths et al., 1976; 
Mello et al., 1980; Keenan et al., 1990) although Httle is known about the 
degree to which acute tobacco smoking increases alcohol consumption. 
2.12 Aicohoi and Cocaïne 
Alcohol has also been identified as being one of the most commonly 
co-administered substances with cocaine. In a population-wide study it was 
estimated that approximately 80% of the 5 million Americans who had used 
cocaine over the preceding month had simultaneously administered alcohol 
(Grant & Hartford, 1990). It is also estimated that up to 90% of cocaine 
abusers have simultaneously used alcohol with co caine (e.g. Wiseman & 
Mcmillan, 1996) and there appears to be a high rate of co-occurrence of 
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alcohol and cocaine-related disorders. Cocaine has been identified as the most 
commonly co-administered illicit substance with alcohol among treatment 
seeking alcoholics (Martin et al., 1996a; Staines et al., 2001) and an analysis of 
consecutive admissions of cocaine dependent individuals revealed that 61 % 
were also alcohol dependent (Heil et al., 2001). In addition, a study of 
alcoholics seeking treatment 40% reported cocaine use during the preceding 
year (Walsh et al., 1991) suggesting a rate of cocaine use among alcoholics 
that is seven to eight times greater than that se en in the general population 
(Pennings et al., 2002). Moreover evidence also suggests a poorer prognosis 
for treatment in cocaine addicts who co-administer alcohol (McKay et al., 
1999) as well as in alcoholics who co-administer cocaine (Carroll et al., 1998), 
with the use of one substance being associated to relapse in the use of the 
other. Although evidence suggests that cocaine and alcohol are frequently co-
administered and that this may be related to dependence on one or both of the 
substances, currently very little is known about how the two drugs are used 
together during the same session, or the degree to which the use of one of these 
drugs influences the administration of the other. It has been suggested that 
cocaine users may frequently administer alcohol at or near the end of a cocaine 
administration session in an effort to 'come down' from the effects of cocaine 
(Maguara & Rosenblum, 2000). Conversely alcohol consumption has been 
demonstrated to increase the reinforcing value of cocaine in non-dependent 
participants offered a post-alcohol choice between co caine and a monetary 
reward (Higgins et al., 1996), suggesting that alcohol use might increase the 
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probability of cocaine use. FinaIly, although evidence also suggests that other 
psychoactive substances might often be simultaneously co-administered with 
cocaine and a1cohol (Martin et al., 1996a) the degree to which these affect 
patterns of cocaine-a1cohol use remains unknown. 
2.13 Alcohol and Other Psychostimulants 
While the lion's share of the research that has examined alcohol co-
administration with stimulant drugs has focused on tobacco and cocaine, 
alcohol also appears to be among the most frequently co-administered 
substances with various other stimulants as weIl. For example there is growing 
evidence that alcohol is also commonly simultaneously used with the 
prescription psychostimulant medication methylphenidate. In a study of the 
drug taking patterns of intravenous methylphenidate abusers 41 % reported that 
they concomitantly co-administered alcohol (Parran & Jasinki, 1991) and we 
recently found that 71 % of recreational methylphenidate users reported 
lifetime simultaneous alcohol use while 34% reported co-administering alcohol 
during their most recent methylphenidate use (Barrett et al., 2005, see 
Appendix 2). Moreover a report of emergency department statistics further 
attests to the high prevalence of alcohol-methylphenidate co-administration 
with 553 alcohol-methylphenidate related emergency episodes reported in 
1997 and 422 being reported in 1999 (DAWN 1997; 1999 as cited in Patrick et 
al., 2005). FinaIly, while l am unaware of any studies that have directly 
assessed the prevalence or patterns of simultaneous a1cohol-amphetamine co-
13 
administration, alcohol has been identified as the drug most frequently 
associated with complications arising from methamphetamine use (e.g. 
Mendelson et al., 1995; Yamamura et al., 1991) and concomitant alcohol use 
has been implicated in approximately 30% of methamphetamine related deaths 
(Molina & Jejurika, 1999). 
Although alcohol appears to be commonly co-administered with a 
variety of abused stimulant drugs and at least in sorne cases alcohol-stimulant 
co-administration appears to be associated with higher levels of dependence 
(e.g. Dawson et al., 2000; McKay et al., 1999), little is known about how 
alcohol and stimulants are used together or the degree to which concomitant 
administration affects patterns ofuse. Nevertheless, a growing body of 
evidence suggest that psychostimulant-alcohol co-administration may result in 
an alteration in subjective effects, a factor that could contribute to their 
propensity to be simultaneously used (e.g. Cami et al., 1998; Perkins et al., 
1995; Barrett & Pih12002, see Appendix 3). The section below reviews the 
literature on the phenomenological effects associated with alcohol-
psychostimulant co-administration. 
2.2 Phenomenology of Alcohol-Psychostimulant Co-administration 
Despite the high prevalence of alcohol-tobacco co-administration little 
is known about the subjective effects associated with it. In a single placebo 
controlled study alcohol was reported to increase the level of 'satisfaction' 
associated with consumption of nicotine containing cigarettes (Rose et al., 
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2002), however the effects of other subjective parameters are not reported. 
Similarly in a retrospective study it was reported that smokers recalled 
experiencing increased 'pleasure' from smoking when tobacco was used with 
alcohol (McKee et al., 2004). Other investigations that have examined the 
combined effects of alcohol with nicotine, the alkaloid associated with 
tobacco's stimulant and reinforcing properties (e.g. Domino, 1998) suggest 
that co-administered nicotine alters certain subjective effects of alcohol. For 
example intranasal nicotine administration has been shown to increase alcohol-
related stimulation when blood alcohollevels are rising and decrease alcohol-
related sedation when blood alcohollevels are falling (Perkins et al., 1995) 
while transdermal nicotine administration has been shown to increase alcohol-
related euphoria (Kouri et al., 2004). 
Interestingly investigations that have examined the subjective responses 
to the combined effects of alcohol with cocaine (e.g. Mannelli et al., 1993, 
Cami et al., 1998) or with amphetamine (Mendel son et al., 1995) under 
controlled conditions have identified similar alterations to subjective effects as 
those observed with alcohol and nicotine. The combination of alcohol and 
cocaine has been reported to significantly increase euphoric and stimulant-like 
effects such as 'high' (e.g. Perez-Reyes & Jeffcoat, 1992) and 'euphoria' (e.g. 
Farre et al., 1993) relative to either substance alone as well as to decrease 
alcohol-related sedation and/or sense of drunkenness (e.g. Pennings et al., 
2002) relative to alcohol alone. Similarly the subjective effects of 
methamphetamine-alcohol combinations were characterized by an increase in 
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stimulant-like effects as well as a diminished sense of alcohol-related 
intoxication (Mendelson et al., 1995). Moreover although the subjective 
responses associated with methylphenidate-alcohol co-administration have not 
been examined under controlled conditions, in retrospective reports the 
combined effects have been described as producing a desirable effect 
characterised by increased euphoria and energy and/or a diminished sense of 
drunkenness (Barrett & Pihl, 2002, see Appendix 3). While these findings 
should be interpreted with caution due to the lack of control of or information 
about participants' use of other substances, similarities between these self-
reports and objectively measured subjective effects associated with alcohol co-
administration with other stimulant drugs are nonetheless striking. 
The evidence described above suggests that when alcohol is co-
administered with various psychostimulant drugs it tends to result in a similar 
phenomenological effect that is characterized by heightened euphoria and/or 
stimulation as well as a decreased sense of sedation and drunkenness, raising 
the possibility that a common pharmacological action may underlie these 
effects. Possible mechanisms involved in alcohol-psychostimulant interactions 
are described below. 
2.3 Alcohol-Psychostimulant Interactions 
Although a number of factors might contribute to the propensity to 
simultaneously use alcohol with different psycho stimulant substances, such as 
various personality variables (e.g. Brunelle et al., 2004, see Appendix 4), the 
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relative availability of the substances and/or the presence or absence of 
substance using peers (e.g. Sloboda, 2002), it is highly probable that the 
behavioural and/or subjective effects associated with the co-administration of 
these drugs are paramount to their simultaneous use (e.g. Leri et al., 2004; ) 
and that such effects are the result of specific pharmacological interactions. 
Pharmacological interactions can be either pharmacokinetic or 
pharmacodynamie in nature. Pharmacokinetic interactions are those in which 
the presence of one substance affects the absorption, distribution, metabolism 
or excretion of another substance resulting in a relative change in the 
concentration of the substance in the blood at a given time point (e.g. 
Weatherman & Crabb, 1999) and in the case of alcohol-psychoactive drug 
interactions this generally results in a change in the availability of the 
substance to exert its effects in brain. In contrast pharmacodynamie 
interactions refer to changes in the way that substances affect different systems 
in the body that are independent of changes in the substances' relative 
concentrations and in the case of alcohol and other psychoactive substances 
many of these interactions commonly occur in the brain and involve additive, 
antagonist or synergistic effects at specifie neurotransmitter sites hypothesized 
to be involved in the production of the substances' subjective or reinforcing 
effects (e.g. Weaterman & Crabb, 1999). 
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2.31 Pharmacokinetics 
The presence (or absence) of a pharmacokinetic interaction is usually 
directly assessed in the laboratory by measuring quantities of the substance in 
the plasma, following the administration of fixed doses of each of the drugs 
combined with each other as weU as with a placebo (e.g. Mendelson et al., 
1995). In many cases, the nature of a particular pharmacokinetic interaction 
willlargely depend on factors such as the relative quantities of each the 
substances, their routes and orders of administration and the degree to which 
other substances are also present (e.g. Perez-Reyes 1994; Perez-Reyes et al., 
1992). However, because most studies that have examined possible 
pharmacokinetic interactions involving alcohol with other substances have 
done so using a very limited range of conditions and prec1inical data on the 
ways that alcohol and other drugs are co-administered is currently lacking, 
very little is known about how pharmacokinetic factors may contribute to the 
simultaneous use of alcohol with other substances. Nevertheless there is 
currently evidence to suggest that alcohol co-administration with sorne, though 
not necessarily aU psychostimulant drugs results in significant pharmacokinetic 
interactions, at least under certain conditions. 
Several studies have examined possible pharmacokinetic interactions 
between cocaine and alcohol (e.g. Pennings et al., 2002; Cami et al., 1998). 
When co caine is administered either at the sarne time as or following alcohol, 
plasma cocaine levels have been demonstrated to increase by up to 30%, while 
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blood alcohollevels appear to remain relatively unaffected (Farre et al., 1993; 
Farre et al. 1997; Perez-Reyes & Jeffcoat, 1992; Cami et al., 1998.). 
Interestingly however, when cocaine is administered prior to alcohol there is 
no evidence of alterations to either plasma cocaine or alcoholleve1s (Perez-
Reyes 1994). While these discrepant effects have been hypothesized to be 
related to competitive inhibition of a hepatic esterase involved in cocaine 
metabolism when alcohol is administered prior to or concurrently with cocaine 
(Pennings et al., 2002) they also highlight the importance of documenting the 
ways in which the substances are co-administered by drug users themselves. 
For example findings of altered cocaine pharmacokinetics when it is 
administered following alcohol may be of limited clinical relevance if drug 
users routinely only administer alcohol after using cocaine. In addition to 
(sometimes) increasing plasma cocaine levels, alcohol-cocaine co-
administration has also been demonstrated to result in the production of a 
novel psychoactive metabolite cocaethylene. Cocaethylene has been 
demonstrated to pro duce similar behavioural and subjective effects to cocaine 
in humans (e.g. Cami et al., 1998) and appears to be produced irrespective of 
the order of cocaine and alcohol administration (Perez-Reyes, 1994). 
Although only a fraction (15-17%) of cocaine is believed to be converted to 
cocaethylene (Harris et al., 2003) and its plasma concentrations tend to be 
relatively low relative to cocaine (e.g. Cami et al., 1998), cocaethylene has a 
slower rate of clearance from the brain (e.g. Pennings et al., 2002) and it is 
possible that this metabolite contributes to the subjective, behavioural or 
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physiological effects associated with alcohol-cocaine co-administration (e.g. 
Cami et al. 1998). 
Pharmacokinetic interactions between alcohol and tobacco have not (to 
my knowledge) been systematically investigated, and the few studies that have 
examined alcohol-nicotine interactions have produced inconclusive results. 
Although evidence suggests that nicotine may alter mechanisms involved in 
hepatic alcohol metabolism (Schoedel & Tyndale, 2003) as well as rates of 
gastric emptying (Gritz et al., 1988), factors that could affect alcohol 
distribution and absorption, in animal studies alcohol and nicotine have failed 
to alter each other's pharmacokinetic properties (Collins et al., 1988). 
Moreover in humans, studies that have examined alcohol-nicotine 
pharmacokinetic interactions suggest that alcohol does not appear to affect 
nicotine metabolism (Benowitz et al., 1986) while nicotine has not been shown 
to pro duce consistent effects on alcohol's pharmacokinetics (Perkins et al. 
1995; Kouri et al. 2004). 
Potential pharmacokinetic interactions between alcohol and 
amphetamine have been examined in two studies that have produced mixed 
results. While the pre-administration of alcohol increased the bioavailability of 
a moderate dose of oral d-amphetamine (0.18 mg/kg) it had no effect on the 
pharmacokinetics of a lower dose (0.09 mg/ kg) (Perez-Reyes et al., 1992). 
Moreover in a study examining alcohol-methamphetamine interactions, 
intravenous methamphetamine administered following alcohol consumption 
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did not significantly alter the pharmacokinetic properties of either substance, 
with the exception of decreasing the apparent volume of distribution of 
methamphetamine, an effect ofunknown significance (Mendel son et al., 1995). 
There is also evidence that alcohol-methylphenidate co-administration 
may result in significant pharmacokinetic interactions. Alcohol co-
administration has been reported to increase plasma concentrations of 
methylphenidate (administration order and dosages were not reported) (Patrick 
et al., 2005) as weIl as result in the production of a novel metabolite 
ethylphenidate (Markowitz et al., 2000) that, like cocaethylene, is produced in 
relatively low concentrations, but might contribute to the combined effects of 
the drugs (Markowitz et al., 2000; Patrick et al., 2005). 
While evidence suggests that concomitant alcohol administration may 
result in significant pharmacokinetic interactions with co caine, amphetamine 
and methylphenidate, at least under sorne conditions, there is currently little 
data to support a significant pharmacokinetic interaction between alcohol and 
tobacco. It is important to note, however, that because most studies have used a 
limited range of substances, doses and administration parameters, and 
descriptive data on how many of the substances are normally used is lacking, 
the results should be interpreted with caution. 
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2.32 Pharmacodynamies 
Unlike pharmacokinetic interactions which are typically directly 
measured, pharmacodynamie interactions between psychoactive substances are 
usually inferred from the behaviourallsubjective changes that result from co-
administering substances known to affect common neurotransmitter systems. 
Support for the involvement of a specific neuropsychopharmacological action 
in the production an effect might include 1) observations that drugs with 
similar actions on the substrate(s) hypothesized to be involved pro duce similar 
behaviourallsubjective changes when co-administered with the target 
substance; 2) observations that treatments with opposite actions on the 
substrate(s) result in opposing behavioural and/or subjective changes; and 3) 
evidence that behavioural and/or subjective changes cannot be attributed to 
actions on substrate(s) other than those hypothesized to be involved. 
In the case of alcohol-psychostimulant interactions, it is proposed that a 
common DAergic substrate may be involved in the production of significant 
pharmacodynamic interactions that contribute to the propensity for alcohol to 
be co-administered with these drugs. In the section below evidence linking 
particular psychostimulant and alcohol-related effects to this substrate will be 
reviewed and because each of the drugs reported is believed to exert a similar 
effect on this substrate, it is proposed that examining the effects of alcohol-co-
administration with each ofthese substances may help delineate the alcohol-
related effects that are associated with DA. 
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2.33 DAergic Effects of Abused Stimulants 
The abuse potential of psycho stimulant drugs is believed to be 
associated with their ability to increase extracellular levels of DA in 
mesocorticolimbic regions (e.g. Wise & Bozarth, 1987; DiChiara & Imperato, 
1988; Wise, 1996; Koob, 2000). Cocaine and methylphenidate achieve their 
DAergic effects through a common mechanism by binding to the DA 
transporter in the presynaptic cell membrane, thereby inhibiting DA reuptake 
(e.g. Volkow et al., 1995). These drugs display similar affinities for DA 
transporters (Gatley et al., 1996; Volkow et al., 1998), their administration lead 
to comparable changes in synaptic DA levels (Kuczenski & Segal, 1997; 
Volkow et al., 1999a) and although cocaine is also believed to have a 
significant affects on serotoninergic neurotransmission ( e.g. Segal & 
Kucezenski, 1999) methylphenidate's central effects appear to be relatively 
DA specific (e.g. Fleckenstien et al. 1999; Segal & Kucezenski, 1999), and as 
a result the similarities in the behavioural effects of these two drugs can be 
inferred to be associated with their DAergic properties. Like cocaine and 
methylphenidate, both amphetamine and nicotine administration also resuIts in 
increased in synaptic DA levels; however these drugs appear to achieve their 
DAergic effects through different mechanisms. While amphetamine increases 
DA neurotransmission both by inhibiting reuptake as weIl as by stimulated of 
DA release from the presynaptic ending (e.g. Segal & Kuczenski, 1999), 
nicotine is believed to increase DA release via stimulation of nicotinic 
receptors located on DA containing ceUs (e.g. Corrigall et al., 1994; Pontieri et 
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al., 1996, Pidopichko et al., 1997 ). Moreover although evidence suggests that 
the magnitude ofnicotine's DAergic effects is not as great as for other 
psycho stimulants in either laboratory animaIs (e.g. Yanagita et al., 1995; 
Tsukada et al., 2002) or in humans (Barrett et al., 2004; see Appendix 5), 
recent animal findings suggest that nicotine administration may facilitate the 
DAergic response to other reinforcers (Rice & Craig, 2004; Zhang & Sulzer, 
2004). 
While there appears to be sorne heterogeneity in mechanisms through 
which cocaine, methy1phenidate, amphetamine and nicotine increase synaptic 
DA levels, in each case these DA effects are thought to be critical to the 
substance's reinforcing effects (e.g. Wise & Bozarth, 1987; DiChiara et al., 
1998). For example, in laboratory animaIs a disruption of DA function has 
been demonstrated to reduce co caine (e.g. Stewart & deWit, 1987), 
amphetamine (e.g. Wise 1996) and nicotine (Corrigall et al., 1992) intake as 
well as prevent the locomotor stimulant effects associated with cocaine (e.g. 
Wise, 1998; Koob; 2000), methylphenidate (Mithani et al., 1986) amphetamine 
(e.g. Wise, 1998) or nicotine (e.g. Clarke et al. 1988; Louis & Clarke 1998) 
administration, while human functional neuroimaging studies in humans have 
linked amphetamine (Martinez et al., 2003; Drevets et al., 2001), 
methylphenidate (Volkow et al. 1999) and nicotine (Barrett et al., 2004; 
Appendix 5) induced changes in DA to the subjective hedonic properties of the 
drugs. 
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2.34 DA and Alcohol 
Although alcohol is known to affect numerous neurochemicals 
including acetylcholine, DA, GABA, glutamate, norepinephrine and serotonin, 
its subjective effects and reinforcing properties are thought to be largely 
mediated by DA and GABA (e.g. Fromme et al., 2003). Each ofthese 
neurotransmitters has been hypothesized to be involved in different aspects of 
the alcohol response and in both cases their effects are believed to be time and 
dose dependent (e.g. Ollat et al., 1988). Like various psycho stimulant drugs, 
alcohol administration increases DA neurotransmission in mesocorticolimbic 
regions in both laboratory animaIs (e.g., Samson et al., 1992; Koob et al. 1998) 
and humans (Boileau et al., 2003) and this action is believed to be involved in 
its reinforcing properties (Di Chiara & Imperato, 1988; Koob et al. 1998). 
Animal studies indicate that alcohol's DAergic effects appear to predominantly 
occur during the ascending limb of the blood alcohol concentration (BAC) 
curve when blood alcohollevels are rising (e.g. Marinelli et al., 2003) and 
alcohol-related DA transmission has been proposed to mediate alcohol's 
stimulant effects (e.g. Enggasser & DeWit, 2001 ) and self-administration (e.g. 
Modell et al., 1993) in humans. In contrast, GABA is thought to mediate 
alcohol's descending limb sedative and anxiolytic actions (e.g. Pihl & 
Peterson, 1995) and with cumulative doses alcohol-induced GABAergic 
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activation may inhibit alcohol-related DAergic effects (e.g. Ollat et al., 1988; 
Gerasimov et al., 1999). 
2.35 Altering Alcohol's DA-related effects 
In rodents alcohol self-administration has been demonstrated to be 
time-Iocked to increases in DA neurotransmission (Weiss et al., 1992) and DA 
antagonists have been demonstrated to attenuate voluntary alcohol intake (e.g. 
Rassnick, 1992; Files et al., 1998). In humans, functional neuroimaging 
studies demonstrate that acute ingestion of alcohol increases DA release 
(Boileau et al., 2003) while decreasing DA neurotransmission leads to 
reductions in alcohol self-administration (Leyton et al., 2000a; Enggasser & de 
Wit, 2001, Modell et al., 1993) and alcohol-related stimulation (Enggasser & 
de Wit, 2001). Although evidence indicates that decreasing DA 
neurotransmission reduces alcohol self-administration and certain alcohol 
related effects, less is known about how these are affected by selective 
increases in DA activity. Animal models that have examined the effect of DA 
agonists on alcohol administration have produced equivocal results, with sorne 
studies finding increased levels of ethanol intake (e.g. Samson et al., 1993) and 
others reporting decreases (Hodge et al., 1997). In human studies alcohol co-
administration with any of nicotine (Pekins et al., 1995), cocaine (Farre et al., 
1993), methamphetamine (Mendel son et al., 1995) or methylphenidate (Barrett 
& Pihl, 2002, see appendix 3) have been reported to be predominantly 
associated with increased stimulant-like effects and diminished sedation, but 
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the effect of these substances on alcohol intake have not been systematically 
investigated. 
2.36 Alcohol Administration and DA Sensitivity 
A growing body of evidence suggests that many problematic drinkers 
as well as individuals at risk for developing alcohol related problems may 
experience exaggerated ascending limb DA effects from alcohol. For example, 
alcoholics, heavy drinkers, and individuals with a family risk for alcoholism 
display greater ascending limb subjective stimulant effects following alcohol 
administration relative to non-alcoholics, light drinkers and individuals with no 
family history of alcoholism respectively (Thomas et al., 2004; Holdstock et 
al., 2000; King et al., 2002; Elbridge et al., 2003). Moreover, in addition to 
subjective stimulation problematic/at risk drinkers also appear to exhibit a 
heightened physiologic response to alcohol during the ascending limb of the 
BAC as indexed by cardiac responsivity to acute alcohol ingestion (e.g. 
Conrod et al., 2001). It has been proposed that a heightened he art-rate (HR) 
response to alcohol is a peripheral marker to identify individuals that exhibit 
heightened alcohol-related DA transmission (Brunelle et al., 2004, see 
Appendix 4; Conrod et al., 2001) and this hypothesis is supported by findings 
that alcohol-induced cardiac effects are proportional to both DA release 
(Boileau et al., 2003) and alcohol-related stimulant effects (Brunelle et al., 
2005) as well as by evidence that treatments that directly (Enggasser & de Wit, 
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2001) or indirectly (McCaul et al., 2001) disrupt DA function attenuate 
alcohol-induced HR increases. Interestingly evidence also suggests that co-
administration of alcohol with any of cocaine (e.g. Cami et al., 1998), 
amphetamine (e.g. Mendelson et al., 1995) or nicotine (e.g. Perkins et al., 
1995) produces HR increases that are greater than those associated with the 
solitary administration of the substances, although the mechanisms mediating 
such changes have yet to be determined. 
2.4 Current investigations 
The present series of studies examines alcohol-psychostimulant co-
administration as well as the role of DA in alcohol self-administration from a 
variety of perspectives. First because descriptive data on the way alcohol and 
psychostimulants are used together is lacking, and such information is 
necessary both for designing ecologically valid studies and for interpreting the 
CUITent literature, studies 1 & 2 examine polysubstance use patterns using 
structured interview techniques, with an emphasis on delineating the order and 
amounts of aIl substances consumed. It was expected that alcohol co-
administration with psycho stimulants would follow an identifiable pattern and, 
because stimulants increase DA transmission, that their co-administration 
would be found to be associated with increased alcohol intake. Second, 
because the effects of stimulant co-administration on alcohol intake have yet to 
be directly investigated in humans, in study 3 the effects of simultaneous 
nicotine use on alcohol self-administration was examined in a laboratory 
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setting using a double-blind placebo controlled study. Finally because DA has 
been linked to alcohol self-administration (e.g. Koob et al. 1998) and evidence 
suggests that certain individuals may be more sensitive to alcohol's DA-related 
effects (e.g. King et al., 2002 ; Conrod et al., 2001 ), in study 4 the effects of 
selectively decreasing DA neurotransmission on alcohol intake was 
investigated in a heterogeneous sample of drinkers, using the acute 
phenylalanine-tyrosine depletion method. This method decreases DA 
neurotransmission through a dietary manipulation and Appendix 6 provides a 
detailed description ofthis technique in a recently published review article 
about this method (Barrett & Leyton, 2004, see Appendix 6). 
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3. Prologue to Study 1 
The first paper presented in this dissertation is a reproduction of the 
manuscript "Patterns of Simultaneous Polysubstance Use Patterns in Canadian 
Rave Attendees" that was published in 2005 in Substance Use and Misuse 40, 
1525-1537. This study was in part a follow-up to a previous investigation that 
examined the drug use patterns in rave attendees (Gross et al., 2002; please see 
Appendix 7), and its purpose was to delineate specific patterns of simultaneous 
polysubstance use in this population. Despite its focus on rave specifie 
substance use, l decided to inc1ude it as part of this dissertation because: 1) it 
uses a method l helped develop to the delineate specific patterns of 
polysubstance use that are related to a particular instance; 2) it examines the 
reliability of drug users' recollections of the type, order and amount of an 
substances used on a particular occasion; and 3) alcohol-specific patterns of 
simultaneous substance are addressed. 
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3.1 Absfract 
The aim of this study was to examine rave-related polydrug drug use and to 
determine if patterns of substance use were associated with previous rave 
attendance. One hundred and eighty-six rave attendees (50% female) 
representing wide range of ages (16 to 47 years; mean=23.5, sd=5.15) and 
levels of rave attendance experience (1 to 400 events) completed structured 
interviews in Montreal, Canada between November 2002 and September 2003 
about their rave attendance patterns and their use of various licit and illicit 
substances at the most recently attended event. On average participants 
reported using 2.5 different psycho active substances (excluding tobacco) at the 
most recent event attended. Cannabis, alcohol, MDMA (ecstasy), 
amphetamine, cocaine, ketamine and GRB were the most frequently reported 
substances and details about their orders of administration, dosages and 
patterns of co-administration are presented and discussed. The total lifetime 
number of raves attended by participants varied considerably (mean=48.6; 
sd=69.7; median=25) and there was a positive correlation between the number 
events attended and number of substances used at the most recent event 
attended (p<.OOl). Analyses revealed individuals reporting the use of 
ketamine, GRB and/or cocaine at the most recent event had attended 
significantly more events than nonusers even when controlling for various 
demographic variables. A subset of respondents (n=27) completed a second 
interview to determine the reliability of their responses. Results indicated that 
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respondents could reliably recall details about which drugs were used, the total 
doses administered as well as order of drug administration. 
Key words: polysubstance use, rave, MD MA, amphetamine, GHB, ketamine, 
cocaine, substance use patterns, substance use trends 
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3.2 Introduction 
Numerous investigations conducted worldwide have documented high 
rates of illicit substance use among rave attende es (Lenton et al., 1997; 
Winstock et al., 2001; Gross et al., 2002; Tossmann et al., 2001; Forsyth, 
1996). Drugs such as 3,4-methylenedioxymethamphetamine (MDMA or 
ecstasy), amphetamine and cannabis have consistently been identified as being 
frequently used within this population (Lenton et al., 1997; Gross et al.,2002; 
Tossman et al., 2001) and recent reports indicate that other substances such as 
gamma-hydroxybutyrate (GHB) and ketamine (e.g. Freese et al., 2002) are 
increasing in popularity. Evidence also suggests that rave-related drug use 
often occurs in a polysubstance context. For example, in an Australian sample, 
80% of rave attendees reporting any using substance used multiple substances 
(Lenton et al., 1997) while 66% of respondents in a Scottish study (Riley et al., 
2001) reported polysubstance use. This trend toward polysubstance use has 
generated concern due to the possibility that simultaneous multiple substance 
administration results in increased toxicity (e.g. Schifano et al., 2003). 
Despite the apparent prevalence and potential adverse consequences 
associated with polysubstance administration, little is known about the specifie 
patterns of rave-related multiple drug use. In a study of British ecstasy users 
Winstock et al. (2001) documented high levels of lifetime ecstasy co-
administration with various licit and illicit substances including alcohol, 
cannabis and amphetamines. However, this study did not provide information 
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about what substances were used concurrently with ecstasy at raves or on any 
particular occasion. In a recent American study, Fendrich et al. (2003) reported 
high levels of concurrent drug co-administration among 'club' drug users 
(identified as MD MA, ketamine, Rohypnol, and/or GHB). However, this 
study did not differentiate among various 'club' drugs and their use was not 
explicitly associated with rave attendance. Finally, in a large European 
investigation of the drug taking patterns of rave attendees, over 90% of ecstasy 
users reported the simultaneous use of at least one additional psychoactive 
substance during their most recent administration of the drug (Tossmann et al., 
2001). However like other studies, this investigation did not delineate rave 
specifie ecstasy use and polysubstance use patterns involving drugs other than 
ecstasy were not reported. The purpose of the present investigation was to 
better delineate the patterns of simultaneous polysubstance use that are 
characteristic of rave attendance by documenting amount, order, and type of aIl 
substances consumed on a single occasion by a sample of rave attendees from 
Montreal, Canada. 
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3.3 Methods 
3.31. Procedure 
Participants were recruited between November 2002 and September 
2003 through advertisements posted at rave venues and on internet rave-related 
bulletin boards as weIl as by word of mouth from individuals already 
participating in the study. Subjects were eligible for inclusion ifthey had 
attended at least one rave in the preceding 6 months and resided in the greater 
metropolitan area of Montreal, Canada. AIl participants were assured that the 
information they provided would remain strictly confidential and were paid 
C$10 for their time. Interviews took approximately 30-40 minutes to complete 
and were conducted by two of the authors (SPB & IG). Prior to the beginning 
of the study each interviewer had completed training in structured interview 
techniques and each had experience in using the 'time-line follow back 
method' (Sobell & Sobell, 1996) of delineating patterns of substance use. 
3.32. Structured Interview 
The structured interview collected details about the participants' 
demographic characteristics as weIl as their 'Rave' attendance patterns 
including age of first attendance and an estimation of total number of events 
attended. In addition, detailed information was collected about drug and 
alcohol consumption at the most recently attended event using an interview 
format based on the time-line follow-back method (Sobell & Sobell, 1996). 
Participants were asked to think about the last event that they attended and 
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provide details about its date and location. They were then asked to recaU aU 
drugs consumed on that particular occasion (prior to, during, and after the 
event), including alcohol and tobacco. After spontaneously generating a list, 
participants were read a list of substances that they had not already mentioned 
and were asked if each substance was used at the time. The drugs included 
were alcohol, tobacco, cannabis, cocaine, amphetamine (speed, 
methamphetamine), MDMA (ecstasy), ephedrine, methylphenidate (Ritalin), 
amyl nitrate (poppers), GHB, ketamine (Special K), psilocybin (magic 
mushrooms), LSD, Heroin, benzodiazepines, pep, inhalants, mescaline, 
morphine, opium, viagra, and 'any other drug not already mentioned' (please 
specify). After listing every drug consumed participants were asked to provide 
an ordered enumeration of their administration of aU of the substances used on 
that occasion (excluding tobacco) as weU as to provide details about the total 
amounts used of every substance. Additional details regarding the context of 
and reasons for specific patterns of drug administration were not routindy 
coUected. 
3.33. Test-Retest Reliability 
In order to determine the reliability ofparticipants' recollections of 
their rave-related substance use, a subset of the sample was contacted 24 to 72 
hours following their initial interview and was asked to complete a second 
interview for the same event that they initially reported on. These participants 
were not randomly selected but rather represented the final 27 subjects 
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interviewed. Although each of these participants were informed that they may 
be re-contacted to provide additional information, they were not told that the 
purpose of the second interview would be to determine the reliability of their 
initial responses. 
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3.4 Results 
3.41. Sample characteristics 
A total of 186 (50% female) rave-attende es completed the interview. 
Participants' age ranged from 16 to 47 years (mean=23.5; sd=5.15; 
median=22; mode=22) and the majority were Caucasian (87.9%). Education 
levels were fairly high among this group with 87.6% having completed high 
school and 59.5% completing at least sorne post secondary education. 72.6% 
of the subjects identified themselves as heterosexual, 14.5 % homosexual and 
12.9 % bisexual. 
3.42. Rave Attendance 
Subjects attended a rave for the first time on average at 18.9 (sd=4.6) 
years of age. The total number of raves attended varied between 1 and 400, 
with a mean of 48.6 events (sd=69.7), a median of25 events and a mode of 50 
events; 31.7% attended 50 events or more. 83.9% of the respondents reported 
using drugs or alcohol 'often' or 'always' when they go to raves. 
3.43. Number of Substances Used at the Most Recently Attended Rave 
Participants' rave substance use varied considerably, ranging from 0 to 
7 different substances (exc1uding tobacco) with a mean of2.5 (sd=1.2) 
different substances consumed. While only 2.7% of participants reported no 
substance use and 17.2 % reported the use of a solitary drug, approximately 
80% reported polysubstance use. 
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3.44. Rave-Related Tobacco Use 
Although 48.7% of participants identified themselves as regular daily 
smokers, 59.1 % reported smoking tobacco at the most recent event attended. 
Concurrent tobacco use was reported in the majority of cases with every other 
type of drug reported (ranging from 61.5% of GHB users to 76.5% of cocaine 
users). However, because tobacco is typically considered to be a substance 
devoid of significant intoxicating properties (e.g. Perkins, 2002) and its use 
was typically continuous throughout an event, it was decided to exclude it from 
all subsequent analyses of poly-drug taking patterns. 
3.45. Rave-Related Polysubstance Use 
In order to begin to delineate the specifie polydrug use patterns at the 
most recent rave event attended we calculated the percentage of respondents 
who had used each drug as well as the percentage of these users who reported 
simultaneous use of each other drug. Table 3.1 presents this data for aU 
substances used by at least 5% of the sample. Additional analyses were 
performed to determine the order of initial administration of each substance, 
the proportion of users administering the drug in multiple sessions, the total 
number of substances concurrently used with each drug as well as the total 
average doses consumed (Table 3.2). 
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Cannabis was the most commonly used substance (n=120, 64.2%) at 
the most recent rave attended, and in 97.5% of the cases at least 1 additional 
psychoactive substance was also administered. Cannabis was co-administered 
by the majority of users of aIl other types of substances reported, ranging from 
65.9% ofamphetamine users to 76.9% ofGHB users (Table 3.1). As shown in 
Table 2, although it was frequently first administered toward the middle of the 
drug taking sequence, in the majority of the cases (55%) it was reported to be 
used in multiple sessions interspersed with other substance use. The average 
cannabis user reported smoking 1.4 (s.d=l.2) grams over the course of the 
evenmg. 
Alcohol was the next most frequently reported substance with 52.2% 
(n=97) of the sample reporting use. In 88.7% ofthese cases it was used with a 
minimum of one additional psycho active substance, although the frequency of 
concurrent a1cohol use varied considerably across substances ranging from 
15.4% ofGHB users to 76.5% ofcocaine users (Table 3.1). Alcohol was 
typically consumed near or at the beginning of the drug taking sequence and in 
only 17 (17.6%) of the cases did its initial use follow other substance 
administration (Table 3.2). 
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Table 3.1: Patterns of substance use at the most recently attended rave.a 
Any use 
Drug Percentage of users reporting concurrent use of each substance 
(%) 
Cannabis Alcohol MDMA Amphetamine Cocaine Ketamine GHB Noneb 
Cannabis 64.9 XXX 55.0 52.5 48.3 10.8 9.2 8.3 2.5 
Alcohol 52.2 68.0 XXX 43.3 36.1 13.4 9.3 2.1 11.3 
MDMA 50.0 68.5 45.2 XXX 48.4 9.8 9.7 8.6 9.7 
Amphetamine 47.8 65.9 39.3 50.6 XXX 5.7 14.6 12.4 11.2 
Cocaine 9.1 76.5 76.5 52.9 29.4 XXX 23.5 11.8 0 
Ketamine 8.6 68.8 56.3 50.0 81.3 25.0 XXX 18.8 0 
GHB 7.0 76.9 15.4 69.2 86.4 15.4 23.1 XXX 0 
aData is reported for aU substances used by a minimum of 5% of the total sample (n=186). The table present the 
percentage of respondents reporting any use of each substance, the percentage of users of each drug reporting 
concurrent use of each other substance. 
~excluding tobacco 
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Table 3.2 : Order of administration, proportion of users administering 
substance in multiple sessions interspersed with other drug use, 
number of drugs co-administered and total dosage for each substance 
used by a minimum of 5% of participants. 
Order of first Multiple Number of Drugs Estimated Total 
Drug 
administration Sessions Co-administereda Dosage 
Mean (sd) % Mean (sd) Mean (sd) 
Cannabis 2.0 (1.0) 55.0 2.0 (1.1) 1.4 (1.2) grams 
Alcohol 1.3 (0.7) 22.7 1.9 (1.2) 6.4 (5.8) drinks 
MDMA 2.5 (1.0) 9.9 2.0 (1.2) 1.1 (0.6) pills 
Amphetamine 1.9 (0.8) 20.2 1.9 (1.2) 1.1 (0.4) pills 
Cocaine 2.9 (1.1 ) 41.2 2.8 (1.0) 0.6 (0.9) grams 
Ketamine 3.1 (lA) 18.8 3.1 (l.4) 004 (0.2) grams 
GHB 3.1 (1.6) 30.8 2.9 (0.9) 1.7 (1.0) uses 
a excluding tobacco 
MDMA and amphetamines were each used by approximately half of 
the sample, although 73.7% reported using at least one ofthese drugs. In close 
to 90% of the cases each of the se drugs was used in a polydrug context (Table 
3.1). The most frequent drugs used with MD MA were cannabis (68.5%), 
amphetamines (48.4%) and/or alcohol (45.2%), while amphetamines were 
most often used with cannabis (65.9%) and MDMA (50.6%). As Table 3.2 
illustrates, on average both amphetamine and MDMA were used with 
approximately 2 additional substances. Moreover, for both drugs, us ers 
typically used a single dose in a single administration. 
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Cocaine (9.1%), Ketamine (8.6%) and GHB (7%) were each reported 
by fewer than 10% of the sample and in every case, each of these drugs was 
used in a polysubstance context (Table 3.1). Moreover, each ofthese drugs 
was typically consumed late in the drug taking sequence and in combination 
with approximately 3 other psychoactive substances (Table 3.2). The most 
frequently co-administered drugs with cocaine were alcohol (76.5%), cannabis 
(76.5%) and MDMA (52.9%). Ketamine was most often used with 
amphetamine (81.3%), cannabis (68.8%), alcohol (56.3%) and MD MA (50%), 
while for GHB, concurrent amphetamine (86.4%), cannabis (76.9 %) and/or 
MDMA (69.2 %) use were most frequently reported. It is interesting to note 
that a full 100% of GHB users reported the concurrent use of at least one 
stimulant drug (amphetamine, co caine, ephedrine, methylphenidate and/or 
MDMA), while 93.7% of Ketamine users reported simultaneous stimulant use. 
Substances reported by fewer than 5% of the sample and thus not 
included in Tables 1 and 2 were ephedrine (3.2%), psilocybic mushrooms 
(3.2%), LSD (2.7%) and methylphenidate (1.8%). In 100% of the cases each of 
these substances was used in conjunction with at least 1 other psychoactive 
substance. However, specifie patterns of polydrug use involving these 
substances were not delineated due to the small number of respondents 
reporting their use. 
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3.46. Order of Drug Administration 
In order to identify the specifie temporal sequence of polydrug 
consumption, a series of Wilcoxon tests for related-samples were performed on 
each possible drug pairing, including aU of the substances noted in Tables 3.1 
and 3.2. Because this resulted in 21 separate analyses, a family Bonferroni 
correction was used and the threshold for statistical significance was placed at 
p=0.002. Analyses revealed that when alcohol was used in drug combinations 
that inc1uded any of cannabis, MD MA, amphetamine or cocaine, its use 
reliably precedes the initiation of each other substance use (P's <.002). 
Moreover a similar trend was also evident for alcohol use preceding ketamine 
(P=.043) use, however a small sample size (9 cases) may have prevented this 
association from reaching the threshold for significance. Despite the high 
levels of drug mixing, there was only one other case where the relative order of 
drug administration was found to be reliable. When used in combinations that 
include MDMA, amphetamine use was found to reliably precede MDMA use 
(p<.001). 
3.47. Relationship Between Rave Attendance and Drug Use 
Using a Pearson's Correlation Coefficient, a significant positive 
relationship was identified between the totallifetime number of Rave events 
attended and the number of drugs used at the most recent event (r=.259, 
p<.OO 1). In order to determine how the use of specifie substances were related 
to level of rave attendance, a series of ANOV As were performed with 'total 
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number of raves attended' as the dependent variable and with the independent 
variables being each drug reported by a minimum of 5% of respondents, while 
controlling for the possible effects of age, gender and sexual orientation by 
including them as covariates. (Table 3.3) Although no significant relationships 
were revealed between rave attendance and the use of alcohol, cannabis, 
amphetamine or MDMA, there were very strong associations between number 
ofraves attended and the use of cocaine, ketamine, and GHB (Ps<.OOl). 
Table 3: Mean (S.D) number of raves attended by users ofvarious 
substances and the relationship between substance use and level of rave 
attendance when controlling for various demographic variables N=186. 
Drug Number of raves attended a F b 
Users Nonusers 
Alcohol 51.1 (74.7) 46.1(61.8) .82 
Cannabis 46.6 (64.0) 53.3(77.2) 1.03 
MDMA 46.1 (61.7) 51.3 (75.3) .01 
Amphetamine 60.6 (80.7) 37.8 (53.6) 1.6 
Cocaine 107.8 (117.1) 42.9 (59.3) 19.7*** 
Ketamine 127.5 (111.7) 41.3 (58.4) 18.5*** 
GHB 132.8 (107.9) 42.3 (60.7) 17.8*** 
a Means (S.D) were calculated separately for individuals reporting use of a 
particular substance at the most recently attended rave (us ers) and those not 
reporting use ofthat substance at the last rave (nonusers). 
b AU analyses of variance were performed with gender, age, and sexual 
orientation as covariates; (df = 1, 181). 
*** P<.OOl 
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Table 3.4: Level of rave attendance predicts the probability of co caine, 
GHB and/or ketamine administration at the most recently attended event 
using logistic regression. 
Predictor Chi Squared Wald Odds ratio 95% Confidence 
Variable X
2 Z Interval for Odds 
Cocaine 
Raves attended 
Age 
Gender 
Sexual 
Orientation 
GHB 
Ravesattended 
Age 
Gender 
Sexual 
Orientation 
Ketamine 
Raves attended 
Age 
Gender 
Sexual 
Orientation 
**P<.017 
***P<.OOl 
9.44** 
1.18 
4.19 
0.71 
12.81 *** 
0.36 
0.20 
0.12 
14.84*** 
0.26 
0.00 
3.63 
Ratio 
13.33*** 1.013 1.006 - 1.021 
0.92 0.939 0.826 - 1.068 
4.60 0.221 0.055 - 0.883 
0.42 0.722 0.328 - 1.588 
9.81 ** 1.010 1.004 - 1.016 
0.28 1.027 0.931 - 1.132 
0.26 1.428 0.360 - 5.663 
0.12 1.116 0.501 - 2.695 
9.08** 1.009 1.003 - 1.016 
0.05 0.989 0.897 - 1.092 
0.21 1.342 0.386 - 4.666 
3.86 1.985 1.001 - 3.933 
In order to further delineate the relationship between rave attendance 
and the use of cocaine, ketamine and/or GHB at the most recent rave attended, 
odds ratios were calculated using a binary logistic regression mode!. In each 
case number of raves attended, age, gender and sexual orientation were used as 
potential predictors of the outcome variable, use or non-use of the drug and 
both chi squared and Wald values were determined. Table 3.4 presents the 
results of these analyses. Because separate analyses were required for each 
substance, a family Bonferroni correction was used and the threshold for 
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statistical significance was placed at P=0.017. In each case, the number of 
raves attended remained the sole variable to reliably distinguish between those 
reporting use of the drug and those not. Moreover, odds ratios revealed that the 
probability of using each of these drugs at the most recent rave attended 
increased between approximately 9%-l3% for every 10 raves attended (Table 
3.4). 
3.48. Test-Retest Reliability 
The final 27 subjects (12 male, 15 female) interviewed were contacted 
by telephone 24 to 72 ho urs following their initial completion of the study and 
were again asked to recount the details of their drug taking for the same event 
they initially reported on. In 25 of the 27 cases (92.6%), participants reported 
the exact same series of substances during both interviews. Pearson' s 
correlation coefficients were calculated to determine the consistency of reports 
for aIl drugs used by 5 or more subjects as well as for the doses reported, while 
Cohen's Kappa was used to determine the reliability of the ordinal drug taking 
sequence data. These data are presented in Table 3.5. Pearson's correlations 
revealed very high correlations for aIl drugs tested (ranging from .87 to 1.0) 
suggesting that participants were consistent in their reports of what drugs were 
used on the particular occasion as well as in the dosages reported. Moreover 
Cohen's Kappa values for drug order data generally indicated very good 
reliability with values ranging from .65 to 1.0. 
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Table 3.5: Test-retest reliability of participants' reports for substance use 
at the most recent rave attended (n=27). 
Drug 
Alcohol 
Cannabis 
MDMA 
Amphetamine 
Cocaine 
** P=.OOI 
*** P<.OO1. 
N 
22 
18 
14 
8 
5 
Pearson's 
correlation: 
substance used 
.88*** 
1.0*** 
.93*** 
.92*** 
1.0*** 
Pearson's Cohen's Kappa: 
correlation: Order of 
reported dose administration 
.98*** .65** 
.96*** .84*** 
.87*** .89*** 
1.0*** .81 *** 
1.0*** 1.0*** 
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3.5 Discussion 
The present results are consistent with previous reports of high levels of 
drug mixing among rave attendees (e.g. Riley et al., 2001; Lenton et al., 1997) 
and suggest that simultaneous' polysubstance use may be normative in this 
population. Approximately 80% of the present sample reported multiple 
substance administration at their most recently attended rave-event, and nearly 
50% reported the concurrent use of three or more drugs. The use of multiple 
substances at raves is increasingly becoming a well-documented phenomenon, 
however to our knowledge the present investigation is the first to delineate the 
specifie patterns of drug administration associated with rave attendance. 
Moreover, this study also presents evidence that participants can reliably 
recount details about the type, order and amount of aIl substances used on a 
specifie occasion. While test-retest reliability data was only collected on a 
subset of participants (n=27), analyses revealed that individuals were highly 
concordant in their reports and despite the mode st sample size, the information 
provided was found to be highly reliable (Table 3.5). 
Cannabis, the most commonly used substance by the present sample, 
was used almost exclusively in a polydrug context. It was reported to be co-
administered by the majority ofusers ofall other substances and in most cases, 
was used over multiple sessions interspersed with other drug administration. 
Given its frequent administration with substances from various 
pharmacological classes as weIl as its pattern of continuous administration, it is 
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reasonable to assume that cannabis use is likely regarded as fairly benign 
activity among rave attendees. Although little is known about the effects of 
cannabis when it is co-administered with other substances, at least in the case 
of a1cohol, cannabis has been demonstrated to pro duce additive intoxicating 
effects (e.g. Ramaekers et al., 2004). It should be noted however, that the 
solitary administration of even large doses of acute cannabis are generally not 
considered toxic (e.g. Grotenhermen, 2003) and to our knowledge there are no 
conclusive reports of acute cannabis use contributing to another drug's 
toxicity. 
A1cohol, the second most frequently reported substance was normally 
used at or near the beginning of the drug taking sequence and did not usually 
continue following other substance administration. Because a1cohol use 
typically preceded other drug administration it is possible that its use may have 
increased the probability of other substance use at least in sorne individuals. 
Altematively alcohol use may occur exclusively in the early stages of the drug-
taking sequence due to more pragmatic reasons. Alcohol's availability is often 
limited or prohibited at many rave venues and because its administration is a 
more conspicuous than most other forms of substance use, its consumption 
may be limited to the time immediately prior to the event. Alcohol co-
administration with substances such as MDMA (Hemandez-Lopez et al., 
2002), cocaine (McCance-Katz et al., 1998), and methylphenidate (Barrett & 
Pihl, 2002) has been reported to augment euphoric drug-effects and it is 
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possible that this may contribute to its propensity to be used concurrently with 
certain drugs. The practice of drug-alcohol co-administration has also 
generated considerable concem. Alcohol use with drugs such as cocaine (e.g. 
McCance-Katz et al., 1998) or methamphetamine (Mendel son et al., 1995) is 
thought to lead to increased toxicity and co-administration with central nervous 
system (CNS) depressants such as GHB may pro duce lethal effects (e.g. Smith 
et al., 2002). The pre'sent finding that alcohol is frequently administered prior 
to the use of drugs from various classes highlights the importance of continued 
research into the effects and consequences of alcohol-illicit drug co-
administration. 
Ecstasy and amphetamine also emerged as two of the most popular 
substances used by the sample, confirming previous reports that these are 
among the most commonly used drugs by Canadian rave attendees (Gross et 
al., 2001). While nearly three-quarters of the sample reported using at least 
one ofthese substances, approximately half of the users of each drug reported 
using both. Interestingly in cases where both drugs were used, amphetamine 
was found to reliably precede MDMA use, suggesting that order of 
administration may contribute to the positive effects that have been associated 
with the concurrent use ofthese drugs (Riley et al., 2001; Winstock et al., 
2001). In most cases MD MA and/or amphetamine use were each limited to the 
administration of a single dose, a practice that presumably minimizes the 
probability of overdose. On the other hand, in the vast majority of cases 
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MDMA and amphetamine were used in a polysubstance context, which might 
increase the occurrence of adverse outcomes. Multiple substance use has been 
implicated in the majority of documented methamphetamine (see Mendelson et 
al., 1995) and MDMA (Schifano et al., 2003) related fatalities. However 
because these drugs seem to be routinely used in a polydrug context, the 
clinical significance of such findings remain unclear. 
A minority of participants reported the use of cocaine, ketamine and/or 
GHB at the most recently attended rave. Each of these substances has been 
demonstrated to have toxic properties (e.g. Smith et al., 2002; Freese et al., 
2002; McCance-Katz, 1998) and the consequences associated with their use in 
a polydrug context remain largely uninvestigated. lndividuals that used any of 
these drugs administered more substances concurrently and had attended 
significantly more raves relative to other participants. These findings are 
consistent with previous research on rave attendees that found that the use of 
any cocaine, ketamine or GHB tended to occur relatively late in the course of 
"drug experimentation" and was most prominent among individuals that 
reported having extensive histories of drug use (Gross et al., 2001). Such 
results also raise the possibility that frequent rave attendance may lead to more 
dangerous drug taking practices and suggest that prevention efforts should be 
directed toward individuals already immersed in 'rave' subculture. 
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The present results should be interpreted in light of the following 
methodologicallimitations. First, because the participants were self-selected 
and the sarnple size was relatively modest, it is possible that the present results 
are not representative of population wide rave-related poly-substance use 
patterns. Although the rave attendees in the present sample represent 
individuals from a wide age rage (16-47 years) and level ofrave experience (1-
400) and the rates of polysubstance use reported were comparable to those 
obtained in different larger scale investigations using a variety of sampling 
techniques (e.g. Fendrich et al., 2003; Tossman et al., 2001; Winstock et al., 
2001), only a true random sarnple of rave attendees would ensure the 
generalizability of these results. Second, because this study relied exciusively 
on retrospective recall, the accuracy of the information reported might be 
questioned. Previous research suggests that when appropriate interview 
methods are used that substance use self-report data can yield both reliable and 
valid results (e.g. Fals-Stewart et al., 2000; Sobell et al., 1996). In the present 
study a measure of test-retest reliability revealed that participants were highly 
consistent in their reports suggesting a high degree of accuracy. However, the 
validity of the reports were not verified using objective drug detection methods 
and it remains possible that in sorne cases that the extent of drug use may have 
been under reported (Fendrich et al., 2004). Finally, although the level and 
type of substance use on any particular occasion is likely related to numerous 
factors such as the availability of different substances, the presence or absence 
of drug using peers and the desire the achieve certain psychoactive effects (e.g. 
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Sloboda, 2002) the present investigation did not systematically address 
contextual and motivational factors surrounding rave-related polysubstance use 
and such issues should to be addressed in future investigations. 
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4. Study 1 Postscript and Abridging Statement to Study 2. 
In study 1, specifie patterns of simultaneous polysubstance use in rave 
attendees were delineated and it was found that concomitant use of multiple 
substances is a very common phenomenon in this population, that rave 
attendees appeared to be able to reliably recount numerous specifie details 
about their patterns of multiple substances, and that alcohol was among the 
most frequently co-administered substances with various other drugs. Because 
most the analyses were selected to delineate overall patterns of rave-related 
drug use and did not specifically address how alcohol is used in combination 
with different abused substances, this paper provides only limited information 
about alcohol use in a polydrug context. When alcohol was used in most drug 
combinations, its initial use tended to precede the onset of other substance 
administration; however the significance of this finding is difficult to decipher 
due to the fact that there may be a limited availability of alcohol at many rave 
events and many are all-night parties that continue well past the time that 
alcohol can be legally sold. Moreover, although restricted alcohol availability 
might also contribute to the observation that alcohol administration did not 
appear to continue following the initiation of other substance use, these 
findings represent the overall drinking trends across the entire sample and it is 
possible that specifie patterns of alcohol use may be associated with its co-
administration with specifie substances. In order to begin to test this 
hypothesis post-hoc analyses were performed to determine if patterns of 
alcohol-drug co-administration were related with the use of any particular 
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substance. Chi-squared analyses were used to determine ifthere were 
significant differences in the proportions of users and nonusers of each 
substance that continued to use alcohol following the ons et of other substance 
use. Analyses revealed that among both cocaine and tobacco users that alcohol 
was significantly more likely to be used in multiple sessions interspersed with 
other substance use when it was used in combination with these drugs 
(Ps<O.Ol) and that this pattern of administration was not related to the 
administration of any other substances (Ps>O.2). While such findings suggest 
that alcohol administration patterns may be affected by the co-administration 
of certain substances the degree to which such findings may extend beyond a 
rave-specific context remains unknown. 
In order to better delineate how alcohol and drugs are simultaneously 
co-administered, in study 2 we examined multiple substance use patterns in a 
sample ofillicit-drug using college students. For each substance ever used, 
participants were asked to provide details of the order, amount and type of all 
substances taken using a specifically recalled event where the substance was 
used (most recent) as a point of reference. By examining simultaneous patterns 
across aU substances ever used, we hoped to determine if patterns of alcohol 
(and other substance) administration were systematically associated with the 
co-administration of particular substances or classes of substances. 
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5. Study 2 
Patterns ofSimultaneous Polysubstance Use in Drug Using College Students 
Sean P Barrett, Christine Darredeau, Robert O. Pihl 
Department ofPsychology, Mc Gill University 
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5.1 Abstract 
Simultaneous polysubstance use (SPU) has been reported to be a common 
phenomenon across different drug using populations, yet little is known about 
how various substances are used with one another. In the present study one 
hundred and forty-nine coIlege students who reported illicit substance use 
completed structured interviews about their use of various substances. For each 
substance ever used, participants provided details about their most recent 
administration the drug including information about the type, order and amount 
of aIl substances co-administered during the session. Patterns of SPU are 
reported for aIl substances used by a minimum of 10% of the sample (alcohol, 
cannabis, tobacco, psilocybin, MDMA, co caine, amphetamine, 
methylphenidate, LSD, ephedrine, ketamine, GHB and mescaline). Alcohol, 
tobacco and cannabis were frequently co-administered with each other as weIl 
as with aIl other substances and across aIl substance the majority of us ers 
reported using the substance in a SPU context during their most recent 
administration. When alcohol was used with other substances its initial 
administration tended to precede the use of aIl other drugs and when it was 
used with psychostimulant drugs (amphetamine, cocaine, or methylphenidate) 
it was found to be reliably used over multiple administrations interspersed with 
the psycho stimulant drug and the quantities of alcohol ingested tended to 
exceed those consumed when it was used in the absence of other substances. 
When cannabis was used with alcohol or psilocybin its initial use tended to 
foIlow the administration of the other substance, however in aIl other cases its 
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pattern of use did not appear to be related to other substance( s) adrninistered. 
Finally, in most cases tobacco use was reported to be increased relative to 
'sober' smoking rates it was used in conjunction with other substances. Results 
suggests that manY different substances appear to be routinely used in a SPU 
context and in sorne cases, that the pattern in which a particular substance is 
administered may largely depend on other substances co-administered. 
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5.2 Introduction 
Substance users often use more than one psychoactive substance 
during the same session, a phenomenon known as simultaneous polysubstance 
use (SPU) (e.g. Martin et al., 1996a). Although SPU is believed to be a 
common practice (e.g. Earleywine & Newcomb, 1997) and has been 
documented across different drug using populations including alcoholics 
(Martin et al., 1996a; Staines et al., 2000), college students (Webb et al., 1997), 
rave attendees (e.g. Barrett et al., 2005b) and adolescents (Martin et al., 1993a, 
1996b), most studies that have described trends in SPU have primarily focused 
on whether or not two or more target substances had been used together over a 
prescribed period of time (e.g. Leri et al., 2004, Martin et al., 1996a) and little 
is known about the specific patterns of co-administration or about how such 
patterns might vary across different substances. 
Because many abused substances may be frequently used in a SPU 
context, delineating the patterns of concurrent multiple substance use may have 
important implications for understanding the abuse potential of such drugs. 
The concomitant use of sorne substances might result in significant 
pharmacological interactions that alter the subjective and/or behavioural 
effects of the drug (e.g. Leri et al., 2003; Herndez-Lopez et al., 2002) and that 
might affect its abuse potential. Moreover because experimental evidence 
suggests that the way that certain commonly co-administered drugs interact 
may depend on factors such as their relative order (s) administration and doses 
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(e.g. Perez-Reyes et al., 1992; Perez-Reyes, 1994), it is possible that polydrug 
users preferentially co-administer sorne substances in a particular orders and 
quantities in order to achieve desirable results. 
We have recently documented the patterns ofSPU in a sample of 'rave' 
attende es using a standardized structured interviews technique where 
participants recounted details of about the order and amounts of all substances 
administered at a specifie (the most recently attended) rave-event. Results 
revealed that for every drug used by the sample (cannabis, tobacco, alcohol, 
MD MA, amphetamine, cocaine, ketamine, GRB, ephedrine, psilocybic 
mushrooms, LSD and methylphenidate) the majority of users administered the 
substance in a SPU context; that participants were to able to reliably recall 
precise details of regarding the order, amount and type of all substances 
administered and that certain substances appeared to follow identifiable 
patterns of co-administration (Barrett et al., 2005b). Rowever because rave-
related substance use patterns may be context specific (e.g. Tossmann et al., 
2002), such findings might not extent to other drug using populations. In the 
present study, we used a similar method to examine the substance 
administration patterns in a sample ofillicit drug using college students. For 
each substance ever used, participants were asked to provide details of the 
order, amount and type of all substances taken using the most recent 
specifically recalled administration of the substance as a point of reference. 
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5.3 Methods 
5.31. Procedure 
Participants were 149 individuals recruited from the McGill University 
student population between April 2003 and August 2004 through 
advertisements posted on campus, on an Internet university classified ads site, 
as weIl as from a pool of volunteers that had expressed interest in participating 
in research in McGill's Department ofPsychology. Participants were 
included in the study if they used at least two substances in their lifetime, 
including alcohol but not tobacco, and were assured that the information 
provided would remain strictly confidential. A subset of the sample (N= 48) 
was recruited on the basis oftheir previous recreational/non-prescribed use of 
the prescription drug methylphenidate or served as matched controls for these 
subjects (N=38). Additional details about these participants have been 
reported elsewhere (Barrett et al. 2005a). 
5.32. Structured Interview 
The structured interview used a retrospective self-report standardized 
measure to collect details about patterns of simultaneous substance use. 
Participants were asked to spontaneously list every substance they had used to 
get 'high, drunk, stoned or buzzed' in their lifetime. Once finished, the 
interviewer read from a standard list of substances in order to stimulate 
participant recall of any use not previously mentioned. The standard drugs on 
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the list were alcohol, cannabis, LSD, psilocybin (magic mushrooms), cocaine, 
mescaline, amphetamine (speed, methamphetamine), methylphenidate 
(Ritalin), Phencyclidine (pep) , ketamine, GHB, MDMA (ecstasy), heroin, 
ephedrine, Adderall, Dexedrine, and 'any other drug not already mentioned' 
(please specify). Participants were asked to provide several details about each 
drug they had used, including their age of first use, and number of uses during 
the preceding 30 days. In addition for each substance, participants were asked 
to indicate if they had ever co-administered other substances during a session it 
had been used and if so to list aU of the substances ever been mixed with the 
drug. The participants were then asked to think about the last time they had 
used each substance and to recall several specific details about this occasion 
including the location and approximate date. These details were elicited in 
order to anchor recollections to a specific occasion. In cases where 
participants were not certain of the details of the most recent event they were 
asked to recall the most recent specific occasion that could be recaUed to be 
used as a reference point. For each substance ever used participants provided 
an ordered enumeration of aH substances used during the recalled session 
(excluding tobacco) as weIl as to provide an estimate of the total amount of 
each substance used using standardised units. Iftobacco had also been used 
during the session, the participant was asked to indicate whether they smoked 
more, less or about the same as they usuaHy do when not using any other 
substances. In addition for alcohol, participants were also asked if they had 
ever used it by itself; that is without any other substances excluding tobacco. If 
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they reported solitary alcohol use they were asked to recall a specifie 
representative occasion when this took place and to provide an estimate of the 
amount ofalcohol that was consumed. Iftobacco was also used during this 
occasion they were again asked whether there were any changes in their 
normal (sober) smoking patterns. 
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5.4 Results 
5.41. Sam pIe Characteristics 
A total of 149 (58.7% female) polysubstance users completed the 
interview. Participants' mean age was 2l.7 (sd=3.5) and the majority were 
Caucasian (78.5%). On average participants reported experience with 6.7 
(sd=3.42; range=2-17; median=6; mode=3) different substances including 
tobacco and aIl participants reported using alcohol and cannabis. 
Table 5.1: Substance use characteristics of the sample 
DRUG Lifetime Age of Use in Lifetime Lifetime 
use first use past 30 alcohol cannabis 
N(%) Mean(SD) days (%) co-use co-use 
(%) (%) 
Alcohol 149 (100) 14.1 (2.4) 97.2 XXX 94.5 
Cannabis 149 (100) 15.4 (2.2) 7l.9 94.5 XXX 
Tobacco 136 (9l.3) 14.7 (2.7) 41.5 b NA NA 
Psilocybin 97 (65.1) 17.0 (2.2) 18.6 66.0 82.5 
Ecstasy 75 (50.3) 18.1 (2.7) 13.2 67.1 68.4 
Cocaine 64 (43.0) 18.8 (2.1) 39.3 91.9 70.0 
Amphetamine 54 (36.2) 18.3 (3.1) 16.3 61.4 45.6 
LSD 44 (29.5) 16.3 (2.8) 0.0 59.2 65.3 
Methylphenidatea 42 (25.1) 18.5 (3.6) 28.6 64.3 52.3 
Ephedrine 27 (18.1) 19.6 (3.0) 20.8 65.2 50.0 
Ketamine 18 (12.1) 18.7 (2.2) 16.7 44.4 6l.6 
GHB 15 (10.1) 20.3 (4.2) 6.7 60.0 33.3 
Mescaline 15 (10.1) 18.5 (2.4) 20.0 53.7 60.0 
a Methylphemdate users were only lllciuded Ifthey reported recreatlOnal use of the drug. 
b Represents only regular daily tobacco use. NA=Data not available 
Table 5.1 presents the proportion of participants reporting lifetime use 
each substance used by a minimum of 10% of the sample (alcohol, cannabis, 
psilocibin, MDMA, cocaine, methylphenidate, amphetamine, LSD, ephedrine, 
ketamine, GHB and mescaline), the age of its first use and the proportion of 
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participants using each substance during the 30 day period preceding the 
interviewas weU as the portion of the participants reporting lifetime co-
administration with alcohol and cannabis (the two substances used by aU of the 
participants). Substances reported by fewer than 10% of the sample are not 
included in Table 5.1 or in any of the subsequent analyses. These were 
morphine (9.4%), benzodiazepines (8.1%), Dexedrine (8.1%), Adderall 
(6.0%), PCP(6.0%), heroin (4.7%), divine sage (4.7%), Percocet (4.7%), 
codeine (3.4%), dextromethorphan (DXM) (3.4%), nitrous oxide (3.4%), 
inhalants (3.4%), steroids (0.7%), and N,N-dimethyltryptamine (DMT) (0.7%). 
5.42. Patterns of simultaneous polysubstance administration 
In order to delineate patterns of simultaneous polysubstance use, for 
each drug the proportion of users that co-administered each other substance 
during the most recent recaUed administration of the drug was calculated. 
These data are presented in Table 2. Tobacco was the most commonly co-
administered drug with aU substances with the exceptions of cocaine and 
mescaline where it was the second most frequently concomitantly used 
substance. Moreover in aU cases tobacco, alcohol, and cannabis were the three 
most commonly concomitantly used substances, with the majority ofusers of 
each drug co-administering at least one of these substances during their most 
recent recaUed administration. 
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Table 5.2: Simultaneous polysubstance use during most recent recalled 
administration of each drug 
Substance Alcohol Cannabis Tobacco Alcohol, Other 
tobacco drug(s) 
and lor 
(%) (%) (%) cannabis (%) 
(%) 
Alcohol XXX 28.2 46.9 55.1 5.3 
Cannabis 37.6 XXX 47.9 65.7 2.0 
Psilocybin 41.2 59.8 61.9 85.6 5.6 
Ecstasy 42.7 27.6 64.0 81.3 20.0 
Cocaine 79.7 40.0 77.0 95.3 7.8 
Amphetamine 41.5 44.9 66.7 83.3 20.4 
LSD 25.0 40.5 69.8 78.6 18.1 
Methylphenidate 35.7 28.2 56.8 66.7 7.1 
Ephedrine 40.7 26.1 65.2 81.5 11.1 
Ketamine 38.3 33.3 83.3 88.9 33.3 
GHB 40.0 26.7 46.7 73.3 26.7 
Mescaline 46.6 60.0 53.3 80.0 20.0 
5.43. Patterns ofpolysubstance use 
None 
(%) 
44.9 
32.9 
9.3 
16.0 
4.7 
13.0 
13.6 
28.2 
18.5 
5.6 
20.0 
20.0 
Additional analyses were performed to determine if patterns of alcohol, 
cannabis or tobacco administration were systematically related to their use 
with other drugs. For each substance analyses were conducted for all cases 
where there were a minimum of 10 reports of the drugs being concomitantly 
administered during the most recent recalled event. 
5.431 Alcohol 
In order to identify the temporal sequence of alcohol-drug 
administration during the most recent recalled administration of each 
substance, a series of Chi -squared tests were performed to determine if there 
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was a systematic order of initial administration as weIl as to determine if 
alcohol was systematically used in multiple sessions interspersed with drug 
use. The results from these analyses are presented in Table 5.3. Analyses 
revealed that across most substances co-administered, that alcohol use 
typically preceded the use of each other substance, an effect that was 
statistically reliable for combinations involving cannabis, psilocybin, ecstasy, 
cocaine, methylphenidate, methamphetamine and LSD. Moreover, when 
alcohol was used in combinations that included cocaine, methylphenidate or 
amphetamine its use was found to reliably continue following the 
administration of the drug and to be interspersed with the substance over 
repeated administrations (Table 5.3). 
Table 5.3: Sequence and pattern of alcohol administration in a SPU context 
Drugs co- Was alcohol Chi- Were alcohol Chi-
administered with used before the Square and drug use Square 
alcohol start of other intermingled? 
(Number of reports) drug use (%) (%) 
Cannabis (55) 80.0 18.00** 45.5 0.36 
Psilocybin (38) 72.5 8.10** 57.1 0.71 
Ecstasy (30) 75.9 7.76** 31.8 2.91 
Cocaine (49) 89.8 31.0** 79.1 14.54** 
Amphetamine (20) 85.7 10.71 ** 73.7 4.26* 
LSD (11) 81.8 4.45* 50.0 0.00 
Methylphenidate (15) 93.3 9.31 ** 84.6 6.23* 
Ephedrine (11) 60.0 0.40 66.7 1.00 
** P<O.Ol; *P<O.05 
Paired samples t-tests where used to determine if the amounts of 
alcohol reported to be ingested differed when it was used in a polydrug context 
relative to when it is used in the absence of other substances (excluding 
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tobacco). Table 5.4 presents the results ofthese analyses. Participants 
reported consuming significantly more drinks when alcohol was used in 
conjunction with either cocaine (p<O.Ol) or methylphenidate (p<0.05) relative 
to when they used alcohol in the absence of other substances (excluding 
tobacco) and there were also a nonsignificant trends toward an increased 
alcohol consumption when it was used in combinations with either 
amphetamine or ephedrine (Ps:S0.1). 
Table 5.4: Amounts alcohol reported to be consumed when co-administered 
with other substance and during solitarya administration 
Substance co- Total number of drinks consumed 
administered - Mean (SD) 
(Number of reports) Alcohol Mixed Alcohol Alonea 
Cannabis (55) 5.7 (4.2) 5.2 (3.5) 
Psilocybin (38) 6.4 (4.2) 5.4 (2.8) 
Ecstasy (30) 5.5 (4.5) 5.0 (3.3) 
Cocaine (50) 7.8 (3.7) 5.3 (3.1) 
Amphetamine (20) 7.5 (3.5) 5.7 (3.4) 
LSD (11) 5.1 (4.0) 3.7 (4.3) 
Methylphenidate (14) 8.3 (5.0) 6.2 (3.6) 
Ephedrine (11) 8.0 (3.6) 6.9 (3.1) 
a alcohol used in the absence of al! other substances except tobacco 
** P<O.Ol; *P<O.05 
T-test 
0.81 
1.35 
0.39 
3.94** 
1.65 
0.72 
2.34* 
1.94 
Because alcohol was often co-administered with more than one 
substance at a time post-hoc analyses were preformed to determine if the 
amounts of alcohol consumed when it was combined with either cocaine or 
methylphenidate significantly differed in the presence and absence of 
additional substances. Independent samples t-tests were used to compare the 
relative differences in alcohol drinks reported (co-administered - alone) 
between those that used additional substances (excluding tobacco) and those 
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that did not, as weIl as between those using tobacco and those not. There were 
no significant differences between the relative increase in amount of alcohol 
reported in cocaine users that administrated additional substances (other than 
tobacco) (N=22; mean=+ 1.6 drinks; SD=4.5) vs. that did those not (N=27; 
mean=+3.3 drinks; SD=4.5) [t (47) = -1.33; p=0.19]; or among 
methylphenidate users using additional substances (N=7; mean=+3.1 drinks; 
SD=3.0) vs. those not (N=7; mean= + 1.2 drinks; SD=3.8) [t (12) = 1.06; 
p=0.31]. Moreover there were also no significant differences among cocaine 
users that used tobacco (N= 40; mean= +2.6 drinks; SD= 4.1) vs. those who 
did not (N=9; mean = + 1.9 drinks; SD=5.8) [t (47)=0.43; p=0.67] or among 
methylphenidate users that concurrently used tobacco (N=II; mean = +2.7 
drinks; SD=3.4) vs. those who did not (N=3; mean= +0.2 drinks; SD= 3.7) 
[t(12)=1.14; p=0.28]. However it should be noted that these latter findings 
should be interpreted with caution given the high levels of variance and 
relatively low number of non-smokers. 
5.432 Cannabis 
Table 5.5 provides details ofpattems of cannabis administration when 
it was used in a polydrug context. When cannabis was used with either alcohol 
or psilocybin, its initial use tended to follow the initial use of these substances, 
however sequence of cannabis use was not systematically re1ated to the use of 
any other substance. Moreover in no cases was cannabis use found to be used 
over multiple sessions interspersed with other drug use and when it was used 
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with psilocybin there was in fact a significant tendency for it not to be used in 
this way. Because participants did not routinely provide standardized 
estimates of the amounts of cannabis administered in the absence of other 
substances it was not possible to examine possible changes in amounts 
administered when cannabis is used in conjunction with other substances. 
T bl 55 S a e . : d f b· equence an pattern 0 canna IS use SPU context 
Drug co-administered Was cannabis Chi- Were cannabis Chi-
with cannabis used prior to Square and drug use Square 
other drug use intermingled? 
(Number of reports) (%) (%) 
A1cohol (36) 33.3 4.00* 45.7 0.26 
Psilocybin (55) 32.7 6.56* 34.0 5.12* 
Ecstasy (32) 37.5 2.00 41.7 0.67 
Cocaine (21) 42.9 0.43 37.5 1.00 
AmjJhetamine (21) 33.3 2.0 33.3 2.00 
LSD (17) 35.6 1.47 38.5 0.69 
Methylphenidate (11) 41.7 0.33 30.0 1.60 
** P<O.Ol; *P<O.05 
5.433 Tobacco 
Substance-related tobacco smoking data were coded as follows: 
decreased smoking relative to normal sober smoking patterns =-1; no change in 
relative smoking patterns = 0; and relative increased tobacco smoking =1. For 
each substance one-samples t-tests were performed to determine ifthere were 
associated changes in tobacco smoking patterns by testing the null hypothesis 
that there would be no change in smoking desire (mean=O). The results from 
these analyses are presented in Table 5.6. Increased tobacco smoking was 
associated with the administration of alcohol, cannabis, psilocybin, ecstasy, 
cocaine, amphetamine, LSD and methylphenidate. In order to determine the 
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specificity of the reported increases a series of independent samples test were 
performed to compare the change smoking patterns associated with each drug 
when the substance was used with multiple substance relative to when it was 
only co-administered with tobacco. Results indicated that when used with 
cannabis that there was a significantly greater relative increase in tobaœo 
smoking when multiple substances were used compared to when only cannabis 
and tobacco were used together [t (68) = 2.78; P <0.01], suggesting that the 
overaU reported increase in tobacco smoking associated with the most recent 
cannabis use may not be specific to an effect of cannabis. In contrast, for aU 
other substances associated with increased tobacco administration there were 
no differences in the rates of smoking when comparing co-administering 
multiple substances relative to those only using the drug with tobacco (Ps>O.2). 
Table 5.6 Changes in tobacco smoking in a SPU context 
Changes in smoking patterns 
relative to normal 'sober' baseline T-test 
Drug co-administered Decrease No change Increase 
with tobacco (%) (%) (%) 
(Number of reports) 
Alcohol (69) 5.9 23.5 70.6 9.00*** 
Cannabis (70) 8.6 40.0 51.4 5.50*** 
Psilocybin (60) 15.0 15.0 70.0 5.71 *** 
Ecstasy (48) 10.4 6.3 83.3 7.85*** 
Cocaine (47) 2.1 10.6 87.2 14.02*** 
Amphetamine (32) 6.3 9.4 84.4 8.00*** 
LSD (30) 16.7 13.3 70.0 3.76** 
Methylphenidate (25) 16.0 28.0 56.0 2.62* 
Ep_hedrine (15) 20.0 40.0 40.0 1.00 
Ketamine (15) 33.3 20.0 46.7 0.58 
***P<O.OOl; **P<O.Ol; *P<O.05 
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Discussion 
The present results suggest that SPU is a very common phenomenon 
among drug-using coIlege students. The majority ofusers of every substance 
investigated reported using multiple substances during their most recent 
recalled administration of the drug, with tobacco, alcohol, and cannabis being 
frequently mixed with each other as weIl as with all other substances. These 
findings are consistent with previous reports that many drugs are often used in 
a polydrug context (e.g. Leri et al., 2004; Martin et al., 1996a; Barrett et al., 
2005), and suggest that patterns SPU should be considered when examining 
the addictive potential of different substances. 
Tobacco was widely concomitantly used with all other drugs and in 
most cases substance administration was associated with overall increased 
levels of smoking. Although data regarding the timing of tobacco 
administration was not collected, smokers are thought to generally administer 
tobacco over multiple sessions (e.g. Batel et al., 1995) and given their reported 
high levels of tobacco use it is likely that participants smoked throughout the 
course oftheir substance administration sessions. Despite the high rates of 
simultaneous tobacco smoking with various abused substances, very little is 
known about how tobacco interacts with most other drugs. Nicotine, the main 
addictive alkaloid in tobacco (e.g. Domino, 1998), is a psychostimulant and 
like other psycho stimulants it is believed to exert its reinforcing central affects 
through promoting midbrain DA neurotransmission (e.g. Pontieri et al., 1996). 
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Although nicotine's DA-related effects are believed to be relatively weak 
relative those produced by either cocaine or amphetamine (e.g. Tsukada et al., 
2002) nicotine may facilitate DAergic response to other reinforcers (Rice & 
Craig, 2004; Zhang & Sulzer, 2004) and it is possible that its propensity to be 
used with certain substances may relate to this effect. While identification of 
the mechanisms responsible for the increased levels of smoking reported when 
tobacco is used in a SPU context remains a matter of conjecture, the high rates 
of simultaneous tobacco use reported in this study highlight the importance of 
considering possible effects of concomitant nicotine when studying the 
addictive properties of different drugs. 
Consistent with previous reports, alcohol was also among the most 
commonly co-administered substances with a variety of drugs (e.g. Martin et 
al., 1996; Barrett et al., 2005). When alcohol was used in a polysubstance 
context its initial use tended to precede the onset of most other substances, 
raising the possibility that alcohol administration increases the probability of 
other substance use. A similar tendency for alcohol intake to precede other 
substance administration has also been recently reported among rave attendees 
(Barrett et al., 2005) indicating that this may be a common phenomenon across 
different drug using populations. The propensity for alcohol to be initially 
administered prior to other substances may be related to its effects on the 
pharmacokinetic properties of other substances. Evidence suggests that 
administering cocaine (e.g. Cami et al., 1998), d-amphetamine (Perez-Reyes et 
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al., 1992) and MDMA (Hemandez-Lopez et al., 2002) following alcohol pre-
treatment may lead to increased plasma concentrations of these substances and 
that at least in the case of cocaine that this effect does not appear to occur 
when drug use precedes alcohol ingestion (e.g. Perez-Reyes, 1994). It is also 
possible sorne substances may be administered following alcohol in order to 
achieve a specific neuropsychopharmacological effect. During the ascending 
limb of the blood alcohol concentration curve when blood alcohol 
concentration are rising, alcohol's subjective effects are thought to be 
stimulant-like (e.g. Newlin & Thomson, 1990; King et al., 2002) and to be 
associated with increased DA neurotransmission and these DAergic effects are 
thought to promote alcohol ingestion (e.g. Weiss et al., 1994). It is thus 
tempting to speculate that certain drugs may be co-administered with alcohol 
due to their ability to augment a1cohol-related DA neurotransmission. This 
notion is appears consistent with findings that when a1cohol was used in 
combinations that included psychostimulant drugs known to increase DA 
neurotransmission such as cocaine (e.g. Wise, 1996), amphetamine (Drevets et 
al., 2001) and methylphenidate (Volkow et al. 1995), it was reliably 
administered over several sessions interspersed with stimulant drug use and the 
number of a1cohol drinks reported tended to exceed doses normally consumed 
in the absence ofthese drugs. 
In addition to tobacco and alcohol, cannabis was also identified as a 
substance that is frequently co-administered with various drugs. However 
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unlike these other drugs its pattern of use did not appear to be systematically 
related to the use of most other substances. While the initiation of cannabis use 
was found to reliably follow alcohol and psilocybin use when it was co-
administered with these substances, the order of cannabis administration did 
not appear to be systematically related to any other substance and in no case 
was cannabis use found to be reliably used over multiple sessions interspersed 
with other substance use. Nevertheless given the high prevalence of cannabis 
co-administration with various other substances the mechanisms and motives 
associated with its propensity to concomitant used with various substances 
c1early warrants further attention. 
The present findings should be interpreted in light of the following 
methodological considerations. First because the sample size was modest, was 
limited to college students and the participants were self-selected these 
findings may not generalise to all college-student drug users. While the present 
study inc1uded drug users with variable levels of experience with different 
substances, further research is required to delineate the SPU patterns of more 
narrowly defined drug using populations. However it is important to note that 
irrespective of the sampling method used or the population targeted, achieving 
a truly representative sample illicit drug users would likely not be feasible. 
Second, because this study relied exclusively on retrospective recall, the 
accuracy of the information reported might be questioned. Previous research 
suggests that when appropriate interview methods are used that substance use 
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self-report data can yield both reliable and valid results (e.g. Fals-Stewart et 
al., 2000; Sobell et al., 1996). Because in the present study participants were 
required to only report on specific events that could be vividly recalled a 
relatively high degree of accuracy would be expected (Sobell et al., 1996). 
However, the validity of these reports were not verified using objective drug 
detection methods and it remains possible that in sorne cases that the extent of 
SPU use may have been under reported (Fendrich et al., 2004). Finally, 
although the level and type of substance use on any particular occasion is 
likely related to numerous factors such as the availability of different 
substances, the presence or absence of drug using peers and the desire the 
achieve certain psychoactive effects (e.g. Sloboda, 2002) the present 
investigation did not systematically address contextual and motivational 
factors surrounding specific patterns of polysubstance use and such issues 
should to be addressed in future investigations. 
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6. Abridging Statement to Study 3 
In study 2 alcohol was found to be widely co-administered with a 
variety of substances and when it was used in combination with the 
psycho stimulant drugs cocaine, methylphenidate or amphetamine its use 
tended to follow a systematic pattern characterized by 1) alcohol being used 
first; 2) subsequent alcohol ingestion being intermingled with psychostimulant 
use and 3) alcohol dose escalation. However, because tobacco was frequently 
co-administered in each of these combinations as weIl as with alcohol alone it 
was not possible to determine the extent to which tobacco use affects alcohol 
administration patterns. In study 3 the effects of nicotine on alcohol self-
administration are directly assessed using a double-blind placebo control 
paradigm. Because nicotine is believed to exert similar neuropharmacological 
effects as other psycho stimulants on DA neurotransmission (e.g. Pontieri et al., 
1996) and alcohol does not appear to significantly alter nicotine's 
pharmacokinetics (Collins et al., 1988; Benowitz et al., 1986), delineating 
nicotine's effect on alcohol administration may help distinguish between 
pharmacodynamie and pharmaeokinetie meehanisms associated with the 
reported inereased aleohol administration with other psyehostimulant drugs. 
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7. Nicotine increases alcohol self-administration in non-dependent male 
smokers 
Sean P. Barrett1, Matthew Tichauerl, Marco Leyton2, Robert O. Pih11,2 
Departments ofPsychologyl and Psychiatry2 Mc Gill University, Montreal 
Canada 
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7.1 Abstract 
Background: Alcohol and tobacco are commonly co-administered, yet little is 
known about the effects of acute nicotine administration on alcohol 
consumption in humans. This study sought to determine how nicotine 
delivered by tobacco smoke influences a1cohol intake in humans using a 
double-blind placebo controlled repeated measures design. Methods: During 
two randomized l20-minute sessions 15 male occasional smokers smoked 4 
nicotine-containing or 4 denicotinized cigarettes at 30-minute intervals. 
Throughout the session, subjects could eam units oftheir preferred alcoholic 
beverage and glasses of water using a progressive-ratio (PR) task. Resu/ts: 
Wi1coxon signed-rank tests indicated that nicotine increased a1cohol self-
administration in a significant proportion of participants (P::::O.03) without 
affecting water consumption (P~O.16). A two-way ANOV A supported this 
observation further, and, compared to denicotinized cigarettes, the nicotine-
containing cigarettes increased PR breakpoints for alcohol but not water, as 
reflected by a Cigarette x Beverage interaction (P::::O.055). Conclusions: The 
present data suggest that acute nicotine administration increases alcohol 
consumption in at least a subset of smokers. 
Key Words: alcohol, nicotine, addiction, self-administration, polysubstance 
use, progressive ratio 
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7.2. Introduction 
The two most commonly abused substances in the general population, 
alcohol and nicotine, are frequently co-administered (e.g., Batel et al., 1995). 
The prevalence oftobacco smoking in a1coholics is thought to be as high as 
90%, compared to less than 30% in the general population (e.g. Sobell et al., 
1990; Romberger and Grant, 2004). Similarly, smokers are 50% more likely to 
drink regularly than adult non-smokers (Kozlowski and Ferrence, 1990). Some 
evidence suggests that these associations reflect an ability of ethanol and 
nicotine administration to increase motivation to obtain the other substance. In 
smokers, acute alcohol administration is consistently reported to increase 
cigarette self-administration (Griffiths et al., 1976; Mello et al., 1980; Keenan 
et al., 1990). In comparison, the converse association is less weIl understood. 
There are several reports that, in rodents, chronic or repeated nicotine 
administration increases alcohol consumption (Smith et al., 1999; Le et al., 
2000; Clark et al., 2001; Soderpalm et al., 2000; Le et al., 2003), but this effect 
has not been uniformly replicated, and decreased a1cohol self-administration 
has also been reported (Sharpe and Samson, 2002). Similarly, acute nicotine 
administration has been reported to increase (Gauvin et al., 1993), decrease 
(Nadal et al., 1998), and have no effect on alcohol intake (Nad al and Sampson, 
1999). Such inconsistent findings may be related to differences in doses, 
administration regimens, or rodent strains (Le at al., 2002). The contribution of 
these factors to the co-administration of nicotine and alcohol in humans 
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remains unknown; to our knowledge, the effect of nicotine on alcohol sdf-
administration in humans has yet to be determined. In a previous investigation 
acute cigarette smoking was found to increase alcohol related responding in 
male social drinkers (Perkins et al., 2000). However because this study did not 
have a placebo smoking condition it was not possible to determine the extent to 
which the findings resulted from a pharmacological effect of nicotine. 
In the present study, we sought to determine how nicotine delivered by 
tobacco smoke influences alcohol administration in humans using a double-
blind placebo controlled repeated measures procedure, in which cigarettes 
made of nicotine-containing or denicotinized tobacco were smoked throughout 
the course of a drinking session. Since nicotine withdrawal may affect alcohol 
craving and consumption in dependent smokers (Palfai et al., 2000; see also 
Cooney et al., 2003; Colby et al., 2004), the present protocol examined non-
dependent occasional smokers to avoid this potential confound. 
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7.3. Methods 
7.31 Participants 
Fifteen non-dependent male 'occasional' smokers (80% Caucasian) 
between the ages of 18 and 30 (mean=22.3 ± 1.8) were recruited from the 
community through advertisements placed in local community newspapers and 
on university websites. AIl were medicaIly healthy, free from current or 
previous mental illness including past or present substance use disorders 
(including nicotine dependence) as determined by a semi-structured clinical 
interview using DSM-IV criteria (First et al., 1995), and aIl scored a 0 on the 
Fagerstrom test for nicotine dependence (Heatherton, 1991). None reported the 
use ofillegal drugs in the 30 days prior to the study, none were daily users of 
tobacco and none had a history of social, occupational or legal problems 
involving alcohol as determined by the Michigan Alcoholism Screening test 
(Pokomy et al., 1972). AIl had reached the minimum age to legaIly consume 
alcohol and tobacco in Quebec Canada and aIl reported having srnoked a 
minimum of four cigarettes throughout the course of a drinking session on at 
least one occasion during the preceding year without experiencing any adverse 
consequences. On average participants reported consuming cigarettes on 2.7 ± 
1.6 days and alcohol on 2.3±0.8 days per week. Average daily consumption on 
days when the substance was used was 5.4 ± 1.6 cigarettes per day and 5.9 
±2.1 drinks per day. Participants were informed that the study involved 
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smoking two different brands of tobacco but not that one of the sessions used 
denicotinized cigarettes. FolIowing a description of the study, alI participants 
provided written informed consent. The study was conducted in accordance 
with the Declaration of Helsinki and was approved by a Mc Gill University 
Research Ethics Committee. 
7.32 Cigarettes 
Prior to the study participants were asked to identify the brand (s) of 
cigarettes that they smoked in order to ensure their unfamiliarity with the 
specifie brands of tobacco used during the testing sessions. Participants were 
informed that on each test day that they would be required to smoke 4 
cigarettes over a two-hour period and that on each test day that a different 
brand of tobacco would be used. AlI cigarettes contained 65 grams of tobacco, 
and were prepared to appear identical. The 'denicotinized' cigarettes were 
prepared using Quest 3 tobacco (Vector Tobacco Inc, USA), and provided 
maximum nicotine yield of 0.05 mg and a tar yield of 10 mg. The 'nicotine' 
containing cigarettes were prepared using Player's Light tobacco (Imperial 
Tobacco Limited, Montreal Canada) and they provided nicotine and tar yields 
of 1.2 mg and 12 mg, respectively. This tobacco was selected for its relatively 
high nicotine to tar ratio and its relatively similar average tar yields to the 
denicotinized tobacco. 
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7.33 Alcoholic Beverages 
Prior to the study sessions, each participant identified a preferred 
alcoholic beverage. The beverage could consist of any 80-proof liquor with a 
non-alcoholic mixer; the same beverage was to be consumed on both days. 
Choice of beverage was restricted to 80-proof liquors due to the high 
variability in the alcohol contents of commercially available brands ofbeer, 
wines and coolers. Participants were informed that on each test day they would 
be required to consume a minimum of one standard drink containing 12 grams 
of 80-proof alcohol (38 ml) and that the maximum dose of alcohol that could 
be consumed on any day was 72 grams or the equivalent of 6-full standard 
drinks. 
7.34 Subjective State 
Participants were administered visual analogue scales (V AS) at 
baseline and immediately following the completion of each cigarette on 
each test day. Items were rated on a ten cm line labelled with the integers 
1-10 and anchored with the words "least" and "most". Items included in the 
VAS were 'high', 'stimulated', 'energetic', 'anxious', 'sedated', 
'intoxicated', 'want alcohol', 'like cigarette', 'crave cigarette', and 'crave 
alcohol'. Similar scales have been widely used to collect information about 
subjective drug effects in humans (e.g. Fishman and Foltin, 1991) and this 
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method of data collection has been demonstrated to have acceptable 
psychometric properties (Bond and Lader, 1974). 
7.35 Design 
The research protocol was comprised of two test sessions. Each was 
conducted between 12pm and 4 pm in the aftemoon, was a minimum of 
three and a maximum of fourteen days apart, was double blind, and was 
given in counterbalanced randomized order. In one condition subjects were 
required to smoke 4 'nicotine' cigarettes and in the second condition 4 
'placebo' cigarettes were smoked. In both conditions, cigarettes were 
smoked at 30-minute intervals throughout the first 90 minutes of the 120-
minute drinking session (t=O min, 30 min, 60 min, and 90 min). An 
participants were tested on separate days. 
Participants arrived for each testing session having abstained from 
cigarettes for a minimum of 12 hours, alcohol for a minimum of 24 hours 
and food and caffeine for a minimum of 4 hours (caffeine-free fluid intake 
was not restricted prior to the study). At this time they provided a breath 
alcohol sample using an a1co-sensor III intoximeter (Thomas Security, 
Montreal, Canada) and a reading of .000 grams of alcohol per 210 liters of 
breath was required to confirm abstinence. Abstinence from tobacco was 
confirmed with a breath carbon monoxide analyzer (Vitalograph Breath 
CO, Lenexa, KS), using a maximum cutoff of 5 parts per million. 
87 
A timeline outlining the sequence of procedures is presented in 
Table 7.1. After completing baseline measures participants were 
comfortably seated in a chair in front of a glass containing 100 ml ofwater, 
a glass containing their preferred alcoholic beverage (containing 38ml of 
80-proof alcohol and 100ml of mix) and a computer on a large table. They 
were told that after smoking their first cigarette of the day that they would 
receive one 'free' alcoholic drink but that all subsequent drinks of either 
type would have to be 'eamed' using a computerized task (described 
below). Participants examined both of the drinks and were given 
instructions on how each could be eamed. They were then told to smoke 
their initial cigarette. For each cigarette consumed they were instructed to 
inhale the smoke as well as to complete the cigarette to the filter. The pace 
and duration of the 'puffs' however was self-determined by the participant. 
Following the completion oftheir first cigarette participants were required 
to complete the VAS and then consume their 'free' alcoholic beverage 
within 10 minutes. The requirement for participants to administer this 
'free' dose of alcohol was included in the protocol to normalize drinking in 
the laboratory, to ensure that alcohol was consumed on both test days and 
to enable comparisons with other studies examining alcohol self-
administration in humans following a pharmacological manipulation 
(Modell et al., 1993; Perkins et al., 2000; Enggasser and de Wit, 2001; 
Petrakis et al., 2002; Ley ton et al., 2004). 
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Immediately after consuming the 'free' dose of alcohol, participants 
could begin using a computerized progressive ratio (PR) task to eam up to 
10 mixed alcoholic drinks, each containing 6 grams (l9ml) of alcohol and 
50 ml ofmix, and up to 10 100ml drinks ofwater. To eam alcoholic 
beverages they would be required to repeatedly press the letters 'd'and 'r' 
a predetermined number of times, while water could be eamed by pressing 
'w' and 'a'. For each type of drink, the first earned beverage required 40 
button presses. To eam subsequent drink of either kind the number of 
required button presses increased one-and-one-halftimes (i.e., 60, 90, 135, 
203,304,456,684 and 1,026, 1,538 clicks). Each type of drink requiredl a 
total of 4,536 button presses to reach the maximum amount aUowed 
(software for this task is available upon request to M.L.). Each session 
lasted until the maximum number of alcohol or water drinks were eamed or 
to a maximum of two hours (exc1uding washroom breaks). While drinks 
could be earned and consumed at any time during the session, there was no 
requirement for participants to eam any drinks during the sessions and they 
were required to remain seated in the testing room until each session was 
completed. Each participant self-determined the rate of administration of 
aU earned beverages, but new drinks of the same kind could not be eamed 
until the previous drink had been completed. Upon completion of the PR 
task, participants were brought a meal and remained in the laboratory until 
their BAC reached 0.04. They were then safely escorted home by one of 
the researchers or by taxi. 
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Table 7.1. Timeline of procedures during both self-administration sessions. 
Time of procedure Tobacco and alcohol administration sessions 
-5 minutes after arrivai Breath alcohol and carbon monoxide analyses 
-10 minutes after arrivai Baseline V AS 
-12 minutes after arrivai Alcohol and water presentation 
-15 minutes after arrivai 1 st cigarette followed by V AS 
lmmediately after V AS completion Prime dose of alcohol 
10 min. after prime alcohol dose Start of PR self-administration task 
30 min. after start of 1 st cigarette 200 cigarette followed by V AS 
60 min. after start of 1 st cigarette 3rd cigarette followed by VAS 
90 min. after start of 1 st cigarette 4th cigarette followed by V AS 
120 min. after start of 1 st cigarette End of PR self administration task 
V AS = Visual Analog Scale. PR = Progressive Ratio. 
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7.4. Results 
7.41 Alcohol and Water Self-Administration 
Because the behavioural PR data increase geometricaUy, the data were 
screened for normality. Using the Kolmogorov-Smimov method, it was 
determined that each PR distribution was satisfactorily normal (Ps>O.05) and 
this was confirmed through an inspection of the skewness and kurtosis of each 
variable (aU absolute values < 2). To screen for outliers, Z-scores were 
calculated on the relative difference scores for PR responding in the two 
conditions (nicotine - denicotinized) and no outliers were identified (alI 
absolute values < 3). Differences in the mean breakpoints for the number of 
butlon presses to eam alcohol and water drinks during the nicotine and placebo 
conditions were analyzed using a 2X2 ANOVA with drink type (water and 
alcohol) and cigarette type (nicotine-containing and denicotinized) as within-
subjects factors. Figure 7.1 presents the PR data for eamed alcohol and water 
during the two smoking conditions. There was a significant main effect of 
drink type (F 1,14=8.79, P:SO.010) reflecting increased responding for alcohol 
relative to water. Analyses also revealed a trend toward a drink X cigarette 
interaction (F 1,14=4.39, P:SO.055) suggesting a greater relative preference for 
alcohol during the nicotine condition. 
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Figure 7.1. Mean PR break points for number ofbutton presses to eam 
alcohol and water drinks during the nicotine and denicotinized tobacco 
conditions. Vertical bars represent ±SEM. Analyses revealed overall increased 
responding for alcohol relative to water (P::SO.Ol) as well as a trend toward a 
relative preference for alcohol during the nicotine condition (P::SO.055). 
Table 7.2 presents the number ofwater and a1cohol units consumed by 
each participant on each test day. Because statistical outliers were identified 
(absolute Z score> 3) in the relative changes in water (participant 7) and 
a1cohol consumption (participant 12) during the two test conditions, these data 
were analysed using non-parametric Wilcoxon signed-rank tests. The analyses 
revealed that a significant proportion of participants increased alcohol 
consumption in the nicotine condition relative to the denicotinized condition 
(Z=-2.13, p::SO.03), while water consumption was not systematically different 
in the two conditions (Z=-1.41, p~O.16) (Figure 7.2). 
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Table 7.2 Number ofwater and alcohol units consumed during PR task in the 
two conditions. Difference values reflect changes in consumption over the two 
sessions (nicotine-placebo). Partially completed units were weighted as ~ unit. 
Subject Units of Units of Difference Units of Units of Difference 
water water in water alcohol alcohol in number 
-nicotine -placebo units -nicotine -placebo ofalcohol 
consumed consumed 
1 5 4 +1 8 5 +3 
2 0 0 0 10 6.5 +3.5 
3 0 0 0 10 10 0 
4 4 3 +1 10 9 +1 
5 0 0 0 10 8 +2 
6 2 2 0 2 1 +1 
7 0 10 
-10 10 5 +5 
8 7 9 
-2 8 7 +1 
9 6 6 0 8 6 +2 
10 3 5 
-2 0 0 0 
11 0 1 
-1 5 4 +1 
12 4 3 +1 2 9.5 -7.5 
13 5 6 
-1 8 8 0 
14 7 10 
-3 7 6.5 +0.5 
15 2 1 +1 10 8.5 +1.5 
12 
10 
[El Increase 0 No change ._Decreas~J 
8 
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Figure 7.2 Number of subjects increasing, not changing, or decreasing alcohol 
and water ingestion during the nicotine test session. A significant proportion of 
subjects increased alcohol consumption in the nicotine condition, while water 
consumption was not systematically different in the two conditions. 
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7.42 Subjective Response to Smoking 
The subjective effects of the nicotine and placebo cigarettes prior to 
alcohol consumption were examined by comparing the relative changes from 
baseline in each VAS score following the tirst cigarette of each test day using 
paired samples t-tests. One subject did not provide a post-cigarette rating for 
'high' on one of the test days limiting analyses for this variable to fourteen 
participants. 
Ingestion of the tirst nicotine cigarette was associated with signiticantly 
increased ratings of 'high' [t (13) = 2.23, P:<s0.044], 'stimulated' [t (14) =2.55, 
P:<s0.023], 'sedated' [t (14) =3.06, P:<s0.009], and 'intoxicated' [t (14) = 2.98, 
P:<sO.OlO] relative to the placebo cigarette. No systematic differences were 
evident for ratings of' energetic', 'anxious', 'want alcohol', 'like cigarette', 
'crave cigarette' or 'crave alcohol' (Ps >0.1). Because simultaneous nicotine-
induced increases in 'stimulated' and 'sedated' were not expected, bivariate 
correlations were performed among the variables signiticantly affected by 
nicotine administration. Nicotine-induced changes in 'stimulated' and 
'sedated' were not related to each other [r=-0.015; P;:::0.96], but each was 
positively associated with change in 'intoxicated' [stimulated-intoxicated: 
r=0.70; P:<s0.004; sedated-intoxicated: r=0.53; P:<s0.043], suggesting that there 
may have been differences in how the participants interpreted nicotine's 
intoxicating effects. Nicotine-induced change in 'high' was not signiticantly 
correlated with change in 'intoxicated' [r=0.44; P;:::0.111], 'sedated' [r=0.43; 
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P~0.128] or stimulated [r=O.50; P~O.067]. Changes in none ofthese variables 
were related to overall nicotine related changes in alcohol consumption 
[Rs<.2;Ps>O.5]. Relative differences in subjective responses following the 
initiation of alcohol consumption could not be meaningfully analysed because 
of substantial variability in both the rate and frequency of alcohol 
administration throughout the testing sessions. 
7.43 Cigarette Administration 
In order to determine if the rates of self-administration for the nicotine-
containing and denicotinized cigarettes significantly varied a 2X2 repeated 
measures ANOV A was performed using time to complete each cigarette (1 st, 
2ud, 3rd, 4th) and cigarette type (nicotine-containing and denicotinized) as 
within subjects factors. There were significant main effects for time of 
cigarette completion (F 3,42=11.77, P:SO.001), reflecting the tendency for the 
first cigarette of each test day to be completed more quickly than subsequent 
cigarettes, as weIl as for cigarette type (F 1,14 =21.91, P:SO.001) reflecting 
slower administration of the nicotine-containing cigarettes (Figure 7.3). The 
cigarette type by time to completion interaction was not statistically significant 
(P>O.1). 
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Figure 7.3 Mean time to complete each nicotine-containing and denicotinized 
cigarette in seconds. Vertical bars represent ±SEM. 
Because VAS ratings were collected immediately following the 
completion of each cigarette, we performed a series of post-hoc stepwise 
regressions to determine if time to cigarette completion was associated with 
subjective state. For each cigarette, aIl corresponding subjective ratings were 
entered as potential predictors for the length oftime of completion. For both 
the second (r=.563; p<O.029) and third (r=.544; p<O.036) nicotine-containing 
cigarettes the sole statistically predictor for time of cigarette completion was 
the respective 'intoxicated' rating, indicating that relatively high levels of 
intoxication were associated with a relatively slower pace of smoking. There 
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was also a significant association between time of completion of the final 
'denicotinized' cigarette and the corresponding 'like drink' rating (r=.614; 
p<O.O 15), indicating that high levels of 'drink liking' were associated with a 
slower pace of smoking for this cigarette. No variables were found to be 
significantly associated with the time of completion of any of the other 
cigarettes (Ps>O.05). 
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7.5 Discussion 
In this study, nicotine administration via tobacco smoke increased 
alcohol consumption in a significant majority of the participants. While these 
findings are consistent with data demonstrating increased overallieveis of 
alcohol consumption among smokers (e.g., Batel et al., 1995), to our 
knowledge this is the first placebo-controlled study to demonstration that 
nicotine acutely increases a1cohol ingestion in humans. 
Although the present study did not directly assess the mechanisms 
underlying nicotine's ability to potentiate alcohol self-administration, nicotine 
may increase alcohol ingestion through a neuropharmacological action. The 
appetitive reinforcing properties of both drugs have been related to midbrain 
dopamine (DA) transmission (e.g., Di Chiara and Imperato, 1988), and 
evid~nce suggests that nicotine and a1cohol may overlap in the mechanisms by 
which they promote DA release. In laboratory animaIs, both drugs appear to 
promote midbrain DA transmission through stimulation of nicotinic 
acety1choline (NACh) receptors in the ventral tegmental area (e.g. Bolmqvist 
et al., 1997; Soderpalm et al. 2000; Tizabi et al. 2002) and the blockade of 
NACh receptors decreases alcohol self-administration in animaIs (Bolmqvist et 
al., 1996; Le et al., 2000) and a1cohol drinking desire in humans (Chi and de 
Wit, 2003). Moreover, nicotine is also believed to enhance the DA response to 
other reinforcers by facilitating burst firing of the DA neurons (Rice and 
Cragg, 2004; Zhang and Sulzer, 2004) raising the possibility that nicotine 
98 
increases a1cohol responding by potentiating alcohol-related DA 
reinforcement. Finally, noradrenaline transmission has also been proposed to 
affect alcohol ingestion (Amit & Brown, 1982; Le et al., 2005), and nicotine 
increases noradrenaline release as well (e.g. Grenhoff and Svensson, 1989). 
An alternative means by which nicotine may affect alcohol 
administration is through a pharmacokinetic interaction. Evidence suggests that 
nicotine alters mechanisms involved in hepatic alcohol metabolism (Schoedel 
and Tyndale, 2003) as well as rates of gastric emptying (Gritz et al., 1988), 
factors that might alter alcohol absorption and distribution. However there is 
little direct empirical evidence to support this. Nicotine has failed to alter 
alcohol's pharmacokinetic properties in laboratory animaIs (Hisaoka and Levy, 
1985; Collins et al., 1988) and evidence from human studies has been 
inconsistent (Perkins et al., 1995; Kouri et al., 2004). Thus there is currently 
insufficient evidence to definitively exclude or support a pharmacokinetic 
explanation for our findings. 
A relatively unexpected finding in the present study was that cigarette 
administration rates varied both within and between conditions. Nicotine-
containing cigarettes were smoked at a slower rate than denicotinized tobacco, 
and for both types of cigarettes the first cigarette was smoked significantly 
faster than all others (Figure 7.3). Although the relatively faster pace of 
denicotinized tobacco administration is consistent with previous research 
indicating that smokers modify their 'puffing' behaviour to achieve and 
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maintain desirable nicotine levels (for review see Scherer, 1999), because 
changes in smoking rates were approximately equivalent in both conditions, it 
is unlikely that within session differences can be solely explained by attempts 
to optimize nicotine levels. An alternative explanation is that alcohol-related 
effects and/or intake may have influenced smoking rates following the 
initiation of drinking. This possibility appears to be consistent with post-hoc 
findings that suggest the rates of administration of sorne cigarettes were 
associated with levels of intoxication (2nd and 3rd nicotine cigarette) or drink 
liking (4th placebo cigarette). While concurrent access to alcohol may have 
contributed to the variability in smoking rates, allowing participants to choose 
when they wanted to drink relative to tobacco administration was important to 
ensure the ecological validity of the findings. 
The present results should be interpreted in light of the following 
methodological considerations. First, because we wished to control for 
potential confounding effects of nicotine withdrawal, participants were 
minimally nicotine dependent and the degree to which these results are 
applicable to heavier smokers remains unknown. Alternative designs to test 
the effects of nicotine on alcohol self-administration in dependent smokers are 
clearly needed. Second, the present protocol only tested men and it is possible 
that the findings may not extend to women. Evidence suggests that women are 
less sensitive to the pharmacological effects of nicotine than men (Perkins et 
al., 2002; Perkins et al., 1999) and that smoking may differentially affect 
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alcohol consumption in men and women (Perkins et al., 2000). Additional 
research should be directed toward examining possible gender differences in 
a1cohol-nicotine interactions. Third, since variability in the rate and frequency 
of a1cohol self-administration was inherent in the research protocol, it was not 
possible to systematically assess the subjective effects associated with 
combined fixed doses of a1cohol and nicotine. While previous research 
suggests that nicotine co-administration enhances several positive alcohol-
related effects (Kouri et al., 2004; Perkins et al., 1995) as weIl as alcohol 
craving (Kouri et al., 2004) the present design did not allow us to determine 
how subjective effects were associated with changes in self-administratÏlon. It 
should be noted, however, that participants in the current study reported 
several discernable subjective effects of nicotine relative to placebo prior to 
alcohol ingestion including increased feelings of high, stimulation, and 
intoxication. Fourth, because the protocol imposed limits on the amount of 
alcohol consumed and the length of the drinking sessions it is possible that 
ceiling and floor limits may have influenced the magnitude of the observed 
effect. lndeed, in five of eleven cases where more alcohol was consumed 
during the nicotine than placebo condition, participants consumed the 
maximum possible dose during the nicotine session; among the three 
participants that ingested equal amounts of a1cohol on both test days, one drank 
the minimum amount allowed on both days and a second consumed the 
maximum on both days. Nevertheless, despite this a significant majority of 
participants exhibited increased a1cohol consumption during the nicotine 
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condition. Finally although the sample size in this study was mode st (n==15), it 
was within the norms for investigations assessing within subject drug effects in 
hum ans and small sample size is typically associated with increased incidents 
oftype II but not type l error. 
In conclusion, to our knowledge, the present study is the first to 
demonstrate that nicotine administration via tobacco smoke increases alcohol 
self-administration in at least sorne smokers using a blinded placebo-controlled 
study. Because concurrent tobacco use may lead to alcohol dose escalation 
during drinking sessions, this practice may place sorne individuals at elevated 
risk for developing alcohol related problems. Future studies are needed to 
further delineate the effects and consequences of nicotine and alcohol co-
administration and to extend these findings to other groups of smokers. 
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8. Abridging Statement to Study 4 
Evidence that tobacco administration acutely increases alcohol self-
administration is consistent with the hypothesis that alcohol co-administration 
with psychostimulant drugs may increase a1cohol ingestion through a DAergic 
action. However because this study did not directly assess nicotine' s effects on 
DA neurotransmission, the precise mechanisms involved in nicotine's 
augmentation of alcohol intake could not be definitively identified in the 
preceding investigation. In order to further examine the possible role of DA in 
mediating changes to alcohol self-administration, in study 4 we directly 
examined the effects of selectively decreasing DA availability on a1cohol 
intake using a similar self-administration paradigm to that used in study 3. 
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9. The effect of acute dopamine precursor depletion on alcohol self-
administration in men. 
Sean P. Barrettl, Robert O. Pihl l,2, Chawki Benkelfat2, Caroline Brunellel, 
Simon N. Young2, Marco Leyton2 
Departments ofPsychologyl and Psychiatrl Mc Gill University, Montreal 
Canada 
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9.1 ABSTRACT: Rationale and Objective: Dopamine (DA) is believed to 
mediate aspects of human alcohol ingestion yet little is known about the degree 
to which this is affected by individual differences. This study sought to clarify 
DA's role in alcohol self-administration in a heterogeneous sample ofnon-
dependent drinkers using the acute phenylalanine/tyrosine depletion (APTD) 
method. Methods: Sixteen men with variable individual and family drinking 
histories completed 4 testing sessions. In one session, cardiac responses to the 
acute ingestion of 0.75 g/kg of alcohol were determined. In 3 randomized 
double-blind sessions participants ingested a nutritionally balanced (BAL) 
amino acid (AA) mixture, a mixture deficient in the DA precursors, 
phenylalanine and tyrosine, and APTD followed by the immediate DA 
precursor L-DOPA (Sinemet, 2 x 100mg/25mg). Beginning 5 hours following 
each AA ingestion participants completed self-administration sessions where 
units of their preferred alcoholic beverage and glasses of water could be eamed 
using a progressive ratio task. Resu/ts: Overall alcohol self-administration was 
reduced in both the APTD and APTD + L-DOPA conditions relative to the 
BAL condition. There were no significant differences in water administration 
among the AA conditions. Stepwise linear regressions were used to determine 
how the observed changes in alcohol self-administration were related to 
various alcohol-related variables. For both APTD and APTD+L-DOPA 
induced changes in alcohol self-administration the sole statistically significant 
predictor was ethanol-induced cardiac change. Post hoc analyses revealed a 
robust effect of AA condition on alcohol consumption in individuals with a 
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high cardiac response to ethanol ingestion but no differences in alcohol intake 
among those displaying a minimal cardiac response. Conclusions: The findings 
suggest that DAergic manipulations affect alcohol self-administration in a 
subset of drinkers, and that this may be predicted on the basis of their cardiac 
response to acute alcohol ingestion. 
Keywords: alcohol, addiction, motivation, self-administration, dopamine, 
heart rate, progressive ratio. 
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9.2 Introduction 
Like virtually every other addictive substance, alcohol administration 
increases dopamine (DA) neurotransmission in mesocorticolimbic regions 
(e.g., Samson et al 1992) an action believed to be involved in the reinforcing 
effects of various abused drugs induding alcohol (Di Chiara & Imperato, 
1988). In rodents, the initiation of alcohol ingestion is time-Iocked to increases 
in DA overflow (Weiss et al., 1992), and DA antagonists attenuate intake 
(Rassnick, 1992; Files et al., 1998). In humans, functional neuroimaging 
studies suggest that alcohol ingestion increases DA release (Boileau et al., 
2003) while decreasing DA neurotransmission leads to overall reductions in 
alcohol self-administration in healthy social drinkers (Leyton et al., 2000a; 
Enggasser & de Wit, 2001) and in patients meeting criteria for alcohol 
dependence (Modell et al., 1993). Despite the consistency of the se findings, 
DAergic reductions do not appear to decrease alcohol consumption in aIl 
subjects (Modell et al., 1993; Enggasser & de Wit, 2001) and a growing body 
of evidence suggests that DA's role in regulating alcohol intake may differ 
across drinking populations. 
Several distinct alcoholism subtypes have been proposed (Windle & 
Scheildt, 2004; Babor et al., 1992; Cloninger, 1987) and numerous recent 
findings suggest a heterogeneous role for DA in alcohol reinforcement in 
different alcohol dependent populations. Genetic markers for separate 
DAergic and GABAergic pathways for alcoholism have been described (Noble 
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et al., 1998; Young et al., 2005) and neuroanatomical findings suggest that 
central DAergic abnorrnalities may not be evident in all alcoholics (e.g. Tupala 
& Tiihonen, 2004; 2005). Moreover, there is considerable variability in the 
response to pharrnacotherapies that directly or indirectly target DA 
neurotransmission in the treatment of alcoholism (e.g. Walter et al., 2001) and 
relapse to drinking following administration of the DAergic drug flupenthixol 
has been proposed to be associated with the degree of DA involvement in 
alcoholic symptom presentation (Walter et al., 2001). 
Evidence from non-dependent drinkers also suggests that there may be 
individual differences in the role of DA in alcohol reinforcement. For exarnple, 
non-dependent heavy drinkers tend to experience more stimulant and less 
sedative alcohol-related effects relative to light drinkers (e.g. Holdstock et al., 
2000; King et al., 2002) and it has been suggested that this may in part reflect a 
differential DAergic response to alcohol (King et al., 2002). It has also been 
proposed that individuals with an exaggerated heart rate (HR) response to the 
ascending limb of the blood alcohol concentration curve display an increased 
sensitivity to alcohol's DA effects and that a heightened HR response to 
alcohol may represent a peripheral marker to identify individuals that exhibit 
DA-specific alcohol reinforcement (Brunelle et al., 2004; Conrod et al., 2001). 
Although this hypothesis is supported by findings that alcohol-induced cardiac 
effects are proportional to both DA release (Boileau et al., 2003) and alcohol-
related stimulant effects (Brunelle et al., 2005) direct evidence linking 
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alcohol's HR effects with its DA-mediated reinforcing effects is currently 
lacking. In an effort to better c1arify DA's role in human alcohol self-
administration, the present investigation examined the effect of decreasing DA 
neurotransmission on alcohol self-administration in a sample of non-dependent 
male drinkers who varied across a number of domains inc1uding CUITent 
drinking patterns, individual and family drinking histories and alcohol-induced 
cardiac responsivity. 
DA neurotransmission was decreased using the acute 
phenylalanine/tyrosine depletion (APTD) method (Moja et al., 1996; Sheehan 
et al., 1996; McTavish et al., 1999; Leyton et al., 2000b). APTD has been 
demonstrated to decrease extracellular DA levels in humans both during basal 
conditions (Montgomery et al., 2003) and in response to drug administration 
(Leyton et al., 2004a). APTD offers several advantages as a research tool. 
Because its behavioural effects develop within three hours and are transitory 
this technique can be used on an outpatient basis (McTavish et al., 2001 a). 
APTD has also been demonstrated to be well tolerated in a variety of normal 
and clinical human populations (e.g. Leyton et al., 2000b; Mctavish et al., 
2001) and it appears to be devoid of many side effects often associated with 
other treatments that reduce DA transmission. Moreover the neurochemical 
effects of APTD appear to be specific to the catecholamines, with the possible 
exception of sorne trace amines (Palmour et al., 1998; McTavish et al., 1999), 
and by acting pre-synaptically, APTD should decrease neurotransmission at an 
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DA receptor subtypes. In a condition, participants ingested both the APTD 
mixture and the direct DA precursor, L-DOPA. It was predicted that L-DOPA 
prevent effects of APTD. 
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9.3 Materials and methods 
9.31 Participants 
Male participants between the ages of 19 and 30 were recruited from 
the community through advertisements placed in local community newspapers 
and on university websites. An initial telephone interview excluded those with 
self-reported medical or psychiatrie illness, with a history of adverse 
consequences from alcohol consumption, with CUITent substance abuse or 
dependence, with a lack of familiarity with the alcohol doses to be 
administered or with insufficient knowledge about the history of alcohol-
related problems in their biological relatives. Potential participants weœ told 
that the study would involve four full days of testing plus an additional half 
day for screening and that they would be required to remain abstinent from aIl 
prescription and illicit drugs throughout the duration of the study. Twenty-nine 
individuals meeting these criteria were invited to the laboratory to complete the 
full screening. AIl were assessed by a routine medical exam and standard blood 
work and a11 completed a psychiatrie evaluation using a semi-structured 
clinical interview using DSM-IV criteria (First et al., 1995). Participants also 
completed the individual and parental form of the Michigan Alcoholism 
Screening Test (MAST, Pokomy et al., 1972; FMAST, MMAST, Crews and 
Sher, 1992), and provided further details about the alcohol use histories of aIl 
first- (parents and siblings) and second- (grandparents, parent's siblings and 
half-siblings) degree relatives using the Family History Research Diagnostic 
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Criteria (Andreas en et al., 1977). Eighteen individuals were deemed eligible to 
complete the study. Those invited to participate were medically healthy, were 
free of aIl current Axis 1 disorders including Major Depressive Disorder, 
Bipolar disorder, Psychosis, Psychoactive Substance Use Disorders, Panic 
Disorder, and Obsessive Compulsive Disorder, and were able to provide 
information about the presence or absence of current or past alcohol abuse or 
dependence in each of their first and second degree relatives. The study was 
carried out in accordance with the Declaration of Helsinki, and was approved 
by the Mc Gill University Health Centre's Research Ethics Board. AU subjects 
provided written, informed consent prior to their participation and were 
compensated C$21 0 upon completion of the protocol. 
9.32 Amino Acid Administration 
There were three test sessions where participants ingested AA 
mixtures. Each was conducted a minimum of three days apart, was double 
blind and in counterbalanced randomized order. Participants ingested APTD, 
APTD foUowed by L-DOPAICarbidopa (100mg/25mg, administered p.o. at 1 
and 3 hours after AA ingestion), or a nutritionally balanced mixture (BAL). On 
the APTD and BAL test days participants ingested identicallooking placebo 
pills in lieu of L-DOP A/Carbidopa. The APTD mixture' s composition, 
preparation and administration were based on a 102.3 gm balanced mixture 
with phenylalanine and tyrosine withheld (Young et al., 1985; Leyton et al., 
2000b). 
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On the day prior to testing, participants were fed a low protein diet 
supplied by the investigators. They were also asked to refrain from drinking 
any alcohol on this day, to restrict themselves to 3 cups of caffeine containing 
beverages, and to fast from midnight. On the moming of each test day 
participants arrived at 8.30. At this time they provided a urine sample that was 
used to ensure that they were drug free (Triage ™ Panel for Drugs of Abuse, 
sensitive to cocaine, amphetamines, barbiturates, benzodiazepines, ;19_ 
tetrahydrocanabinol, opiates, and phencyclidine. Biosite Diagnostics ©, San 
Diego, CA, USA) as weIl as a breath alcohol sample using an alco-sensor III 
intoximeter (Thomas Security, Montreal, Canada) to ensure alcohol abstinence. 
9.33 Plasma Amino Acid Measurements 
Plasma samples were collected at moming baseline as weIl as 4.5 hours 
post-AA ingestion. Plasma phenylalanine and tyrosine concentrations were 
determined by HPLC with precolumn derivatization and fluorometric 
detection. Plasma samples were missing from 8 of the 48 test days. 
9.34 Alcoholic Beverages 
Prior to the study, each participant selected an a1coholic beverage to 
consume on each AA test day. The beverage could consist of any 80-proof 
liquor (inc1uding preferred brand) and a non-a1coholic mixer, and the same 
beverage was to be consumed on an three test-days. Choice of alcoholic 
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beverage was restricted to 80-proof liquors due to the high variability in the 
alcohol contents of commercially available brands ofbeer, wines and coolers, 
and the only restrictions on the choice of non-alcoholic mixer was that it 
contained no caffeine or aspartame (which contains phenylalanine). 
Participants were informed that on each test day they would be required to 
consume a minimum of the equivalent of one standard drink containing 12 
grams of alcohol, and that the maximum dose of alcohol that could be 
consumed on any day was 72 grams or the equivalent of 6-full standard drinks. 
9.35 Alcohol Exposure and Administration 
The alcohol administration phase of the study was scheduled to 
commence 5 hr after the AA ingestion to coincide with the time frame that 
other APTD pharmacological and behavioural effects have been observed 
(e.g., McTavish et al., 2001; Harmer et al., 2001; Leyton et al., 2000b, 
2004a). Fifteen minutes prior to each alcohol administration session 
participants were comfortably seated in a chair in front of a computer on a 
large table and were presented with a glass containing 100 ml of water. 
Participants were instructed to handle the glass, and were told to look at 
and smell the drink but not to consume any of it. After three minutes had 
elapsed the subject completed a subjective assessment. Approximately 7.5 
minutes prior to alcohol administration participants were presented with 
their preferred alcoholic beverage (containing 12 grams of alcohol and 
100ml ofmix). Again they were instructed to handle the glass and were 
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told to look at and smell the drink but not to consume any of it and after 
three minutes had elapsed they completed another subjective assessment. 
Following the cue exposure, participants were instructed to 
consume the previously presented alcoholic beverage within 10 minutes. 
This initial priming drink was included to measure responses to a fixed 
dose of alcohol, to normalize drinking in the laboratory, to model the 
influence of an initial drink on subsequent drinking behaviour in the self-
administration paradigm, and to enable comparisons with other studies 
using a similar self-administration paradigm (Petrakis et al. 2002; Barrett et 
aI2005c). 
9.36 Alcohol and Water Self-administration 
Following the consumption ofthe first alcoholic drink, participants 
were given the opportunity to work on a computer to earn up to 10 mixed 
alcoholic drinks, each containing 6 grams of alcohol and 50 ml of mix 
and/or 10 100ml drinks ofwater using a progressive ratio (PR) task. To 
earn each alcoholic beverage participants were required to repeatedly press 
the letters 'd'and 'r' a predetermined number oftimes, while water was 
similarly eamed using the letters 'w' and 'a'. For each type of drink, the 
first eamed beverage required 40 button presses and the number of button 
presses required to eam each subsequent drink of the kind increased one-
and-one-halftimes (Le., 60,90, 135,203,304,456,684 and 1,026, 1,538 
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clicks). Each type of drink required a total of 4,536 button presses to reach 
the maximum amount allowed. Each session lasted until the maximum 
number of alcohol or water drinks were eamed or to a maximum of two 
hours. Participants were not required to eam any drinks during the 
sessions, but were required to remain seated in the testing room until each 
session was completed. Upon completion of the self-administration task, 
participants were brought a high protein meal and remained in the 
laboratory until their BAC reached 0.04. They were then safely escorted 
home by one of the researchers or by taxi. 
9.37 Subjective State 
Participants were administered visual analogue scales (V AS) 
immediately prior to ingesting the AA mixture, following water exposure, 
following a1cohol exposure and then following every 12 grams of alcohol. 
Items were rated on a ten cm line labelled with the integers 1-10 and 
anchored with the words "least" and "most". Items included in the VAS 
were 'high', 'euphorie', 'sedated', 'intoxicated', 'rush', 'excited', 
'anxious', 'energetic', 'mind racing', 'alert', 'like drink', 'want drink', 
'urge for drink', 'desire drink', and 'crave drink'. In addition, the final 13 
participants who completed the protocol also verbally rate their level of 
nausea immediately prior to receiving their priming dose of alcohol on 
each test day using a 10-point scale (1 = not at all to 10= extreme). This 
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nausea measure was added to the protocol after a participant that withdrew 
from the study cited feelings of nausea as his reason for termination. 
9.38 Alcohol induced cardiac reactivity 
On a fourth test day, participants' cardiac reactivity to alcohol ingestion 
was measured. Participants arrived at the laboratory in the moming, having 
fasted a minimum of 4 hours and abstaining from alcohol for a minimum of 24 
hours. A ten-minute sober baseline HR measurement was taken using the Polar 
8810 monitor (Polar electro, Finland). Participants then consumed 0.75 grams 
of pure ethanol per kg of body weight mixed with 5 parts orange juice 
separated into two glasses. The time interval for the ingestion of each glass 
was 7.5 minutes. Following a 15-minute wait, HR was again measured for 10 
minutes (between 30-40 minutes post-onset of alcohol ingestion). During each 
HR measurement, the first five minutes were not used in the calculation of the 
average HR as they served to control for adjustment to the procedure. 
Participants were explicitly told to remain still, and compliance to this 
instruction was verified through observation via a camera placed in the testing 
room. Ethanol-induced cardiac change was calculated by subtracting the 
baseline HR value from the intoxicated HR value and the dividing the 
difference by baseline HR in order to produce a percent change value. This HR 
measurement procedure has been demonstrated to provide a reliable and valid 
index of ethanol-induced cardiac change in male social drinkers (Conrad et al., 
2001; Brunelle et al., 2004). 
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9.39 Statistical Analyses 
All data were analyzed using the statistical software package for the 
social sciences (SPSS), version 11.0. The primary outcome variables in this 
study were the number of button presses during the PR task to eam alcohol and 
water in each AA session. Because the behavioural PR data increase 
geometrically, these data were screened for normality using the Kolmogorov-
Smimov method prior to analyses, and it was determined that logarithmic 
transformations were necessary in order for each variable to satisfy the 
normality assumption. The data were initiaUy analyzed using a 3x2 repeated-
measures ANOV As using AA condition (BAL, APTD, & APTD+L-DOPA) 
and beverage type (water & a1cohol) as within subjects factors. Unless 
otherwise specified aU other comparisons involving AA-specific effects were 
conducted using repeated-measures ANOV As using AA condition (BAL, 
APTD, & APTD+L-DOPA) as the within subjects factor and pairwise 
comparisons were evaluated with Least Significant Difference tests. Step-wise 
linear regressions were used to examine how changes in alcohol self-
administration in the APTD and APTD + L-DOPA conditions relative to the 
BAL condition were related to various a1cohol-related variables. Correlations 
among the alcohol-related variables were evaluated with Pearson's correlation 
coefficient. Family-wise Bonferroni corrections were applied when related 
analyses were conducted on several variables. 
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9.4 Results 
9.41 Participants 
Sixteen participants (age: 21.8±3.3 years old) completed the entire 
protocol, and two discontinued during their first AA test day. One withdrew 
due to experiencing nausea following the ingestion of the AA mixture 
(APTD+L-DOPA) while the second participant withdrew after completing the 
BAL session, citing concems about the dietary restrictions of the study. Table 
1 presents the alcohol-related data for the participants completing the study. 
Although none met DSM-IV criteria for CUITent a1cohol abuse /dependence, as 
Table 9.1 shows individual and family drinking histories varied considerably. 
Table 9.1. lndividual and family drinking characteristics 
Subject Weekly Weekly MAST Alcohol Alcohol-
alcohol drinks alcohol drinks dependent induced cardiac 
-cuITent l _peak2 relatives3 change 
1 6 18 0 0 +2.3% 
2 7 7 0 0 +16.67% 
3 7 7 0 0 +15.80% 
4 2 8 0 0 +26.92% 
5 20 20 0 3 +22.92% 
6 3 24 0 3.5 -6.00% 
7 13 30 0 0 +11.48% 
8 8 18 0 0 +1.61% 
9 13 30 0 3 +4.48% 
10 14 28 0 2.5 +6.90% 
11 18 48 5 3 +8.16% 
12 16 30 4 2 +5.36% 
13 2 24 2 0 +14.00% 
14 17 18 0 0 +18.03% 
15 9 24 2 3 +11.86% 
16 9 26 0 0 +25.45% 
. . 2 .. Reflects weekly dnnkmg amounts over the precedmg 30 days. Reflects weekly drmkmg amounts dunng month of 
heaviest use. 3 Number of relatives with a Iifetime diagnosis of alcohol dependence. First-degree relatives received a 
weight of 1 and second-degree relatives were weighted 0.5. 
119 
9.42 Amino Acid Depletion 
Figure 9.1 presents plasma tyrosine and phenylalanine at moming 
baseline and 4.5 hours following ingestion of the AA mixture for each test day. 
Relative to the moming baseline the BAL mixture increased plasma 
phenylalanine by 237% and tyrosine by 166%. APTD decreased phenylalanine 
to 16% and tyrosine to 27% ofmoming levels. The administration of L-DOPA 
did not affect the degree of AA depletion produced by APTD. 
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Figure 9.1: Plasma tyrosine and phenylalanine levels at morning baseline and 4 hours 
following AA ingestion each AA test condition. 
9.43 Nausea 
Analyses revealed no significant differences among the AA conditions 
in reported levels ofnausea; F(2, 24) = 1.34, p=0.281. 
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9.44 Alcohol and Water Self-Administration 
Analyses revealed main effects of AA condition beverage type F(l, 
15)=4.56, p~0.05, as well as a significant AA condition X beverage type 
interaction F (2,30)=3.52, p~0.04 (Fig 2.) Because there appeared to be 
systematic differences in the administration of alcohol and water, additional 
analyses were performed considering each beverage type separately. There 
were no significant differences in water administration among the AA 
conditions (F (2, 30)= .82, p~0.449). There was however a significant main 
effect of AA condition for alcohol self-administration (F (2,30) =4.7546 
p~0.016), reflecting significantly greater alcohol intake on the BAL test 
session relative to the APTD (p~0.03) and APTD+L-DOPA (p~O.OI) 
conditions. Beverage administration on the APTD and APTD+L-DOPA 
sessions did not differ significantly (p~0.35). 
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Figure 9.2. Log transformed P R values for alcohol and water self-
administration across AA conditions. Alcohol self-administration was 
significantly reduced in both the APTD and the APTD + L-DOPA conditions 
relative to BAL. Water administration did not significantly differ among the 
conditions. 
To determine whether the observed changes in alcohol self-
administration were related to various alcohol-related variables stepwise linear 
regressions were performed using CUITent and peak number of weekly 
alcoholic beverages consumed, number offirst- and second-degree relatives 
with alcohol dependence, MAST score, and alcohol-induced HR change scores 
as potential predictor variables. For both APTD (r=O.713; p:SO.002) and 
APTD+L-DOPA (r=O.651; p:SO.006) induced changes in alcohol self-
administration relative to the BAL condition the sole statistically significant 
predictor was ethanol-induced HR change. In order to verify specificity of 
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these relationships as weIl to determine the associations among the alcohol-
related variables a series ofPearson's bi-variate correlations were performed. 
Because these analyses were preformed using 7 different variables the 
threshold for statistical significance was adjusted to P::;O.007 using a family-
wise Bonferroni correction. 
Results from the correlational analyses are presented in Table 9.2. 
Alcohol-induced HR change was associated with both APTD and APTD+L-
DOPA induced changes in alcohol self-administration (p::;O.007). However no 
other variables were associated with change in drinking or with alcohol-
induced cardiac change (Ps2:0.09). While there was a significant positive 
correlation between peak number of weekly drinks and MAST score, no other 
relationships exceeded the threshold for statistical significance (Ps2:0.007). 
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Table 9.2. Correlations among alcohol related variables. 
Weekly MAST Alcoholic Alcohol Change in Change in 
drinks Relatives cardiac alcohol alcohol 
-peak change eamed eamed 
(APTD) (APTD+L-
DOPA) 
Weekly 
drinks 0.52* 0.30 0.41 0.06 -0.16 0.26 
-current 
Weekly 
drinks 0.65** 0.56* -0.36 -0.35 -0.05 
-peak 
MAST 0.36 -0.17 -0.08 -0.18 
Alcoholic 
Relatives -0.40 -0.40 -0.04 
A1cohol 
cardiac 0.71** 0.65** 
change 
Change in 
alcohol 0.22 
(APTD) 
*p ~ 0.05, ** p ~ 0.007 
To further examine the relation between ethanol-induced cardiac 
changes in alcohol self-administration, a median split of the ethanol induced 
cardiac change distributions was performed to create a group ofhigh (n=8) and 
low (n=8) HR responders. High HR responders displayed a mean ethanol-
induced HR increase of 19%( ± 5.2%), while the low HR group had an average 
HR increase of 4.3% (±5.5). Repeated-measures ANOVAs were then 
performed to determine if these groups exhibited differential responses to the 
AA conditions. In high HR response group there was an overall effect of the 
AA condition on alcohol self-administration (F(2, 14) = 4.41; p::::O.05) with 
participants earning significantly more alcohol in the BAL condition relative to 
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either the APTD (p~O.O 17) or APTD+L-DOP A (p~0.024) conditions. In 
contrast, in the low HR response group no differences in a1cohol self-
administration were revealed among any of the AA conditions. Moreover, 
independent samples t-tests revealed that although the low HR group earned 
significantly greater quantities ofa1cohol during the APTD (t=2.51; p~0.024) 
and APTD + L-DOPA (t=3.00; p~O.Ol) conditions relative to the high HR 
group, there were no differences between the groups in alcohol self-
administration during the BAL condition (t=1.19; p2:0.25) (Fig 9.3). 
[!BAL III APTO 0 APTD + L-OOP~J 
3 
2.8 
2.6 
2.4 
2.2 
2 
1.8 
1.6 
1.4 
1.2 
High HR Law HR 
Figure 9.3: Log transformed PR values for alcohol self-administration in 
individuals displaying high or low cardiac responses to acute alcohol 
ingestion. Participants with a high HR response to alcohol earned more 
alcoholic drinks on the BAL day relative to the APTD or the APTD+ L-DOPA 
test days. No differences in alcohol self-administration were evident in low HR 
responders. 
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9.45 Subjective Effects 
Changes in VAS subjective ratings were analysed using 4x3x2 
ANOV A using time (baseline, post water cue, post alcohol cue, post alcohol 
consumption), and AA condition (BAL, APTD & APTD + L-DOPA) as within 
subjects factors and HR group (high, low) as a between subjects factor. 
Because this analysis was performed on 14 different variables the threshold for 
statistical significance was adjusted to P:::;O.004 using a family-wise Bonferroni 
correction. 
V AS ratings were not significantly associated with HR group or AA 
condition and there were no significant AA x HR, AA x Time, HR x Time or 
AA x HR x Time interactions for any of the V AS measures. A number of 
V AS ratings were significantly affected by the cue exposures and alcohol 
administration. Significant main effects of Time for 'High', and 'Euphoria' 
each reflected elevated ratings of these variables post-alcohol ingestion relative 
to the two cue exposure ratings, while an effect for 'Intoxicated' resulted from 
an increased rating post-alcohol ingestion relative to each of the three other 
time points. The main effect for 'Desire Drink' reflected increased ratings 
following alcohol cue exposure and consumption relative to baseline and water 
cue exposure. Finally ratings for 'Sedation' were significantly elevated at 
moming baseline relative to each other time point, while the main effect for 
excited reflected decreased ratings following the water cue exposure relative to 
baseline, post alcohol cue exposure and post alcohol ingestion. 
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9.5 Discussion 
In this study APTD significantly decreased alcohol self-administration 
in men, an effect that was proportional to participants' HR response to acute 
alcohol ingestion. While previous studies have reported decreased alcohol 
reinforcement following disruption of DA functioning (Modell et al., 1993; 
Enggasser & de Wit, 2001; Leyton et al., 2000a), to our knowledge this is the 
first study to identify an individual difference that is associated with a 
differential sensitivity to the DAergic manipulation. These results are 
consistent with the hypothesis that the neurobiological mechanisms affecting 
susceptibility to alcohol abuse are different in separate populations. The 
present results suggest that alcohol-induced changes in DA transmission may 
be especially relevant for individuals with elevated DA cell reactivity, as 
indexed by a heightened cardiac response to alcohol. In comparison, DA may 
have much less importance for alcohol self-administration in drinkers with a 
minimal cardiac response to alcohol ingestion. 
Cardiac response to acute alcohol ingestion has been proposed to be an 
index of alcohol-related DA reinforcement (Conrod et al., 2001, Brunelle et al., 
2004, Brunelle et al., 2005) and a recent functional neuroimaging study 
suggests that individual differences in alcohol-induced increases in HR are 
correlated with changes in alcohol-induced changes in DA neurotransmission 
(Boileau et al., 2003). In the present study ethanol-induced HR response was 
the sole alcohol-related variable to predict reduced alcohol self-administration 
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following DA depletion suggesting that HR response to acute alcohol ingestion 
may be a marker for the degree to which motivation to drink alcohol is 
dependent on DAergic mechanisms. Because the present study used a 
standardised method for determining alcohol-induced cardiac change that 
involved the administration of a relatively high dose of alcohol (Brunelle et al., 
2005; Brunelle et al., 2004; Boileau et al., 2003; Conrod et al., 2001) a separate 
test day was required for HR measurement and we did not directly assess the 
effect of DA depletion on alcohol-induced cardiac change in the present 
protocol. Nevertheless reports that both the DA D2 antagonist haloperidol 
(Enggasser & de Wit, 2001) and the opioid receptor antagonist naltrexone 
(McCaul et al., 2001) attenuate alcohol-induced HR increases are consistent 
with the hypothesis that there is a direct relationship between DA 
neurotransmission and alcohol-related HR response. 
While the present findings suggest that HR response to alcohol may be 
a marker for DA-specifie alcohol reinforcement, they also indicate that the 
degree of DA involvement in alcohol reinforcement may not in and of itselfbe 
predictive ofproblematic drinking. Both HR response to alcohol and change in 
drinking following DA depletion, were unrelated to numerous indices of 
alcohol dependence risk including current and peak-drinking amounts, past 
alcohol related problems and family history of alcoholism. Nevertheless 
because DA depletion appeared to decrease alcohol self-administration in 
individuals with a high HR response to alcohol irrespective of other individual 
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differences, problematic drinkers with an elevated cardiac response to alcohol 
ingestion might especially benefit from treatments that target DA 
neurotransmission. 
In the present study we used APTD to decrease DA synthesis. This 
method has been previously demonstrated to significantly decrease DA release 
in humans (Montgomery et al., 2003; Leyton et al., 2004a) and it has been 
demonstrated to be a sensitive tool for measuring DA-related drug effects. For 
example, APTD has been previously shown to decrease stimulant effects of 
amphetamine (McTavish et al., 1999b; McTavish et al., 2001), to decrease 
cocaine- and cocaine cue-induced craving (Leyton et al., 2004b), and to reduce 
alcohol self-administration in female social drinkers (Leyton et al., 2000b). 
Although the CUITent findings extend these previous results and further validate 
APTD as a tool for investigating DA in human drug reinforcement, they also 
call into question the ability of L-DOPA to reverse APTD-related effects. 
Although L-DOPA was initially hypothesised to attenuate the effects of APTD 
on alcohol self-administration, there actually appeared to be a trend towards it 
increasing the magnitude of the APTD effect. Interestingly, similar results 
were recently reported in a study examining the effect of APTD on co caine 
craving (Leyton et al., 2004b). While such findings are consistent with 
evidence that acute L-DOPA administration decreases DA ceU firing in 
animaIs with compromised DA function (Harden & Grace, 1995; Robinson et 
al., 2004) because the present protocol did not directlY assess the effect of 
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APTD + L-DOPA on DA function, the nature of interaction must remain 
speculative. 
The present results should be interpreted in light of the following 
considerations. First, APTD might decrease norepinephrine (NE) synthesis 
(Palmour et al., 1998; though see McTavish et al., 1999), and it is possible that 
the observed effects on alcohol administration in part reflect changes to NE 
neurotransmission. However, because abundant evidence suggests that DA is 
more involved in alcohol and drug self-administration than NE (e.g. Wise, 
1996) this does not seem likely. Second, the present protocol only tested men 
and it is possible that the findings may not extend to women. In a previous 
study of female social drinkers APTD was shown to reduce alcohol self-
administration (Leyton et al., 2000a), however the degree to which this 
associated with cardiac response to ethanol remains unknown. Third, since 
there was considerable variability in the rate and frequency of alcohol self-
administration in the research proto col, it was not possible to systematically 
assess the effect of APTD on alcohol effects following the priming dose. While 
previous research suggests that decreasing DA function may affect several 
alcohol-related effects (e.g. Enggasser & de Wit, 2001) the present design did 
not allow us to determine if changes in self-administration were systematically 
related to changes in the subjective effects of alcohol in dose ranges normally 
administered by most participants. Fourth, although the sample size in this 
study was modest (n=16), it was within the norms for investigations assessing 
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within subject drug effects in humans and small sample size is typically 
associated with increased incidents oftype II but not type l error. 
Nevertheless, because we wished to examine APTD effects in a heterogeneous 
sample of drinkers it is likely that certain subtypes of non-dependent drinkers 
were not adequately represented by this small sample. Further research is 
clearly needed to delineate the role of DA in alcohol self-administration in 
different alcohol consuming populations. 
In conclusion, DA precursor depletion decreased alcohol self-
administration in a subset of non-dependent male drinkers and this was 
predicted by cardiac responses to acute alcohol administration. These findings 
suggest that among sorne drinkers DA may play only a limited role in alcohol 
reinforcement and highlight the importance of considering individual 
differences in determining treatments for alcohol misusing populations. 
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10. General Discussion 
The main novel findings presented in this dissertation are that 1) when 
appropriate interview techniques are used polysubstance users appear to be 
able to reliably recall details of the order and amounts of all substances used on 
a particular occasion; 2) most substances appear to be routinely administered in 
a simultaneous polysubstance use context and sorne substances appear to co-
administered in a systematic fashion; 3) a1cohol is commonly concomitantly 
used with various psychostimulant drugs that are known to affect DA 
neurotransmission and when it is used with these substances drug users 
retrospectively report consuming greater than normal volumes of alcohol; 4) 
under blinded placebo controlled conditions the psychostimulant nicotine 
increases a1cohol ingestion in humans; and 5) decreasing DA function reduces 
alcohol ingestion in a subset of drinkers who are thought to display a 
heightened sensitivity to a1cohol's DA-related effects. Collectively these 
findings suggest that examining patterns of simultaneous multiple substance 
use may provide insight into the mechanisms underlying certain addictive 
processes and that for the case of alcohol, drinkers may co-administer DAergic 
substances in order to achieve specific neuropharmacological effects. 
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In studies 1 & 2, simultaneous polysubstance use patterns were 
elucidated in two different drug-using populations and high rates of drug 
mixing were documented in each. In both studies the majority ofusers of every 
drug reported the simultaneous administration of additional substances and for 
most substances (i.e. ecstasy, cocaine, amphetamine, LSD, psilocybin, 
ephedrine, ketamine, GHB, mescaline) a minimum of 80% of us ers reported 
co-administering at least one additional substance during their most recent use 
of the substance. Because most drugs appear to be routinely co-administered 
with others, and this practice may alter a drug's behavioural and lor subjective 
effects (e.g., Barrett et al., 2003c; Pennings et al. 2002; Leri et al., 2003), it is 
possible that concomitantly used substances might contribute to the abuse 
liability of a given drug. As study 3 demonstrates, even a drug with seemingly 
innocuous intoxicating effects such as nicotine might affect the reinforc:ing 
effects of a co-administered substance and such findings highlight the 
importance of considering co-administered substances as potentially 
contributing to the aetiology and maintenance of various forms of substance 
use. 
Not only do certain substances appear to be frequently co-administered 
with each other, but in many cases their patterns of concomitant use appeared 
to follow a particular sequence of administration. For example, when 
amphetamine was co-administered with MDMA, its use was reliably reported 
to precede ecstasy administration and when alcohol was used in combination 
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with most other substances (cannabis, psilocybin, MDMA, cocaine, 
amphetamine, methylphenidate and LSD) its initial use was reliably reported to 
precede the onset of other substance intake. Although reason (s) for these 
particular orders of administration were not directly examined, the description 
of relative drug taking sequences is potentially important both for designing 
ecologically valid research protocols that examine drug interactions as weIl as 
for determining the clinical importance of current research findings. For 
example, recent animal evidence suggests that the neurotoxic effects associated 
with MDMA-amphetamine co-administration are more pronounced when 
MDMA is administered prior to amphetamine (Clements et al. 2005), however 
this finding may be of only limited clinical significance since this does not 
appear to be a common pattern of administration for these drugs (Barrett et al., 
2005b). On the other hand evidence that prior (but not subsequent) alcohol 
administration in cocaine users leads to increased plasma cocaine levels in 
humans (Perez-Reyes, 1994) may be more important to understanding the 
nature and consequences of alcohol-cocaine interactions since alcohol appears 
to be routinely administered prior to the onset of cocaine consumption. 
While initial alcohol consumption appears to precede the intake of most 
concomitantly administered substances, when it is used with various 
psycho stimulant drugs (i.e. cocaine, amphetamine, methylphenidate) alcohol 
ingestion appears to reliably resume following drug administration and 
evidence from both the retrospective and prospective studies reported in this 
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dissertation suggest that alcohol co-administration with various 
psychostimulant drugs is associated with increased levels of alcohol 
consumption. In study 2 both cocaine and methylphenidate users 
retrospectively reported consuming greater than normal amounts of alcohol in 
the presence of these drugs, while in study 3 nicotine was demonstrated to 
increase alcohol self-administration using a double-blind placebo controlled 
procedure. 
Because each ofthese psycho stimulants is believed to increase DA 
neurotransmission (e.g. Di Chiara & Imperato, 1988; Volkow et al., 1995; 
Pontieri et al., 1996), and DA is believed to mediate alcohol's ascending limb 
reinforcing effects (e.g. Fromme et al., 2003; Pihl & Peterson, 1995; Ollat et 
al., 1988) it is proposed that alcohol-psychostimulant co-administration may 
result in a DAergic neuropharmacological interaction that leads to alcohol dose 
escalation. This interpretation appears to be consistent with a number of 
observations. For example, although alcohol has been shown to affect the 
pharmacokinetic properties ofboth cocaine (e.g. Cami et al., 1998) and 
methylphenidate (Patrick et al., 1995), there do not appear to be signifiçant 
pharmacokinetic interactions between nicotine and alcohol (Collins et al., 
1988; Benowitz et al., 1986; Kouri et al., 2004) suggesting that any similarities 
in the interaction effects ofthese drugs with alcohol are likely not (solely) due 
to common pharmacokinetic effects. Moreover, evidence also suggests that the 
co-administration of any of nicotine, cocaine or methylphenidate augments 
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alcohol's subjective stimulant-effects and attenuates its subjective sedative 
effects (e.g. Pekins et al. 1995; Perez-Reyes & Jeffcoat, 1992; Barrett & Pihl, 
2002), while alcohol's DAergic effects have been associated with both 
subjective stimulation (e.g. Newlin & Thomson, 1990; King et al., 2002) and 
continued alcohol ingestion (e.g. Weiss et al., 1994), and its sedative effects 
are believed to be most salient following the termination of DA release (e.g. 
Lewis & June, 1990). Finally there are several reports that selectively 
decreasing DA neurotransmission decreases human alcohol consumption 
(Leyton et al., 2000; Enggasser & de Wit, 2001; Modell et al., 1993). 
Although the results of study 4 suggest that only a subset of drinkers who 
display heightened ascending limb alcohol induced cardiac reactivity may be 
sensitive to such alterations in DA neurotransmission, we (Brunelle, Barrett & 
Pihl) have recently demonstrated that tobacco, cocaine and amphetamine users 
tend to have significantly elevated ascending limb heart rate responses to 
alcohol relative to non-us ers of the drugs (unpublished data currently in 
preparation). These results suggest that alcohol's DAergic effects may be of 
particular importance to psycho stimulant users' drinking motives. 
While evidence presented in this dissertation suggests that examining 
patterns of concomitant multiple substance use may help provide insight into 
the mechanisms underlying certain addictive processes, there remain a number 
of methodological challenges to developing scientifically rigorous, yet 
ecologically valid research protocols for examining the patterns and 
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consequences of simultaneous polysubstance use. In order to make meaningful 
measurements it is often nècessary to impose a degree of experimental control 
over sorne of the variables of interest, and doing so might affect the 
phenomenon under investigation. Because in studies 3 & 4 we were primarily 
interested in patterns of alcohol self-administration we allowed participants a 
considerable degree of freedom in self-determining the pace, timing and 
amount of alcohol to be consumed (albeit using a highly controlled method to 
'eam' the substance). However by not controlling these variables we 
compromised our ability systematically to measure subjective and behavioural 
effects associated with specific dosages. In addition had we not imposed 
controls over the administration of the other pharmacologie agents in these 
studies the alcohol self-administration data may not have been interpretable. 
While such considerations highlight the importance of having an a priori 
knowledge of the substance use patterns of the population of interest when 
designing experimental protocols, the use of retrospective methods to collect 
such descriptive data may be subject to reporting bias and certain details such 
as orders and amounts of substances typically consumed are not easily 
verifiable through the use of more objective measures. Nevertheless despite 
such potential methodologicallimitations in the present series of studies there 
appeared to be a high level of concordance between the findings of the 
retrospective and prospective approaches (i.e. with both methods alcohol 
administration was similarly affected by drugs with similar properties). Given 
the frequency of concomitant drug administration and its potential importance 
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for understanding addictive processes, continued efforts are c1early needed to 
devise reliable and valid methods for examining the patterns and consequences 
of simultaneous polysubstance use. 
138 
References 
Amit, Z., Brown, Z. W.(1982). Actions of drugs of abuse on brain reward 
systems: a reconsideration with specific attention to alcohol. Pharmacology 
Biochemistry & Behavior, 17:233-8. 
Andreasen ,N.C., Endicott, J., Spitzer, R.L., Winokur, G., (1977). The family 
history method using diagnostic criteria. Reliability and validity. Archives of 
General Psychiatry, 34:1229-1235. 
Andlin-Sobocki, P. (2004), Economic evidence in addiction: a review. 
European Journal ofHealth Economics.5 SuppI1:S5-12. 
Barrett, S.P., Archambault, J., Engelberg, M.J., & Pihl, R.O. (2000) 
Hallucinogenic drugs attenuate the subjective response to alcohol in humans. 
Human Psychopharmacology - Clinical and Experimental, 15, 559-565. 
Barrett S.P. & Pihl, R.O. (2002). Oral methylphenidate-alcohol co-abuse. 
Journal ofClinical Psychopharmacology, 22,633-4. 
Barrett, S.P., Boileau, 1., Okker, l, Pihl, R.O., Dagher, A., (2004). The hedonic 
response to cigarette smoking is proportional to dopamine release in the human 
striatum as measured by positron emission tomography and [(II)C]raclopride. 
Synapse, 54,65-71. 
139 
Barrett, S. P., Leyton M., (2004). Acute phenylalanine-tyrosine deplation: A 
new method to study the role of catecholamines in psychiatrie disorders. 
Primary Psychiatry, 11, 48-52. 
Barrett, S. P., Darredeau, C., Bordy, L.E., Pihl R. O., (2005a). Characteristics 
of methylphenidate misuse in a university student sample. Canadian Journal of 
Psychiatry,50 457-451. 
Barrett, S. P., Gross, S. R, Garand, 1., Pihl, RO., (2005b). Patterns of 
simultaneous polysubstance use in Canadian Rave attendees. Substance Use & 
Misuse, 40: 1525-1538. 
Barrett, S. P., Tichauer, M, Leyton, M., Pihl, R O., (2005c). Nicotine increases 
alcohol self-administration in non-dependent male smokers. Drug and Alcohol 
Dependence, In Press. 
Batel, P., Pessione, F., Maitre, C., Rueff, B., (1995). Relationship between 
alcohol and tobacco dependencies among alcoholics who smoke. Addiction, 
90, 977-980. 
Benowitz, N.L., Jones, RT., Jacob, P. (1986). Additive cardiovascular effects 
of nicotine and ethanol. Clinical Pharmacology & Therepeutics 40:420-4. 
140 
Blomqvist, O., Ericson, M., Johnson, D.H., Engel, J.A., Soderpalm, B., (1996). 
Voluntary ethanol intake in the rat: effects of nicotinic acety1choline receptor 
blockade or subchronic nicotine treatment. European Journal of 
Pharmacology, 314,257-267. 
Blomqvist, O., Ericson, M., Engel, J.A., Soderpalm, B., (1997). Accumbal 
dopamine overflow after ethanol: localization of the antagonizing effect of 
mecamylamine. European Journal of Pharmacology, 334, 149-156. 
Blomqvist, O., Hernandez-Avila, C.A., Van Kirk, l, Rose, lE., Kranzler, 
H.R., (2002). Mecamylamine modifies the pharmacokinetics and reinforcing 
effects of a1cohol. Alcoholism - Clinical and Experimental Research 26, 326-
331. 
Boileau, I., Assaad, J.M., Pihl, R.O., Benkelfat, C., Leyton, M., Diksic, M., 
Dagher, A. (2003). Alcohol promotes dopamine release in the human nucleus 
accumbens. Synapse 49:226-231. 
Bond, A., Lader, M. (1974). The use of analogue scales in rating subjective 
feelings. British Journal of Medical Psychology 47: 211-218. 
141 
Brody, A.L., Olmstead, RE., London, E.D., Farahi, 1., Meyer, J.H., Grossman, 
P., Lee, G.S., Huang, J., Hahn, E.L., Mandelkem, M.A., (2004). Smoking-
induced ventral striatum dopamine release. American Journal of Psychiatry. 
161, 1211-1218. 
Brunelle, C., Assaad, J.M., Barrett, S.P., Avila, C., Conrod, P.J., Tremblay, 
RE., & Pihl, RO. (2004). Heightened heart rate response to alcohol 
intoxication is associated with a reward-seeking personality profile. Alcoholism 
- Clinical and Experimental Research, 28,394-401. 
Brunelle, C., Barrett, S. P., Pihl, R. O. (2005). Alcohol-related stimulant 
effects are associated with the cardiac response to acute intoxication in male 
social drinkers. Alcoholism - Clinical and Experimental Research, 29, 868. 
Butcher, L.L. & Engel, J. (1969). Behavioral and biochemical effects ofL-
dopa after peripheral decarboxylase inhibition. Brain Research, 15, 233-242. 
Cauli, O., Morelli, M. (2005). Caffeine and the dopaminergic system. 
Behavioural Pharmacology 16:63-77. 
142 
Cami, J., Farré, M., GonzaIez, M.L., Segura, J., & de la Torre, R. (1988). 
Cocaine metabolism in humans after use of alcohol: Clinical and research 
implications. Galanter (ed). Recent Developments in Alcoholism, 4, New York: 
Plenum Press, 437-453. 
Carroll, K.M., Nich, C., BalI, S.A., McCance, E., Rounsavile, B.J.,(1998). 
Treatment of cocaine and alcohol dependence with psychotherapy and 
disulfiram. Addiction, 93:713-27. 
Chi, H., de Wit, H., (2003). Mecamylamine attenuates the subjective stimulant-
like effects of alcohol in social drinkers. Alcoholism- Clinical and 
Experimental Research 27, 780-786. 
Clark, A., Lindgren, S., Brooks, S.P., Watson, W.P., Little, H.J., (2001). 
Chronic infusion of nicotine can increase operant self-administration of 
alcohol. Neuropharmacology. 41: 108-117. 
Clarke, P.B., Fu, D.S., Jakubovic, A., Fibiger, H.C. (1988).Evidence that 
mesolimbic dopaminergic activation underlies the locomotor stimulant action 
of nicotine in rats. Journal ofPharmacology and Experimental Therapeutics 
246:701-8. 
143 
Clemens, K.J., Comish, J.L., Li, K.M., Hunt, G.E., McGregor, I.S.(2005). 
MDMA ('Ecstasy') and methamphetamine combined: order of administration 
influences hyperthermic and long-term adverse effects in female rats. 
Neuropharmacology 49: 195-207. 
Cloninger, C.R. (1987). Recent advances in family studies of alcoholism. 
Progress in Clinical and Biological Research 241:47-60. 
Colby, S.M., Rohsenow, D.J., Monti, P.M., Gwaltney, C.J., Gulliver, S.B., 
Abrams, D.B., Niaura, R.S., Sirota, A.D., (2004). Effects oftobacco 
deprivation on alcohol cue reactivity and drinking among young adults. 
Addictive Behaviors. 29, 879-892. 
Collins, A.C., Burch, J.B., de Fiebre, C.M., Marks, M.J., (1988). Tolerance to 
and cross tolerance between ethanol and nicotine. Pharmacology Biochemistry 
& Behavior 29: 365-373. 
Conrod, P.J, Peterson, lB., Pihl, R.O. (2001). Reliability and validity of 
alcohol-induced heart rate increase as a measure of sensitivity to the stimulant 
properties of alcohol. Psychopharmacology, 157: 20-30. 
Cooney, lL., Cooney, N.L., Pilkey, D.T., Kranzler, H.R., Oncken, C.A., 
(2003). Effects of nicotine deprivation on urges to drink and smoke in 
alcoholic smokers. Addiction. 98: 913-921. 
144 
Corrigall, W.A., K.B.J. Franklin, K.M. Coen & B.S. Clarke. 1992. The 
mesolimbic dopaminergic system is implicated in the reinforcing effects of 
nicotine. Psychopharmacology 107: 285-289. 
Corrigall, W.A., Coen, K.M., Adamson, K.L.,(1994). Self-administered 
nicotine activates the mesolimbic dopamine system through the ventral 
tegmental area. Brain Research 653:278-84. 
Crews, T.M. & Sher, K.J. (1992). Using adapted short MASTs for assessing 
parental alcoholism: reliability and validity. Alcoholism - Clinical and 
Experimental Research, 16 :576-584. 
Dawson, D.A., (2000). Drinking as a risk factor for sustained smoking. 
Drug and Alcohol Dependence 59:235-49. 
Darke, S., Ross, 1. (1997). Polydrug dependence and psychiatrie comorbidity 
among heroin injectors. Drug and Alcohol Dependence 48: 135-41. 
Di Chiara, G., Acquas, E., & Tanda, G. (1996). Ethanol as a neurochemical 
surrogate of conventional reinforcers: the dopamine-opioid link. Alcohol, 
13,13-17. 
145 
Di Chiara, G., Imperato, A., 1988. Drugs abused by humans preferentially 
increase synaptic dopamine concentrations in the mesolimbic system of freely 
moving rats. Proceedings of the National Academy of Science USA. 85, 5274-
5278. 
Domino, E. F.(1998). Tobacco smoking and nicotine 
neuropsychopharmacology: sorne future research directions. 
Neuropsychopharmacology 18: 456-68. 
Drevets, W. C., Gautier, C., Price, lC., Kupfer, D.l, Kinahan, P.E., Grace, 
A.A., Price, J.1., Mathis, c.A., (2001). Amphetamine-induced dopamine 
release in human ventral striatum correlates with euphoria. Biological 
Psychiatry 49:81-96. 
Dunn, M.E. & Earleywine, M. (2001). Activation of alcohol expectancies in 
memory in relation to limb of the blood alcohol curve. Psychology of Addictive 
Behaviours, 15, 18-24. 
During, M.J., Acworth, LN., & Wurtman, R.J. (1988). Effects ofsystemic L-
tyrosine on dopamine release from rat corpus striatum and nucleus accumbens. 
Brain Research, 452, 378-380. 
146 
Earleywine, M., Newcomb, M.D., (1997). Concurrent versus simultaneous 
polydrug use: prevalence, correlates, discriminant validity, and prospective 
effects on health outcomes. Experimental and Clinical Psychopharmacology 
5:353-64. 
Enggasser, J.L. & de Wit, H. (2001). Haloperidol reduces stimulant and 
reinforcing effects of ethanol in social drinkers. Alcoholism - Clinicat and 
Experimental Research, 25, 1448-1456. 
Erblich, J., Earleywine, M., Erblich, B., Bovbjerg, D.H., (2003). Biphasic 
stimulant and sedative effects of ethanol: are children of alcoholics reaUy 
different? Addictive Behavahior. 28:1129-39. 
Erblich, J., Earleywine, M. (2003). Behavioral undercontrol and subjective 
stimulant and sedative effects of alcohol intoxication: independent predictors 
of drinking habits? Alcoholism- Clinical and Experimental Research 27: 44-
50. 
Fals-Stewart W. O'Farrell TJ. Freitas TT. McFarlin SK. Rutigliano P (2000). 
The timeline followback reports of psychoactive substance use by drug-
abusing patients: psychometric properties. Journal of Consulting and Clinical 
Psychology, 68:134-44. 
147 
Farré, M., de la Torre, R., Llorente, M., Lamas, x., Ugena, B., Segura, J., & 
Cami, J. (1993). Alcohol and cocaine interactions in humans. Journal of 
Pharmacology and Experimental Therapeutics, 226, 1365-1373. 
Farré, M., de la Torre, R., GonzaIez, Tarran, M.T., Roset, P.N., Menoyo, E., & 
Cami, J. (1997). Cocaine and alcohol interactions in humans: Neuroendocrine 
effects of cocaethylene metabolism. Journal of Pharmacology and 
Experimental Therapeutics, 283,164-176. 
Fendrich, M., Wislar, J.S., Johnson, T.P., & Hubbell, A. (2003) A contextual 
profile of club drug use among adults in Chicago. Addiction, 98 (12),1693-703. 
Fendrich, M., Johnson, T.P., Wislar, lS., Hubbell, A., Spiehler, V. (2004). The 
utility of drug testing in epidemiological research: results from a general 
population survey. Addiction, 99:197-208. 
First, M.B., Spitzer, R.L., Gibbon, M., & Williams, J.B.W. (1995). The 
Structured Clinical InterviewJor DSM-III-R Personality Disorders (SCID-II): 
1. Description. Journal of Personality Disorders, 9, 83-91. 
148 
Fleckenstein, A.E., Haughey, H.M., Metzger, R.R., Kokoshka, J.M., Riddle, 
E.L., Hanson, J.E., et al. (1999). DifferentiaI effects ofpsychostimulants and 
related agents on dopaminergic and serotonergic transporter function. 
European Journal of Pharmacology, 382, 45-9. 
First, M.B., Spitzer, R.I., Gibbon, M., 1995. Axis l disorders. New York: New 
York State Psychiatric Institute. 
Fischman, M.W., Foltin, R.W., 1991. Utility ofsubjective-effects 
measurements in assessing abuse liability of drugs in humans. British Journal 
of Addiction 86, 1563-1570. 
Foltin, R.W., Fichman, M.W., Pippen, P.A., & Kelly, T.H. (1993). Behavioral 
effects of cocaine alone and in combination with ethanol or marijuana in 
humans. Drug and Alcohol Dependence, 32, 93-106. 
Forsyth, A.J. (1996). Places and patterns of drug use in the Scottish dance 
scene. Addiction, 91 (4), 511-21. 
Fowles, D.C. (1993). Biological variables in psychopathology: a 
psychobiological perspective, in Comprehensive Handbook of 
Psychopathology. Sutker P.B., Adams, H.E. (eds) New York: Plenum Press, 
57-82. 
149 
Freese, T.E., Miotto, K., & Reback, C.J. (2002). The effects and consequences 
ofselected club drugs. Journal of Substance Abuse Treatment, 23 (2),151-6. 
Fromme K, de Wit H, Hutchison KE, Ray L, Corbin WR, Cook TA, Wall TL, 
Goldman D. (2004) Biological and behavioral markers of alcohol sensitivity. 
Alcoholism- Clinical and Experimental Research. 28:247-56. 
Gatley, S.J., Pan, D., Chen, R. & Ding, Y. (1996). Affinities of 
methylphenidate derivatives for dopamine, norepinephrine and serotonin 
transporters. Life Sciences, 58, 231-8. 
Gauvin, D.V., Moore, K.R., Holloway, F.A., (1993). Do rat strain differences 
in ethanol consumption reflect differences in ethanol sensitivity or the 
preparedness to leam? Alcohol. 10,37-43. 
Gerasimov, M.R., Ashby, C.R. Jr., Gardner, E.L., Mills, M.J., Brodie, lD., 
Dewey, S.L., (1999). Gamma-vinyl GABA inhibits methamphetamine, heroin, 
or ethanol-induced increases in nucleus accumbens dopamine. Synapse, 34: 11-
19. 
Gonzales, R.A., Weiss, F. (1998). Suppression of ethanol-reinforced behavior 
by naltrexone is associated with attenuation of the ethanol-induced increase in 
150 
dialysate dopamine levels in the nucleus accumbens. Journal ofNeuroscience, 
18, 10663-10671. 
Grace, A.A., Gerfen, C.R, & Aston-Jones, G. (1998) Catecholamines in the 
central nervous system. Overview. Advances in Pharmacology, 42, 655-670. 
Grant, B.F. & Harford, T.C. (1990). Concurrent and simultaneous use of 
alcohol with cocaine: Results of national survey. Drug &Alcohol Dependence, 
25,97-104. 
Grenhoff, J., Svensson T.H., (1989). Pharmacology of nicotine. British Journal 
of Addiction 84, 477-492. 
Griffiths, RR, Bigelow, G.E., Liebson, L, (1976). Facilitation ofhuman 
tobacco self-administration by ethanol: a behavioral analysis. Journal of 
Experimental and Analytic Behavior 25, 279-292. 
Gritz, E.R., Ippoliti, A., Jarvik, M.E., Rose, lE., Shiffman, S., Harrison, A., 
Van Vunakis, H., (1988). The effect of nicotine on the delay of gastric 
emptying. Aliment Pharmacology and Therapeutics 2, 173-8. 
151 
Gross, S.R., Barrett, S.P., Shestowsky, J.S. & Pihl, R.O. (2002) Ecstasy and 
drug consumption patterns: Canadian rave population study. Canadian Journal 
of Psychiatry, 47 (6), 546-51. 
Grotenherman, J., (2003). Pharmacokinetics and pharmacodynamies of 
cannabinoids. Clinical Pharmacokinetics 42:327-60. 
Harmer C.J., McTavish, S.F., Clark, L., Goodwin, G.M., & Cowen, P.J. 
(2001). Tyrosine depletion attenuates dopamine function in healthy volunteers. 
Psychopharmacology: 154, 105-111. 
Harris, D.S., Everhart, E.T., Mendelson, J., Jones, R.T., (2003). The 
pharmacology of cocaethylene in humans following cocaine and ethanol 
administration. Drug and Alcohol Dependence 72: 169-182 
Heatherton, T.F., Kozlowski, L.T., Frecker, R.C., Fagerstrom, K.O., (1991). 
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom 
Tolerance Questionnaire. British Journal of Addiction 86, 1119-1127. 
Heil, S.H., Badger, G.J., Higgins, S.T., (2001). Alcohol dependence among 
cocaine-dependent outpatients: demographics, drug use, treatment outcome 
and other characteristics. Journal ofStudies on Alcohol, 62:14-22. 
152 
Hemandez-Lopez, C., Farre, M., Roset, P.N., Menoyo, E., Pizarro, N., Ortuno, 
J., et al. (2002). 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol 
interactions in humans: psychomotor performance, subjective effects, and 
pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 
300 (1),236-44. 
Higgins, S.T., Rush, C.R., Bickel, W.K., Hughes, J.R., Lynn, M., & Capeless, 
M.A. (1993). Acute behavioral effects of cocaine and alcohol combinations in 
humans. Psychopharmacology, 111, 285-294. 
Higgins, S.T., Roll, J.M., & Bickel, W.K. (1996). Alcohol pretreatment 
increases preference for cocaine over monetary reinforcement. 
Psychopharmacology, 123, 1-8. 
Hisaoka, M., Levy, G., (1985). Kinetics of drug action in disease states XI: 
effect of nicotine on the pharmacodynamics and pharmacokinetics of 
phenobarbital and ethanol in rats. Journal of Pharmaceutical Science 74,412-
415. 
Hodge, C.W., Samson, H.H., & Chappelle, A.M. (1997). Alcohol self-
administration: Further examination of the role of dopamine receptors in the 
nucleus accumbens. Alcoholism - Clinical and Experimental Research, 21, 
1083-1091. 
153 
Jaffe, S.L. (1991). Intranasal abuse ofprescribed methylphenidate by an 
alcohol and drug abusing adolescent with ADHD. Journal of the American 
Academy ofChild and Adolescent Psychiatry, 30, 773-5. 
Keenan, RM., Hatsukami, D.K., Pickens, R.W., Gust, S.W., Strelow, L.J., 
(1990). The relationship between chronic ethanol exposure and cigarette 
smoking in the laboratory and the natural environment. Psychopharmacology. 
100, 77-83. 
Kessler, RC., Crum, RM., Warner, L.A., Nelson, C.B., Schulenberg, 1., & 
Anthony, J.C. (1997). Lifetime co-occurrence of DSM-III-R alcohol abuse and 
dependence with other psychiatrie disorders in the National Comorbidity 
Survey. Archives of General Psychiatry, 54, 313-321. 
King, A.C., Houle, T., de Wit, H., Holdstock, L., Schuster, A. (2002). Biphasic 
alcohol response differs in heavy versus light drinkers. Alcoholism - Clinical 
and Experimental Research, 26, 827-835. 
Kollins, S.H., MacDonald, E.K., & Rush, C.R (2001). Assessing the abuse 
potential of methylphenidate in nonhuman and human subjects: a review. 
Pharmacology Biochemistry and Behaviour, 68, 611-27. 
154 
Koob, G.F. (2000) Neurobiology of addiction. Toward the development ofnew 
therapies. Annals of the New York Academy of Sciences, 909, 170-185. 
Koob, G.F., Roberts, AJ., Schulteis, G., Parsons, L.H., Heyser, c.J., Hyytia, 
P., et al. (1998). Neurocircuitry targets in ethanol reward and dependence. 
Alcoholism - Clinical and Experimental Research, 22, 3-9. 
Kouri, E.M., McCarthy, E.M., Faust, AH., Lukas, S.E., (2004). Pretreatment 
with transdermal nicotine enhances sorne of ethanol's acute effects in men. 
Drug and Alcohol Dependence 75,55-65. 
Kozlowski, L. T., & Ferrence, R. G., (1990). Statistical control in research on 
alcohol and tobacco: An example from research on alcohol and mortality. 
British Journal of Addiction 85, 271-278. 
Kuczenski, R. & Segal, D.S. (1997). Effects ofmethylphenidate on 
extracellular dopamine, serotonin, norepinephrine: Comparison with 
amphetamine. JournalofNeurochemistry, 68,2032-2037. 
Le, A.D., Corrigall, W.A., Harding, J.W., Juzytsch, W., Li, T.K., (2000). 
lnvolvement of nicotinic receptors in alcohol self-administration. Alcoholism 
Clinical and Experimental Research 24, 155-163. 
Le, AD., (2002). Effects of nicotine on alcohol consumption. Alcoholism-
Clinical and Experimental Research 26, 1915-1916. 
155 
Le, A.D., Wang, A., Harding, S., Juzytsch, W., Shaham, Y., (2003). Nicotine 
increases alcohol self-administration and reinstates alcohol seeking in rats. 
Psychopharmacology. 168,216-221. 
Lenton, S., Boys, A., & Norcross, K.(1997). Raves, drugs and experience: drug 
use by a sample of people who attend raves in Western Australia. Addiction, 92 
(10), 1327-37. 
Leri, F., Stewart, J., Tremblay, A., Bruneau, J., (2004). Heroin and cocaine co-
use in a group of injection drug us ers in Montreal. Journal of Psychiatry and 
Neuroscience, 29:40-7. 
Leri, F., Bruneau, J., Stewart, J., (2003). Understanding polydrug use: review 
ofheroin and cocaine co-use. Addiction, 98:7-22. 
Lewis, M.J., June, H.L., (1990). Neurobehavioral studies of ethanol reward and 
activation. Alcohol, 7:213-219. 
Leyton, M., Young, S.N., Blier, P., Baker, G.B., Pihl, R.O., & Benkelfat, C. 
(2000a). Acute tyrosine depletion and alcohol ingestion in healthy women. 
Alcoholism- Clinical and Experimental Research, 24, 459-464. 
156 
Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C, Blier P, et al. (2000b). 
Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. 
Neuropsychopharmacology, 22, 52-63. 
Leyton, M., Barrett, S.P., Casey, K., Pihl, R.O., Young, S.N., Benkelfat, C., 
(2004a). Cocaine and alcohol self-administration in humans: The effect of 
dopamine depletion. Canadian College ofNeuropsychopharmacology 27th 
annual meeting. Kingston, Canada May 29th -June 1 st 2004. 
Leyton, M., Dagher, A., Boileau, I., Young, S.N., Benkelfat, C., (2004b). 
Decreasing amphetamine-induced dopamine release by acute 
phenylalanine/tyrosine depletion: A PET /[ Il C]raclopride study in healthy 
men. Neuropsychopharmacology, 29, 427-432. 
Louis, M., Clarke, P.B. (1998) Effect of ventral tegmental6-hydroxydopamine 
les ions on the locomotor stimulant action of nicotine in rats. 
Neuropharmacology 37:1503-13. 
Magura, S. & Rosenblum, A. (2000). Modulating affect of alcohol use on 
cocaine use. AddictiveBehaviors, 25, 117-122. 
157 
Mannelli, P., Janiri, L., Tempesta, E., & Jones, RT. (1993). Prediction in drug 
abuse: Cocaine interactions with a1cohol and buprenorphine. British Journal 
of Psychiatry, 163 (21), 39-45. 
Marinelli, P.W., Quirion, R., Gianoulakis, C., (2003). A microdialysis profile 
ofbeta-endorphin and catecholamines in the rat nucleus accumbens following 
alcohol administration. Psychopharmacology 169:60-67. 
Markowitz, J.S., Devane, L., Boulton, D.W., Nahas, Z., Risch, S.C., Diamond, 
F., & Patrick, KS. (2000). Ethylphenidate formation in human subjects after 
the administration of a single dose of MPH and ethanol. Drug Metabolism and 
Disposition, 28,620-624. 
Markowitz, J., Logan, B.K, Diamond, F., & Patrick, KS. (1999). Detection of 
the novel metabolite ethylphenidate after methylphenidate overdose with 
alcohol coingestion. Journal of Clinical Psychopharmacology, 19, 362-366. 
Martin, C.S., Arria, A.M., Mezzich, A.C., Bukstein, D.G., (1993a). Patterns of 
polydrug use in adolescent alcohol abusers. American Journal of Drug 
Alcohol and Abuse, 19:511-21. 
158 
Martin, C.S., Earleywine, M., Must y, R.E., Perrine, M.W., & Swift, R.M. 
(l993b). Development and validation of the Biphasic Alcohol Effects Scale. 
Alcoholism - Clinical and Experimental Research, 17, 140-146. 
Martin, C.S., Clifford, P.R., Maisto, S.A., Earleywine, M., Kirisci, L., 
Longabaugh, R., (l996a). Polydrug use in an inpatient treatment sample of 
problem drinkers. Alcoholism- Clinical and Experimental Research;20(3):413-
417. 
Martin, C.S., Kaczynski, N.A., Maaisto, S.A., & Tarter, R.E. (l996b). 
Polydrug use in adolescent drinkers with and without DSM-IV alcohol abuse 
and dependence. Alcoholism - Clinical and Experimental Research, 20, 1099-
1108. 
Martinez, D., Slifstein, M., Broft, A., Mawlawi, O., Hwang, D.R., Huang, Y., 
Cooper, T., Kegeles, L., Zarahn, E., Abi-Dargham, A., Haber, S,N" Laruelle, 
M., (2003). Imaging human mesolimbic dopamine transmission with positron 
emission tomography. Part II: amphetamine-induced dopamine release in the 
functional subdivisions of the striatum. Journal of Cerebral Blood Flow and 
Metabolism 23:285-300. 
159 
McCance-Katz, E.F., Kosten, T.R. & Jatlow, P. (1998). Concurrent use of 
cocaine and alcohol is more potent and potentially more toxic than use of 
either alone--a multiple-dose study. Biological Psychiatry, 44 (4), 250-259. 
McCaul, M.E., Wand, G.S., Stauffer, R., Lee, S.M., & Rohde, C.A. (2001). 
Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-
pituitary-adrenal axis activation. Neuropsychopharmacology, 25,537-547. 
McKay, 1.R., Alterman, A.I., Rutherford, M.J., Cacciola, 1.S., & McLellan, T. 
(1999). The relationship of alcohol use to cocaine relapse in cocaine dependent 
patients in an aftercare study. Journal of Studies on Alcohol, 60, 176-180. 
McKee, S.A., Hinson, R., Rounsaville, D., Petrelli, P., (2004) Survey of 
subjective effects of smoking while drinking among college students. Nicotine 
& Tobacco Research, 6: 111-11 7. 
McLellan, A.T., Luborsky, L., O'Brien, c.P., Woody, G.E. (1980). An 
improved diagnostic instrument for substance abuse patients: the Addiction 
Severity Index. Journal ofNervous and Mental Disease, 168,26-33. 
160 
McLellan, A.T., Meyers, K., (2004). Contemporary addiction treatment: a 
review of systems problems for adults and adolescents. Biological Psychiatry. 
56:764-770. 
McTavish, S.F., Cowen, P.J., & Sharp, T. (1999). Effect of a tyrosine-free 
amino acid mixture on region-al brain catecholamine synthesis and release. 
Psychopharmacology, 141, 182-188. 
McTavish, S.F., McPherson, M.H., Harmer, C.J., Clark, L., Sharp, T., 
Goodwin, G.M., & Cowen, P.J. (2001). Antidopaminergic effects ofdietary 
tyrosine depletion in healthy subjects and patients with manic illness. British 
Journal of Psychiatry 179, 356-360. 
McTavish, S.F., McPherson, M.H., Sharp, T., & Cowen, P.J. (1999). 
Attenuation of sorne subjective effects of amphetamine following tyrosine 
depletion. Journal of Psychopharmacology, 13, 144-147. 
McTavish., S.F., Raumann, B., Cowen, P.J., & Sharp, T. (2001). Tyrosine 
depletion attenuates the behavioural stimulant effects of amphetamine and 
cocaine in rats. European Journal ofPharmacology, 424, 115-119. 
161 
Mello, N.K., Mendelson, J.H., Sellers, M.L., Kuehnle, J.c., (1980). Effect of 
alcohol and marihuana on tobacco smoking. Clinical Pharmacology & 
Therapeutics 27,202-209. 
Mendelson, J., Jones, R.T., Upton, R., & Jacob, P. (1995). Methamphetamine 
and ethanol interactions in humans. Clinical Pharmacology & Therapeutics, 57 
(5), 559-568. 
Mithani, S., Martin-Iverson, M.T., Phillips, A.G., Fibiger, H.C., (1986). The 
effects ofhaloperidol on arnphetarnine- and methylphenidate-induced 
conditioned place preferences and locomotor activity. Psychopharmacology 
90:247-252. 
Modell, J.G., Mountz, lM. Glaser, F.B., & Lee, J.Y. (1993). Effect of 
haloperidol on measures of craving and impaired control in alcoholic subjects. 
Alcoholism - Clinical and Experimental Research, 17, 234-240. 
Moja, E.A., Lucini, V., Benedetti, F., & Lucca, A. (1996). Decrease in plasma 
phenylalanine and tyrosine after phenylalanine-tyrosine free arnino acid 
solutions in man. Life Sciences, 58, :2389-2395. 
162 
Montgomery, A.J., McTavish, S.F., Cowen, P.J., & Grasby, P.M. (2003). 
Reduction ofbrain dopamine concentration with dietary tyrosine plus 
phenylalanine depletion: an [llC]raclopride PET study. American Journal of 
Psychiatry, 160, 1887-1889. 
Morzorati, S.L., Ramchandani, V.A., Flury, L., Li, T.K., & O'Connor, S. 
(2002). Self-reported subjective perception of intoxication reflects family 
history of alcoholism when breath alcohollevels are constant. Alcoholism -
Clinical and Experimental Research, 26, 1299-1306. 
Munzar, P. & Goldberg, S.R. (2000). Dopaminergic involvement in the 
discrimination-stimulus effects on methamphetamine in rats. 
Psychopharmacology, 148, 209-216. 
Nadal, R., Chappell, A.M., Samson, H.H., (1998). Effects of nicotine and 
mecamylamine microinjections into the nucleus accumbens on ethanol and 
sucrose self-administration. Alcoholism-Clinical and Experimental Research 
22, 1190-1198. 
Nadal, R., Samson, H.H., (1999). Operant ethanol self-administration after 
nicotine treatment and withdrawal. Alcohol. 17, 139-147. 
163 
Newlin, D.B. & Thomson, J.B., (1990). Alcohol challenge with sons of 
alcoholics: a critical review and analysis. Psychological Bulletin, 108,383-
402. 
Noble, E.P., Zhang, X., Ritchie, T., Lawford, B.R., Grosser, s.e., Young, 
RM., Sparkes, RS., (1998). D2 dopamine receptor and GABA(A) receptor 
beta3 subunit genes and alcoholism. Psychiatry Research, 81:133-147. 
Ollat, H., Parvez, H., Parvez, S.,(1998).Alcohol and central neurotransmission. 
Neurochemistry International 13:275-300. 
Palfai, T.P., Monti, P.M., Ostafin, B., Hutchison, K., (2000). Effects of 
nicotine deprivation on alcohol-related information processing and drinking 
behavior. Journal of Abnormal Psychology, 109, 96-105. 
Palmour, RM., Ervin, F.R, Baker, G.B., & Young, S.N. (1998). An amino 
acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal 
fluid catecholamine metabolites and alcohol consumption in vervet monkeys. 
Psychopharmacology, 136, 1-7. 
Parran, T.V. & Jasinski, D.R (1991). Intravenous methylphenidate abuse: 
prototype for prescription drug abuse. Archives of Internai Medicine, 151, 781-
783. 
164 
Patrick, K.S. (2000). Ethylphenidate formation in human subjects after 
administration of a single dose of methylphenidate and ethanol. Drug 
Metabolism Distribution, 28, 620-624. 
Patrick, K.S., Williard, RL., VanWert, A.L., Dowd, J.1., Oatis, J.E Jr., 
Middaugh, L.D. (2005). Synthesis and pharmacology of ethylphenidate 
enantiomers: the human transesterification metabolite of methylphenidate and 
ethanol. Journal of Medicinal Chemistry 48:2876-2881. 
Pennings, E.J., Leccese, A.P., Wolff, F.A., (2002). Effects of concurrent use of 
alcohol and cocaine. Addiction 97:773-783. 
Perkins, K.A., Sexton, J.E., DiMarco, A., Grobe, J.E., Scierka, A., Stiller, RL. 
(1995). Subjective and cardiovascular responses to nicotine combined with 
alcohol in male and female smokers. Psychopharmacology. 119,205-212. 
Perkins, K.A., Donny, E., Caggiula, A.R, (1999). Sex differences in nicotine 
effects and self-administration: Review of human and animal evidence. 
Nicotine & Tobacco Research 1,301-315. 
Perkins, K.A., Fonte, C., Grobe, J.E., (2000). Sex differences in the acute 
effects of cigarette smoking on the reinforcing value of alcohol. Behavioural 
Pharmacology Il, 63-70. 
165 
Perkins, K.A., Jacobs, L., Sanders, M., Caggiula, A.R, (2002). Sex differences 
in the subjective and reinforcing effects of cigarette nicotine dose. 
Psychopharmacology. 163, 194-201. 
Perkins, K.A., (2002). Chronic tolerance to nicotine in humans and its 
relationship to tobacco dependence. Nicotine & Tobacco Research, 4:405-422. 
Petrakis, LL., Buonopane, A., O'Malley, S., Cermik, O., Trevisan, L., Boutros, 
N.N., Limoncelli, D., Krystal, J.H., (2002). The effect oftryptophan depletion 
on alcohol self-administration in non-treatment-seeking alcoholic individuals. 
Alcoholism- Clinical and Experimental Research 26, 969-975. 
Perez-Reyes, M., White, W.R, McDonald, S.A., & Hicks, RE. (1992). 
Interaction between ethanol and dextroamphetamine: Effects on psychomotor 
performance. Alcoholism - Clinical and Experimental Research, 16, 16:75-81. 
Perez-Reyes, M. & Jeffcoat, R (1992). Ethanol/Cocaine interaction: Cocaine 
and coethylene plasma concentrations and their relationship to subjective and 
cardiovascular effects. Life Sciences, 51, 553-563. 
Perez-Reyes, M., (1994). The order of drug administration: Its effects on the 
interaction between cocaine and alcohol. Life Sciences, 55: 541-550. 
166 
Pidoplichko, V.l., DeBiasi, M., Williams, lT., Dani, J.A., (1997). Nicotine 
activates and desensitizes midbrain dopamine neurons. Nature 390, 401-404. 
Pihl, R.O. & Peterson, J.B. (1995). Alcoholism: the role ofdifferent 
motivational systems. Journal Psychiatry & Neuroscience, 20,372-396. 
Pokorny, A.D., Miller, B.A. & Kaplan, H.B. (1972). The briefMAST: a 
shortened version of the Michigan Alcoholism Screening Test. American 
Journal of Psychiatry, 129, 342-345. 
Pontieri, F.E., Tanda, G., Orzi, F., Di Chiara, G.(1996). Effects of nicotine on 
the nucleus accumbens and similarity to those of addictive drugs. 
Nature, 382:255-257. 
Ramaekers, J.G., Berghaus, G., van Laar, M., Drummer, O.H., (2004). Dose 
related risk of motor vehicle crashes after cannabis use. Drug and Alcohol 
Dependence 73 :109-119. 
Rassnick, S. Pulvirenti, L., & Koob, G.F. (1992). Oral ethanol self 
administration in rats is reduced by the administration of dopamine and 
glutamate receptor antagonists into the nucleus accumbens. 
Psychopharmacology, 109, 92-98. 
167 
Rice, M.E., Cragg, S.1., 2004. Nicotine amplifies reward-related dopamine 
signaIs in the striatum. Nature: Neuroscience 7, 583-584. 
Rice, D.P., (1999) Economic costs of substance abuse, 1995. Proceedings of 
the Association of American Physicians 111: 119-125. 
Riley, S.C., James, C., Gregory, D., Dingle, H., & Cadger, M. (2001).Pattems 
of recreational drug use at dance events in Edinburgh, Scotland Addiction, 96 
(7),1035-1047. 
Romberger, D.1., Grant, K., 2004. Alcohol consumption and smoking status: 
the role of smoking cessation. Biomedical Pharmacotherapy 58,77-83. 
Romach, M.K., Glue, P., Kampman, K., Kaplan, H.L., Somer, G.R., Poole, S., 
et al. (1999). Attenuation of the euphoric effects of cocaine by the dopamine 
D1/D5 antagonist ecopipam (SCH 39166). Archives of General Psychiatry, 
56, 1101-1106. 
Rose, lE., Brauer, L.H., Behm, F.M., Cramblett, M., Calkins, K., Lawhon, 
D.(2002) Potentiation of nicotine reward by alcohol. Alcoholism - Clinical and 
Experimental Research, 26: 1930-1931. 
168 
Ross, J., Darke, S., (2000). The nature ofbenzodiazepine dependence among 
heroin users in Sydney, Australia. Addiction. 95,60-69. 
Samson, H.H., Tolliver, G.A., Haraguchi, M., & Kalivas, P.W. (1991). Effects 
of d-Amphetamine injected into the nucleus accumbens on ethanoi reinforced 
behavior. Brain Research Bulletin, 27, 267-271 . 
Samson, H.H., Tolliver, G.A., Haraguchi, M., Hodge, C.W. (1992). Aicohoi 
self-administration: Role ofmesolimbic dopamine. Annals of the New York 
Academy of Science, 654, 242-253. 
Samson, H.H., Hodge, C.W., Tolliver, G.A., & Haraguchi, M. (1993). Effect 
of dopamine agonists and antagonists on ethanol-reinforced behavior: The 
involvement of the nucleus accumbens. Brain Research Bulletin, 30, 133-141. 
Scherer, G., (1999). Smoking behaviour and compensation: a review of the 
literature. Journal of Psychopharmacology 145, 1-20. 
Schifano, F., Oyefeso, A., Corkery, J., Cobain, K., Jambert-Gray, R., & 
Martinotti, G. Ghodse, A.H. (2003). Death rates from ecstasy (MDMA, MDA) 
and polydrug use in England and Wales 1996-2002. Human 
Psychopharmacology, 18 (7), 519-524. 
169 
Schoedel, K.A., Tyndale, R.F., (2003). Induction ofnicotine-metabolizing 
CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary 
and implications. Biochimica. et Biophysica. Acta. 1619,283-290. 
Segal, D.S., Kuczenski R., (1999). Sensitization of amphetamine-induced 
stereotyped behaviors during the acute response: role of DI and D2 dopamine 
receptors. Brain Research 822: 164-174. 
Shaham, Y., Shalev, U., Lu, L., De Wit, H., Stewart, J., (2003). The 
reinstatement model of drug relapse: history, methodology and major findings. 
Psychopharmacology 168, 3-20. 
Sharpe, A.L., Samson, H.H., (2002). Repeated nicotine injections decrease 
operant ethanol self-administration. Alcohol. 28, 1-7. 
Sheehan, B.D., Tharyan, P., McTavish, S.F.B., Campling, G.M., & Cowen, 
P.J. (1996). The use of dietary manipulation to deplete plasma tyrosine and 
phenylalanine in healthy subjects. Journal of Psychopharmacology, 10, 231-
234. 
Sloboda Z. (2002) Changing patterns of "drug abuse" in the United States: 
connecting findings from macro- and microepidemiologic studies. Substance 
Use and Misuse, 37:1229-1251. 
170 
Smith, B.R., Horan, J.T., Gaskin, S., Amit, Z., (1999). Exposure to nicotine 
enhances acquisition of ethanol drinking by laboratory rats in a limited access 
paradigm. Psychopharmacology, 142,408-412. 
Smith K.M. Larive L.L. Romanelli F. (2002). Club drugs: 
methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, 
and gamma-hydroxybutyrate. American Journal of Health Systems and 
Pharmacology, 59:1067-1076. 
Sobell L.C. Brown J. Leo G.!. Sobell M.B. (1996) The reliability of the 
Alcohol Timeline Followback when administered by telephone and by 
computer. Drug and Alcohol Dependence, 42:49-54. 
Sobell, L.C. and Sobell, M.B., (1996). Alcohol Timeline Followback (l'LFB) 
Users' Manual, Addiction Research Foundation, Toronto. 
Sobell, L. C., Sobell, M. B., Kozlowski, L.T., Toneatto, T., (1990). Alcohol or 
tobacco research versus alcohol and tobacco research. British Journal of 
Addiction 85, 263-269. 
Soderpalm, B., Ericson, M., Olaus son, P., Blomqvist, O., Engel, J.A., (2000). 
Nicotinic mechanisms involved in the dopamine activating and reinforcing 
properties of ethanol. Behavioral Brain Research 113, 85-96. 
171 
Somers, J.M., Goldner, E.M., Waraich, P., Hsu, L., (2004). Prevalence studies 
ofsubstance-related disorders: a systematic review of the literature. Canadian 
Journal of Psychiatry 49:373-384. 
Staines, G.L., Magura, S., Foote, J., Deluca, A, Kosanke, N., (2001). 
Polysubstance use among alcoholics. Journal of Addictive Diseases 20 :53-69. 
Stewart, J. & de Wit, H. (1987). Reinstatement of drug-seeking behavior as a 
method of assessing the reinforcing properties of abused drugs. In: Bozarth, 
M.A (ed) Methods of Assessing the Reinforcing Properties of Abused Drugs. 
New York: Springer, 211-227. 
Thomas, S.E., Drobes, DJ., Voronin, K. & Anton, RF. (2004). Following 
Alcohol Consumption, Nontreatment-Seeking Alcoholics Report Greater 
Stimulation but Similar Sedation Compared with Social Drinkers. Journal of 
Studies on Alcohol, 65, 330-335. 
Tizabi, Y., Copeland, RL. Jr., Louis, V.A, Taylor, RE., (2002). Effects of 
combined systemic alcohol and central nicotine administration into ventral 
tegmental area on dopamine release in the nucleus accumbens. Alcoholism-
Clinical and Experimental Research 26, 394-339. 
172 
Tossmann, P., Boldt, S., & Tensil, M.D. (2001). The use of drugs within the 
techno party scene in European metropolitan cities. European Addiction 
Research, 7 (1),2-23. 
Tsukada, H., Miyasato, K., Kakiuchi, T., Nishiyama, S., Harada, N., Domino, 
E.F., (2002). Comparative effects of methamphetamine and nicotine on the 
striatal [(lI )C]raclopride binding in unanesthetized monkeys. Synapse.45 :207-
212. 
Tupala, E, Tiihonen, J. (2004). Dopamine and alcoholism: neurobiological 
basis of ethanol abuse. Progress in Neuropsychopharmacological and 
Biological Psychiatry 28:1221-1247. 
Tupala, E., Tiihonen, J. (2005). Striatal dopamine DI receptors in type 1 and 2 
alcoholics measured with human whole hemisphere autoradiography. 
Brain Research 1031:20-29. 
Volkow, N.D., Ding, Y.S., Fowler, J.S., Wang, G.J., Logan, J., Gatley, J.S., et 
al. (1995). Is methylphenidate like cocaine? Studies on their pharmokinetics 
and distribution in the human brain. Archives o/General Psychiatry, 52, 456-
463. 
173 
Volkow, N.D., Wang, G.J., Fischman, M.W., Foltin, R.W., Fowler, J.S., 
Abumrad, N.N., et al. (1997). Relationship between subjective effects of 
cocaine and dopamine transporter occupency. Nature, 386, 827-830. 
Volkow, N.D., Wang, G.J., Fowler, J.S., Gatley, J.S., Logan, J., Ding, Y.S., et 
al. (1998). Dopamine transporter occupancies in the human brain induced by 
therapeutic doses of methylphenidate. American Journal of Psychiatry, 155, 
1325-1331. 
Volkow, N.D., Wang, G.J., Fowler, J.S., Gatley, J.S., Logan, J., Ding, Y.S., et 
al. (1999a). Blockade of striatal dopamine transporters by intravenous 
methylphenidate is not sufficient to induce self-reports of "high." Journal of 
Pharmacology and Experimental Therapeutics, 288, 14-20. 
Volkow, N.D., Fowler, J.S., Gatley, lS., Dewey, S.L., Wang, G.J., et al. 
(1999b) Comparable changes in synaptic dopamine induced by 
methylphenidate and by cocaine in the baboon brain. Synapse, 31, 59-66. 
Volkow, N.D., Gatley, J.S., Fowler, lS., Wang, G.J. (2000). Serotonin and 
therapeutic effects ofritalin. Science, 288, 5463. 
174 
Walter, H., Ramskogler, K., Semler, B., Lesch, a.M., Platz, W. (2001). 
Dopamine and alcohol relapse: Dl and D2 antagonists increase relapse rates in 
animal studies and in clinical trials. Journal of Biomedical Science 8:83-88. 
Weathermon, R, Crabb, D.W., (1999). Alcohol and medication interactions. 
Alcohol Research Health. 23:40-54. 
Weiss, F., Hurd, Y.L., Ungerstedt, u., Markou, A., Plotsky, P., & Koob, G. 
(1992). Neurochemical correlates of cocaine and ethanol self-administration. 
Annals of the New York Academy of Sciences, 654,220-241. 
Windle, M., Scheidt, D.M., (2004). Alcoholic subtypes: are two sufficient? 
Addiction, 99: 1508-1519. 
Winstock, A.R, Griffiths, P., & Stewart, D. (2001) Drugs and the dance music 
scene: a survey of current drug use patterns among a sample of dance music 
enthusiasts in the UK. Drug and Alcohot Dependence, 64 (1), 9-17. 
Wise, RA. & Bozarth, M.A. (1987). A psychomotor stimulant theory of 
addiction. Psychological Review, 94, 469-492. 
Wise, RA. (1998). Drug-activation ofbrain reward pathways. Drug and 
Alcohot Dependence, 51, 13-22. 
175 
Wise, R.A. (1996). Neurobiology of addiction. Current Opinion in 
Neurobiology, 6, 243-251. 
Yamamura, T., Hisida, S., Hatake, K. (1991). Alcohol addiction of 
methamphetamine abusers in Japan. Journal of Forensic Sciences, 36, 754-
764. 
Young, S.N., Smith, S.E., Pihl, R.O., Ervin, F.R. (1985) Tryptophan depletion 
causes a rapid lowering ofmood in normal males. Psychopharmacology 
87:173-177. 
Young, R.M., Lawford, B.R" Feeney, G.F., Ritchie, T., Noble, E.P., 
(2004).Alcohol-related expectancies are associated with the D2 dopamine 
receptor and GABAA receptor beta3 subunit genes. Psychiatry Research, 
127:171-183. 
Zhang, H., Sulzer, D., (2004). Frequency-dependent modulation of dopamine 
release by nicotine. Nature: Neuroscience 7, 581-582. 
176 
Appendix 1: 
Hallucinogenic drugs attenuate the subjective response to alcohol in 
hum ans 
HUMAN PSYCHOf'HARMACOLOGY 
Hum. Psychopharmacol. Clin. Exp. 15, 559";565 (2000) 
Hallucinogenic Drugs Attenuate the Subjective 
:,Response to Alcohol in Humans 
.SEAN P. BARRETT*, JENNIFER ARCHAMBAULT, MARLA J. ENGELBERG and 
ROBERT O. PlHL . 
Dëpartment of Psychology, McGill University, Montreal, Canada 
This study investigated possible interactions between alcohol and hallucinogens in 22 Iysergic add diethylamide 
(LSD) and/or psilocybin users through retrospective structured interviews. Of those who had used LSD with aJcobol 
86·7 per cent reported a complete blockade of subjective alcohol effects, wbile the remaining cases reported ~ 
dim~sbed respo~se. ln ad~tio~, 60 per cent of respondents who had used alcohol and psilocybin together reported 
a partlaI antagorusm of subjectIVe alcohol effects. T-test analyses revealed that LSD's antagonism of alcohoI effects 
were significantly greater than those assodated with psilocybin. It is proposed that LSD's effect on alcohol intoxication 
may involve interactions with various serotonergic and/or dopaminergic receptor systems. Copyright © 2000 John 
Wiley & Sons, Ltd. 
KEYWORDS -lysergic add diethylamide; a1cohol; psilocybin; halludnogensi serotonin; dopamine 
INTRODUCTION 
The therapeutic use of lysergic acid diethylamide 
(LSD) has been studied ex~ensively as a possible 
adjunct to psychotherapy for the treatment of 
aJcoholism (e.g. Abraham et al., 1996; Mangini, 
1998). Such studies have produced inconsistent 
results and this area of research was abandoned in 
the early 1970s due to concerns over LSD's safety 
(Mangini, 1998). Despite the fact that several c1ini-
cal trials were conducted over a 25-year period, the 
effects of the combined use ofaJcohol and LSD 
were never elucidated. Nevertl)eless, the phar-
macological profiles ofthese two substances suggest 
the possibility of a c1inically significant interaction. 
For ex ample, LSD binds with high affinity at both 
5-HT, and 5-HT2 receptors (e.g. Peroutka, 1994), 
and drugs that act on either of these receptor sub-
types have been shown to alter both ethanol intake 
and discriminative stimulus effects in rats (Szeliga 
and Grant, 1998; Kostowski and Bienkowski, 
1999). Furthermore, LSD is thought to act as a 
• Correspondence to: S. P. Barrett, Department of Psychology, 
McGill University, 1205 Dr. Penfield Avenue, Montreal, QC, 
Canada H3A lB!. Tel: 514-982-5013. Fax: 514-398-4896. E-
mail: barrett@ego.psych.mcgiILca 
Copyright © 2000 John Wiley & Sons, Ltd. 
partial agonist at dopamine (DA) receptors (Watts 
et al., 1995; Giacome1li et al., 1998), and mid-brain 
DA transmission has been implicated in several of 
alcohol's reinforcing properties (e.g. Koob et al., 
1998). Given the fact that LSD is known to affect 
neural systems implicated in ethanol intake, 
reinforcement, and discriminative stimulus, one 
might expect the subjective human response to etha-
nol to be altered by LSD administration. Inter-
estingly, a recent study of the drug taking patterns 
of adolescent drink ers suggests that the simul-
taneous use of alcohol and hallucinogens is quite 
common, with 16 per cent of the sample reporting 
combining alcohol with hallucinogens on at least 
one occasion (Martin et al., 1996). The current 
investigation presents systematically collected 
information from individuals who have reported 
using ethanol with LSD and/or psychotic mush-
rooms, a related hallucinogenic drug. 
METHODS 
Participants for tbis retrospective self-report study 
were recruited through the 'snowball' method of 
sampling. This sampling method has been widely 
used to study hidden or clandestine populations 
560 s. P. BARRElT ET AL. 
(Jackson, 1997), and requires the researcher to 
make an initial set of contacts and to ask these 
contacts to introduce himjher. to potentiaI par-
ticipants. In the present study four contacts whose 
past hallucinogenic use was known a priori were 
used to recruit subjects. Potential participants were 
contacted either in person or by teJephone and were 
asked if they would answer sorne questions about 
theif alcohol and drug use for a scientific study. 
Of the 25 individuals contacted, three declined to 
participate, leaving a final sample of 22 subjects. 
Structured interviews were conducted orally and 
recorded via audio-tape. Participants were assured 
of their anonymity and informed that their audio-
tapedresponses wouId remain strictly confidential. 
The interview consisted of a series of standardized 
open-ended questions designed to elicit information 
about the participant's previous experiences with 
alcohol, LSD, and psilocybic mushrooms when 
used alone or in combination. In order to avoid any 
possible investigator influence, ail questions about 
possible alcoholjhallucinogenic interactions were 
always phrased as follows: have you ever used alco-
hol while under the influence ofLSD (magic mush-
rooms) or LSD (magic mushrooms) while under 
the influence of alcohol? Did you notice any differ-
ence in the effect of either the alcohol or the LSD 
(magic mushrooms) when you used the two to-
gether? What was the nature of the difference? Can 
you give me a specific example about a time when 
this happened? In order for a report to be con-
sidered usable, the subject had to have used at least 
the minimum dose required to detect the subjective 
effects of each drug when used alone. 
Reported drug interaction effects were rated by 
the principal investigator and by an independent 
rater who was blind to the study's hypotheses. Dis-
crepancies in the coding were resolved by having a 
second independent rater score any interviews in 
question. Using a five-point Likert scale (1 = com-
pleteJy blocked, 2 = somewhat diminished, 3 = neu-
tral, 4 = somewhat enhanced, 5 = strongly 
enhanced), the raters first scored the reported effect 
of alcohol when it was taken with LSD. Using the 
same Likert scale, the raters then coded the reported 
effect of LSD when it was taken in conjunction with 
alcohol. Ratings of reported effects of alcohol and 
psilocybin when the two drugs were used in com-
bination were assessed in the same manner. Raters 
were instructed to eliminate cases in which inter-
viewer bias was present. A complete transcript of 
ail interviews is available from the authors ùpon 
request. 
Copyright © 2000 John Wiley & Sons, Ltd. 
RESULTS 
Nineteen males and three females were interviewed 
for the present study. The participants ranged in 
age from 18 to 28 years (M = 23·73, SD = 2·86). 
Most participants reported extensive past use of 
hallucinogens, with 73 per cent of subjects reporting 
20 or more lifetime uses of LSD and 73 per cent 
reporting 20 or more lifetime uses of psilocybin. 
Drug interaction effects were not analysed for four 
subjects who reported that they had never used 
intoxicating levels of alcohol in combination with 
either LSD or psilocybin and for one participant 
who provided inconsistent, and thus uncodable, 
responses to interview questions. Only partial 
effects were analysed for two subjects who reported 
never having used intoxicating levels of alcohol with 
LSD, and for two subjects who reported never hav-
ing used intoxicating levels of alcohol with psilo-
cybin. 
Pearson correlation coefficients were ca1culated 
in order.to determine the inter-rater reliabilities for 
the coding of the interviews. These analyses 
revealed a very high concordance betweenraters 
for both LSD-a1cohol interactions (r = 0·985, 
p < 0·001) and psilocybin-alcohol interactions 
(r = 0·871,p < 0·001). An analysis of the interview 
ratings revealed a striking antagonisin of subjective 
alcohol effects when it was used in. combination 
with LSD (see Table 1). Specifically, 86·7 per cent 
of the sample reported experiencing a complete 
blockade of subjective alcohoi effects, while the 
remainder reported a diminished effect. No differ-
ences in subjective LSD effects were associated with 
alcohol use in any of the subjects. There was also a 
weaker tendency for subjects to report a diminished 
effect of alcohol when used in conjunction with 
psilocybic mushrooms, with 60 per cent of the sam-
pie noting a diminished effect, 34 per cent reporting 
no change and 6·7 per cent reporting an enbanced 
effect. The majority of the sample (80 per cent) also 
reported no change in psilocybin's effects when it 
was used with alcohol. However, two subjects 
reported a diminished effect, and one subject 
reported an enhanced effect of psilocybin when used 
in combination with a1cohol. In addition, one par-
ticipant voluntarily reported experiencing a ple-
asant synergistic effect when taking psilocybin with 
a1cohol, while another participant reported having 
a very unpleasant synergistic effect. 
In order to compare the effects of LSD and psi-
Jocybin on the subjective response to alcohol, a 
paired samples (-test was performed. This analysis 
revealed that LSD's antagonism of the aJcohol 
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Table 1. Subjective effects associated with concurrent use of aJcohol and hallucinogens 
Id Age Sex Estimated Estimated 
lifetime lifetime 
useofLSD use ofpsilocybin 
A 21 M 100-150 50-100 
B 26 M 20 20 
C 21 M 50 40-50 
G 25 M. 60-90 60-90 
H 27 F 60-75 30-35 
1 28 M 30-50 20-30 
J 24 M 25 50 
K 28 M 10-25 10-25 
L 25 M 35 50 
M 24 M 40 50 
p 24 M >50 30-40 
R 24 F 30 2 
S 23 F 3 30 
T 24 M 25 30 
U 26 M 200-300 50 
V 28 M 25 50 
W 22 M 15 30-35 
effect is significantly greater than that associated 
with psilocybin t(12) = 5,741, P < 0·001. 
REPRESENTATIVE SUBJECTIVE REPORTS 
LSD-a/coho/ interactions 
G, a 25-year-old male, reported extensive experi-
ence with LSD, using it on 60-90 separate 
occasions. Typically, G can begin to discern the 
effects of a1cohol after four drinks and it takes 
approxima tel y seven or eight drinks for G to 
become significantly intoxicated. According to G, 
'When 1 was on LSD 1 found that no matter what 
quantity of a1cohol 1 consumed .on the high, 1 did 
not notice any of the effects of the alcohoI'. G 
recalled one' specific occasion when he drank 
approximately 12 beers over the course of an eve-
ning after ingesting LSD: ' ... at that point, 1 didn't 
notice the effects of the a1cohol at ail. 1 was not 
drunk, nothing. 1 just felt a little bloated.' 
H, a 27-year-old female, reported extensive 
experience with LSD, using it on between 60 and 
75 separate occasions. She reported using an intoxi-
cating dose of aJcohol (more than seven drinks) in 
combination with LSD 'severa!' times. According 
Copyright © 2000 John Wiley & SOI)S, Ltd. 
Concurrent use of Concurrent use of alcohol and 
a1cohol and LSD psilocybin 
Subjective Subjective Subjective Subjective 
alcohol LSD alcohol psiJocybin 
effects effects effects effects 
blocked no change no change no change 
blocked no change no change no change 
diminished diminished 
blocked no change diminished no change 
blocked nochange 
blocked no change diminished no change 
blocked no change no change no change 
blocked no change diminished no change 
diminished no change diminished no change 
blocked no change no change no change 
diminished no change 
blocked no change 
blocked no change no change diminished 
blocked no change enhanced enhanced 
blocked no change diminished no change 
blocked no change diminished no change 
diminished no change diminished no change 
to H, LSD-alcohol interactions work two ways. 
'The first example would he if 1 were to use LSD 
and then drink, 1 wouldn't feel any of the effects of 
aIcohol until after the effects of the LSD had worn 
off ... and if 1 were to take LSD once 1 was already 
subjectively feeling drunk, the aIcohol effects would 
go away after taking the LSD.' 
T, a 24-year-old male, reported using LSD on 
25 occasions. T reported that there were several 
occasions where he consumed an intoxicating dose 
of alcohol (more than six drinks) while under the 
influence of LSD. According to T, 'You can't get 
drunk when you are on LSD ... One time 1 drank 
about 18 beers, a half bottle of Bailey's and a 
Mickey of vodka on two hits of acid and 1 didn't 
feel anything from the booze ... it was just a normal 
LSDhigh.' 
Psilocybin-alcohol interactions 
B, a 26-year-old male, has used psilocybic mush-
rooms on 20 separate occasions. When using aIco-
hol concurrently with psilocybic mushrooms, B 
daims that '} could feel a combination of both. It is 
not like LSD where the alcohol effects are blocked. 
Sometimes o~e would be stronger than the other, 
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but that would just depend on how much 1 took of 
each'. 
L, a 25-year-old male, has used psilocybic mush-
rooms on 50 separate occasions. According to L, 
when using psilocybin with a normally intoxicating 
dose of alcohol (more than four drinks), ' ... it pro-
duces a more mellow buzz. The alcohol effect was . 
deadened'. When asked to compare this experience 
with that of LSD, '1 could fee! the alcohol more for 
sure onmushrooms'. 
V, a 28cyear-old male, reported 50 previous uses 
of psilocybic mushrooms, including several 
occasions where he consumed a normally intoxi-
cating dose of aJcohol (more than six drinks). 
According to V, when using aJcohol and psilocybic 
mushrooms together. 'Y ou can tell thatyou've 
drunk alcohol when on mushrooms, but there 
would be less .of an effect ... you could feel it more 
than when on LSD'. 
DISCUSSION 
The present data indicate that the subjective 
response to ethanol is strongly attenuated by the 
administration of LSD. Of the 15 LSD users who 
reported concurrent use of aJcohol, 13 reported a 
complete blockade of aJcohoI's subjective effects, 
while the remaining two cases reported experi-
encing a virtual elimination of subjective alcohol 
effects when the drug was combined with LSD. The 
finding that LSD's antagonism of alcohoI's effects 
reportedly occurred irrespective of whether the sub-
ject had consumed LSD prior to drinking or the 
LSD was ingested when already intoxicated further 
supports the conjecture that LSD's effect on the 
subjective response to alcohol may be due to a direct 
pharmacological interaction. In contrast to LSD, 
the use ofpsilocybic mushrooms failed to fully anta-
gonize the subjective effects of alcohoL Although 
nine of the 15 psilocybin users reported a dimin-
ished response to alcohol, no participants reported 
that the administration of psilocybin completely 
blocked the subjective effects of alcohol. Of the 
remaining six participants, five reported that psi-
10cybin had no impact on their subjective response 
to alcohol,· while the final subject stated that psi-
Iocybin actually enhanced the subjective effects of 
aJcohol (i.e. caused an increase in the subjective 
sense of intoxication). Thus, although sorne par-
ticipants reported a tendency for psilocybin to 
weaken the subjective effects of alcohol, this effect 
was not as pronounced as that associated with LSD; 
while 100 per cent of LSD users reported at least 
Copyright © 2000 John WiJey & Sons, Ltd. 
partially diminished aJcohol effects, a full 40 per 
cent of psilocybin users failed to report any anta-
gonizing effect. Because very little is known about 
the pharmacological actions of psilocybin, and the 
precise nature of the interaction between psilocybin 
and alcohol was not c1early revealed by the present 
data, the remainder of the discussion will focus 
primarily on findings conceming the concurrent 
administration of LSD and alcohol. 
Prior to commencing a discussion of hypo-
thesized mean~ by which LSD could attenuate sub-
jective aJcohol effects, it would seem appropriate to 
address sorne possible limitations of the present 
study. The first issue concerns whether or not study 
participantscould reliably recount theirexperiences 
with the concurrent use of alcohol and hal-
lucinogenic drugs. There are several indications 
that memory is not significantly impaired by the 
administration of hallucinogens. For example, 
there are numerous reports that LSD experiences 
can be,' accurately and vividIy recalled (e.g. 
Hofmann, 1980; Abraham et al., 1996) suggesting 
that LSD intoxication has a negligible impact on 
memory storage and retrieval. The accuracy of rec-
ollections reported by subjects in the present study 
is further supported by the fact that most of these 
participants had extensive past halJucinogenic use 
and reported having used hallucinogens and aJco-
hol in combination on several occasions. Thus, par-
ticipants' responses to questions concerning 
alcohol-hallucinogen interaction effects were based 
on numerous experiences rather than a single event 
and compared to their own extensive experience 
with hallucinogenic drugs alone or in combination. 
A second consideration concems whether par-
ticipants' recollections of aJcohol effects were sim-
ply overwhelmed by the hallucinogenic properties 
of LSD and/or psilocybin. The observation that 
participants were able to reliably distinguish 
between LSD and psilocybin in terms of each drug's 
effect on the subjective aJcohol experience when 
taken concurrently argues against this possibility. 
In addition, participants were highly consistent in 
their reportiilg concerning both the nature and 
strength of a1cohol-drug interactions, despite their 
differential drug histories and being blind to the 
study's hypotheses. Finally, the amount of alcohol 
reportedly consumed by sorne participants while 
under the influence ofLSD argues against the possi-
bility that alcohol effects were sim ply overwhelmed 
by hallucinogen intoxication. For example, par-
ticipant M described an occasion on which he had 
24 drinks following the use of LSD and T recalled 
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drinking 18 beers, a half bottle of liqueur and } 3 
ounces of vodka while in a state of LSD intoxi-
cation. 
While both the consistency and magnitude of 
reports. of LSD's effect on aIcohol intoxication 
'lUest to its reliability, it is important to note that 
-in any retrospective study certain issues of potential 
J?ias may arise. Because subjects were not randomly 
selected it remains possible that their experiences 
arë not characteristic of ail hallucinogenic drug 
users. However, this possibility was minimized by 
thefact that participants were recruited from four 
different 'communities' of drug users through snow-
baIl sampling. It should also be noted that several 
additional steps were taken to avoid possible inter-
viewer bias. First, questions used for queries about 
potential drug interactions were standardized and 
neutrally worded. Second, three different inter-
viewers were used and ail interviews were blindly 
rated. Finally, raters were instructed to eliminate 
cases were interviewer bias was present. 
The present data are consistent with the notion 
that there is a direct, pharmacological interaction 
between LSD and aIcohol. Although the current 
methodology did not directly examine either of 
these drugs' pharmacological effects, LSD is known 
to act at various serotonergic and dopaminergic 
receptor types (e.g. Peroutka, 1994; Watts et al., 
1995) implicated in ethanol reinforcement (e.g. 
Koob et al., 1998) and discriminative stimulus (e.g. 
Kostowski and Bienkowski, 1999). This raises the 
possibility that LSD's effect on the subjective 
response to alcohol may involve an action at one 
or more of these systems. 
LSD exerts effects at several 5-HT receptor sub-
types, displaying affinity for 5-HT1A, 5-HTI8, 5-
HTID, 5-HT1E, 5-HT2A> 5-HT2C, 5-HT5A, 5-HT58, 5-
HT6, and 5-HT7 (Peroutka, 1994; Bonson et al., 
1996). With respect to LSD's multiple 5-HT 
actions, activity at 5-HT2C and/or 5-HT lB receptors 
would seem to represent the best candidates for 
LSD's attenuation of subjective aIcohol effects, as 
these are the only 5-HT receptor subtypes that have 
been directly implicated in the formation of the 
ethanol cue (Maurel et al., 1998; Wilson et al., 1998; 
Kostowski and Bienkowski, 1999). Mixed 5-
HT lB/2C receptor agonists completely generalize to 
the ethanol cue in rats (Kostowski and Bienkowski, 
1999; Maurel et al., 1998; Szeliga and Grant, ] 998), 
and are known to produce ethanol-like responses 
in humans (Kostowski and Bienkowski, 1999). Evi-
dence also suggests that the blockade of 5-HTlB 
and 5-HT2C receptors, alone or in combination, 
Copyright © 2000 John Wiley & Sons, Ltd. 
interferes with alcohol's discriminative stimulus 
properties (Maurel et al., 1998). In their review 
article, Kostowski and Bienkowski (1999) refer to 
such findings, and conclude that serotonergic 
neurotransmission plays a key role in the formation 
of the ethanol cue, and that this cue is primarily 
mediated through 5-HT lB and 5-HT2Ç receptors. 
Unfortunately, the precise nature of LSD's 
action at 5-:'HTIB remains unknown (peroutka, 
1994). The present discussion will therefore foeus 
on the actions of LSD at 5-HTzc receptors. LSD 
displays partial agoni st effects at 5-HT2C receptor 
sites (G1ennon, 1990; Fiorella et al., 1995; Egan et 
al., 1998). Thus, aithough LSD displays high affin-
ity, its agonist actions at 5-HT2C are oflow efficacy. 
Because LSD is a partial agonist at 5-HT2C recep-
tors, the precise nature of its effect at these sites will 
depend on available 5-HT concentrations and on 
the presence of other 5-HT agonists and/or antag-
onists (Glenn on, 1990; see also Bonson et al., 1996). 
At low 5-HT concentrations and/or in the absence 
of another agonist, LSD behaves as a low-efficacy 5-
HT 2C agonist, achieving approximately 30 per cent 
maximal excitation (Marek and Aghajanian, 1996; 
Egan et al., 1998). In the presence of a high efficacy 
agonist (i.e. at higher 5-HT concentrations), LSD 
exerts its own maximal effect while suppressing the 
receptor's responsiveness to the other agonist, 
thereby blocking the other agonist from achieving 
maximal excitation. Under such conditions, LSD 
may thus appear to function as an antagonist. 
LSD's partial agonist actions are consistent with 
the hypothesis that LSD may prevent the level of 
5-HT2C excitation required for the alcohol cue to 
be subjectively experienced, and this mechanism 
may underlie the findings of the present study. 
The hypothesis that LSD attenuates the ethanol 
eue in humans through such serotonergic mech-
anisms is consistent with the present observation 
that this effect was diminished or absent following 
the administration of psilocybin. Although LSD 
and psilocybin are considered similar in terms of 
subjective effects, they differ with regard to ser-
otonergic pharmacological properties. For exam-
pie, LSD is known to bind to various 5-HT sites 
with a greater affinity than psilocybin (G1ennon 
et al., 1985; McKenna et al., 1990). Furthermore, 
psilocybin is currently believed to act as a full agon-
ist at 5-HT 2 receptors (Vollenweider et al., 1998), 
whereas LSD acts as a partial agonist at these sites. 
If, as hypothesized, LSD exerts an effect on the 
alcohol cue via suppression of the requisite 5-HT2 
response, then one might expect psilocybin to fail 
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to fully attenuate the subjective effects of aIcohol. 
Aside from its actions at 5HT receptors, LSD 
has also beeil demonstrated to exert partial agonist 
effects at dopamine DI (Watts et al., 1995) and 
D 2 (GiacomelIi et al., 1998) receptors. Midbrain 
dopaminergic activity is thought to be critical for 
the reiriforcement of ethanol administration (e.g. 
Koob et al., ] 998). Although DA transmission is 
implicated in ethanol reinforcement, there is cur-
rently only limited evidence to suggest that DA 
transmission substantiaIly contributes to ethanol's 
subjective effects. Blocking DA neurotransmission 
with preferential DA receptor antagonists does not 
appear to affect either the discriminative stimulus 
effects of alcohol in rats (Kostowski and Bien-
kowski, 1999) or the subjective effects of alcohoI in 
humans (Litten, 1996). Although dopamine antag-
onists fail to significantly alter subjective ethanol 
effects, there is nevertheless some indication that 
dopamine agonists may attenuate aspects of the 
ethanol cue. For example, amphetamine, a potent 
DA reeeptor agonist, has been reported to anta-
gonize ethanol effects in rats (Schechter, 1974) and 
cocaine administration has been shown to attenuate 
the sedative effects of alcohol in humans (e.g. Foltin 
et al., 1993). Such evidence suggests that LSD's 
blockade of subjective a1cohol effects may relate to 
its agonist activity at DA receptors. Unlike LSD, 
psilocybin does not display an affinity for DA recep-
tors, although there is some evidence that it may 
increase DA transmission indirectly through ser-
otonergic mechanisms (e.g. VoIlenweider et al., 
1999). Nevertheless, the differential affinity ofLSD 
and psilocybin for DA receptors may help to 
explain reported differences in the effects of LSD 
and psilocybin on the subjective response to alco-
hol. 
In summary, the subjective effects of alcohol are 
antagonized by LSD and, to a lesser extent, by 
psilocybin. Although it is proposed that these 
effects may be at least partly mediated by ser-
otonergic and/or dopaminergic mechanisms, 
actions at either ofthese systems are likely to influ-
ence a variety of physiological and neurochemical 
processes and the interdependence among these 
should not be underestimated. It should also be 
emphasized that the pharmacological profiles of 
a1cohol and hallucinogens remain incompletely 
understood and more research is needed in order to 
fully understand the precise nature of the inter-
actions among these drugs. This point is par-
ticularly relevant in the case of psilocybin, which 
has not been examined as extensively as either LSD 
Copyright © 2000 John Wiley & Sons, Ltd. 
or a1cohol. Indeed, without a fuller characterization 
of each of these drugs' effects, interpretation of the 
present results must remain largely speculative. 
Despite the fact that the present analysisis unable 
to fully elucidate the mechanisms governing alco-. 
hol-hallucinogen interactions, the present findings 
are highly relevant for several reasons. First, this 
is, to .the best of the authors' knowledge, the first 
documentation of a recreational drug eliminating 
subjective alcohol effects in humans. Further explo-
ration of the interaction between LSD and alcohol 
revealed by the present findings may ultimately 
enhance our understanding of the mechanisms that 
mediate the subjective effects of ethanol. Second, 
evidence suggests that alcohol is often co-admin-
istered with hallucinogenic drugs (Martin et al., 
1996). Given the amounts of alcohol reportedly 
consumed by some participants in the present study 
while under the influence ofLSD and the illustrated 
potential for LSD to attenuate alcohol effects, this 
practice: may pose significant health risks. Third, 
this analysis demonstrates that, despite the fact that 
similarity between LSD and psilocybin has been 
assumed by some researchers (e.g. Strassman, 
1992), iliere is likely some discordance in the phar-
macoJogical effects of these two hallucinogens. 
FinaIly, this study illustrates a distinctive and effec-
tive approach for delineating drug-aJcohol inter-
actions in humans. 
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Characteristics of Methylphenidate Misuse in a 
University Student Sample 
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Robert 0 Pihl,PhD3 
Objective: Methylpbenidate (MPH) is a prescription stimulant drug with known abuse potential; bowever, little is 
known about its patterns of misuse or the characteristics of ils abusers. 
Methods: A sample of 50 university students reporting MPH misuse and 50 control subjects matcbed for age, sex, 
and etbnicity completed structured face-to-face interviews about their MPH and other drug use. For each substance 
ever used, they provided information regarding routes of administration and otber substances ever coadministered, as 
weil as details about the most recent administration. MPH users provided additional information about tbeir reasons 
for use and, in 36 cases, about bow they obtained tbe drug. 
Results: Relative to control subjects, those who misused MPH were more likely.lo bave used various other 
prescription and nonprescription stimulant drugs over their lifetime, and most MPH users reported mixing the drug 
with other psychoactive substances. Of the MPH sample, 70% reported recreational use of the drug, whiJe 30% 
reported that MPH was used exclusively for study purposes. Relative to those using it exclusively for study, 
recreational users were more likely to report using MPH intranasally, as weil as coadministering MPH with other 
substances. Most of those who reported their source of MPH obtained it from an acquaintance with a prescription. 
Conclusions: Those who misuse MPH are more likely than their peers to misuse various other substances, and MPH 
misuse frequently occurs in the context of simultaneous polydrug use. Because the primary supply of inappropriately 
used MPH appears to be prescribed users, efforts should be directed toward preventing its diversion. 
(Can J Psycbiatry 2005;50:457-461) 
Information on funding and support and author affiliations appears at tbe end of the article. 
Clinicàl Implicati()ns 
• MPH users reported greater lifetÏine use of other stimulants than did controlsubjects, and MPH misuse ilself freejUently 
occurred in a polysubstance use conlexl. 
• Oral MPH misuse may be more common than expected relative 10 other rollles of administration. 
• The priinary source of misùsed MPH was identified as prescription .llversionfrom prescribed users, suggesting that 
increased efforts should he directed toward ensuring prescription compliance;' . 
Limitations 
• The self-seleèted sainplè was moderately sized and may not he representative; 
• Inimediate- and 'exteuded-release formulations ofMPH were not distirlgoished; 
• Other reasons for MPH use in recreationàl users wére not delineatéd: 
Key Words: methylphenidate, prescription drug abuse, polysubstance, alcohol 
'.' 
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.. 
M etbylphenidate is a stimulant medication widely used for treating ADHD. Despite its wide margin of safety, 
MPH is thougbt to bave high abuse potential (1). Cases of 
oral (2,3), intranasal (4,5), and intravenous (6,7) MPH abuse 
bave been documented. However, consistent information is 
lacking regarding the prevalence ofMPH abuse through the 
various routes of administration or regarding its use in a 
polysubstance context. Althougb rates of MPH abuse are 
thought to be lower than rates for other stimulants, it has been 
suggested that MPH misuse may be underreported (1). In a 
college student sample, rates of reported recreationaI MPH 
use among traditional-age students were comparable to rates 
of cocaine and amphetamine use, but any overlap in the rates 
ofMPH and other stimulant use was not specified (8). A study 
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Abbreviations used in this article 
AOHO altention-defieil hyperactivily disorder 
GHB gamma hydroxybutyrate 
lSD Iysergic aeid diethylamide 
MOMA 3,4-methylenedioxymethamphetamine 
MPH methylphenidate 
PCP phencycfidine 
SO standard deviation 
SSRI selective serotonin reuptake inhibitor 
of child and adolescent MPH abuse reported to poison centres 
found that polysubstance use was involved in 30% of the 
cases overall; however, il was more common in adolescents 
aged 15 to 19 yearsthan inchildren aged 1010 14 years, andit 
was more likely 10 be associaled with clînical toxicity (9). 
Although the mos! common route of administration was oral 
in both age groups, the older group was also more likely to 
report intranasal use (9). However, because this sample con-
sisted exclusively of cases reported to poison centres, it may 
not represent generaJ patterns of MPH misuse, and ils rele-
vance to adults who misuse MPH is unknown. In a recent 
study examining illicit MPH use in a university student sam-
pIe, individuals who misused MPH reported using signifi-
cantly more psychoactive substances during the preceding 
year than did peers with no history of MPH misuse (10). 
Although such findings suggest that individuals who inappro-
priately use MPH may be more prone to substance misuse in 
general, the context and patterns ofMPH administration were 
not delineated, and little is currently known about how MPH 
is related to the use of other specifie substances. 
The present study aimed to elucidate patterns ofMPH misuse 
and characteristics of MPH misusers in a university student 
population, including information on routes of administra-
tion, reasons for use, methods of obtaining MPH, and related 
patterns of past and concurrent polysubstance use. 
Metbod 
The study involved 50 individuals who reported recreational 
and (or) nonprescribed use ofMPH and 50 control subjects 
matched for age, sex, and ethnicity. Participants were 
recruited from the McGiII University student population 
between July 1,2003, and May 31,2004, as part of an ongoing 
study examining polydrug use in different populations. Sub-
jects who misused MPH were recruited through advertise-
ments posted on a university-based, c1assified Internet site, 
and control participants were recruited from a pool of volun-
leeTS who had expressed interesl in participating in research at 
McGill's Department of Psychology. During confidential 
face-to-face interviews (which were standardized and 
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strnctured), participants provided details about their recre-
ational and (or) nonprescribed use ofvarious licit and iIlicit 
substances. Participants answered questions about their life-
time use of several specific substances, including tobacco, 
alcobol, cannabis, LSD, psilocybin (magic mushrooms), 
cocaine, mescaline, methamphetamine, MPH, ketamine, 
GHB, MDMA (ecstasy), PCP, heroin, ephedrine, AdderaUlM, 
d-amphetamitie, and "any other drug not already mentioned 
(please specify)." For each substance, subjects provided 
information regarding routes of administration and other sub-
stances ever coadministered with the drug, as well as details of 
ail substances used simultaneously dnring the most recent 
administration. Participants were asked why they used MPH; 
36 of them also indicated how they obtained the MPH. Ail 
subjects provided informed consent before participating, and 
ail were paid $15 after their interview. The study was con-
ducted in accordance with the Declaration of Helsinki and 
was approved by a McGilI University research ethics 
committee. 
Statistical Analyses 
Weused SPSSVersion 11.0(1I)to analyzeall data. Weused 
independent sample t tests 10 test for differences in the total 
number of drugs used between subjects who misused MPH 
and matched control subjects, as weil as between recreational 
MPH users and those reporting using MPH exclusively for 
study purposes. Chi-square tests were used to examine differ-
ences in the prevalence of the use of specific snbstances 
among these groups. Because analyses were conducted for 18 
different substances, we used familywise Bonferroni correc-
tions; the alpha level used to determine statistical significance 
for these tests was 0.003. Chi-square tests were a1so used to 
determine whether there were differences in the proportion of 
recreational MPH users and "studiers" who reported different 
routes ofMPH administration or reported polysubstance use 
involving MPH. 
Results 
In each subject group, 46% of the participants were men and 
54% were women, 86% were white (while several other eth-
nic backgrounds were represented, none exceeded 5% ofthe 
sample), and the mean age was 21.4 yeaTS, SD 2.6. Table 1 
presents lifetime history of substance use for both snbject 
groups. MPH misusers reported using a greater variety of sub-
stances recreationally throughout their lifetimes (mean 7.7, 
SD 3.0) relative to control subjects (mean 3.8, SD 3.1) (t = 
5.98, df 98, P < 0.001). Chi-square tests revealed that MPH 
users were more likely 10 report recreational use of ecstasy, 
cocaine, ephedrine, d-amphetamine, and psilocybin (ail Ps < 
0.00 1) than were control subjects. 
Seventy percent ofthose who used MPH reported using it for 
recreational purposes, while the remaining 30% reported 
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Ta!llê ,1 Perèehtàg\{sofMPH;61is 
:'f~erèatiomij'ûsé.of1iiiWùs ii!iii'iÎ 
brùgtype 
'A1cohol 100.0. 
Tobaceo 98:0 
. Cannabis 96.0' 
psirocYbin 82.0 
MDMA 78.0 
. Cqcaine 60.0, 
Amphetamine 46.0 
. Ephedrine 42.0 
lSD 30.0 
Dexedrine 24.0 
Adderall™ 16 .. 0 
Ketamine 14.0 
GHB 14.Q 
Sedatives 10.0 
Opium or morphine :10.0 
f>hericvclidine .. "10.0· 
.. 
Mescaline '.8.0''':'' 
'Herbin :.sI);,:" 
. -Thé BOnf.ITon' correCtéd a'phalèV';';s' 0;003," 
using it exclusively as an aid for study. The proportion of rec-
reational users also taking MPH as a study aid was not consis-
tently recorded. Among the recreational users, 77.1 % 
reported the simultaneous use of other psychoactive sub-
stances (excluding tobacco) with MPH, and 26.7% ofthose 
reporting MPH use exclusively for study purposes reported 
using other substances simultaneously. Chi-square analysis 
revealed that a greater proportion of recreational users 
reported using MPH in a polydrug context (P < 0.001). How-
ever, there were no differences between the 2 groups in life-
timenumberofdrugsused (/= 1.67, df48,P=0.10) orin the 
proportion reporting lifetime use of any given substance (ail 
Ps> 0.05). Table 2 presents the prevalence of using other sub-
stances concurrently with MPH, for both Iifetime and most 
recent use, in recreational users and in those reporting use for 
study only, as weil as in the total sample. 
Overall, the most common routes of MPH administration 
reported were oral (88%) and intranasal (50%); other routes 
reported included smoking (4%) and injection (2%). When 
participants reported multiple administration routes, the rela-
tive frequency of each was not recorded. Among the recre-
ational MPH users, 82.9% reported oral administration, and 
62.9% reported intranasal use. In contrast, the mtes of oml and 
intranasal use in those using MPH only for study were 100% 
and 20%, respectively. Chi-square analysis showed that those 
reporting MPH use exclusively for study were less likely to 
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·48;.0 
24.0 
22.0 
.26.0 
2.0 
20.0 
0.0 
0.0 
1(î.O 
10.0 
:1103', 
1:zà 
19:~ 
14:.9' 
4.3 
23:3 
1:3 
13.6. 
8.7 
OA 
0.4 
.·0.008.' .. 
o.QÔf 
0.001 
O.QO' 
O.OM 
o.OM 
0.17S 
0.601 
report intranasaJ use (P < 0.01); however, there were no 
differences in the relative proportions reporting oral adminis-
tration (P> 0.05). Of the 36 MPH users who provided addi-
tional information about their source(s) of MPH, most 
(77.8%) reported obtaining it from a friend or acquaintance 
with a prescription. Othermethods included black market pur-
chases (16.7%), getting one's own prescription (1 1.1%), and 
theft (4%). 
Discussion 
In this study, we sought to elucidate characteristics of a sam-
pie of university students who misused MPH and to identify 
their patterns of misuse and sources of the drug. Relative to 
matched control subjects, the MPH users reported the recre-
ational use of more drugs thmughout their Iifetime, particu-
larly other prescription and nonprescription stimulant drugs 
such as cocaine, ephedrine, Adderall™, and d-amphetamine. 
This suggests that MPH misusers may possess a general vul-
nerability to stimulant misuse mther than a preference for 
MPH per se and that MPH may sometimes be used as substitu-
tion for more expensive or difficult-to-obtain substances, 
such as cocaine. It is also possible that in some cases the pro-
pensity to misuse MPH may represent an attempt to self-
medicate undiagnosed ADHD symptoms (12). This may be 
especially true among subjects who reported nonprescribed 
MPH use for study purposes only. However, because these 
individuals reported high levels of other iIlicit substance use, 
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Aloohol 
eanria~is 
CoCâine 
PSifoCybiri 
;S!idàlives 
Mbt;,A' 
GI'lEi 
Amphetamine 
Ep/lè<Jrihe 
Oexedrine. 
LSD 
TobàCCO· 
na= nol available. 
aExcluding tObacCo 
Total MPHsample. 
(n=50) 
UfeJime last use" 
62.0 36.6 
50.0 24.0 
42.0 16:0. 
10:0 0.0 
6.0 0,0 
4;0 4.0 
4.0 2.0 
4.0 0.0 
2.0 0.0 
2.0 0.0 
2.0 0.0 
2.0 0.0 
na 54.0 
\ifetime prevalence data not oollected for. tobacco coadministration 
it would be difficull 10 ascertain the degree to which ADHD 
symptoms were a cause or a consequence oftheir drug misuse 
without an adequate period of abstinence (12). 
The most common route ofMPH misuse in this sample was 
oral, and the second most common was intranasal. Oral 
administration was the most frequent method reported by both 
recreational MPH users and those using it exclusively for 
study, whereas intranasal use was relatively more common 
among recreational users. Because we did not record ail the 
polential reasons for MPH use in recreational users or the fre-
quency of their different administration routes, we cannot 
determine the relative prevalence of oral and intranasal MPH 
use for recreational purposes in this study. Nevertheless, our 
findings of oral MPH misuse are consistent with sorne previ-
ous reports IhatMPH may frequently be misused orally (1,3). 
The MPH users in tbis study often used the drug in a polydrug 
context, especially with alcohol or cannabis (Table 2). Little is 
known about the effects of mixing MPH with other sub-
stances. Although we do not know whether the use of addi-
tional substances with MPH is associated with increased 
morbidity and mortality, a study of MPH overdoses in chil-
dren and adolescents suggests that polysubstance use may he 
associated with increased toxicity (9). Alcohol-MPH 
coadministration is associated with the production of a novel 
metabolite, ethylphenidate (13), and toxic effects have been 
reported following the ingestion of high doses of both sub-
stances (14). There are also reports that combined alco-
hol-MPH administration results in enhanced euphoria and a 
diminished sense of drunkenness (3), which could lead to 
460 
17;1 
~71.4 
48 .. 6 
14.3 
6:6. 
.. 2.9 
5;7' 
.. 5.7 
2.9. 
·2".!Î 
0.0 
2.9 
na 
'. ·:Ô~O 
2.:9 
:0:0'. 
0.0 .. 
"tl:o 
0.0. 
0.0 
'54,3 
stüëlY'!iriIY.~v~i's " 
..(n:;ii1!1) , 
f6:i; 
0:0 
. ":,0:0" 
:0,0: 
6;6 
"Q:() 
0.0 
i3.'! 
0:0 
dose escalation. To our knowledge, the specific effects and 
consequences of the concurrent use of cannabis (or other 
illicit drugs) with MPH have yet to he systematically investi-
gated. Given the high rates of drug mixing by MPH users in 
the present sample, further research in this area seems 
warranted. 
Because the primary source of MPH in this sample was pre-
scription diversion, increased attention should he directed to 
ensuring prescription compliance as weil as to identi:f'ying 
those individuals most likely to divert their medication. Previ-
ous research found that adolescents who misused their own 
prescription stimulant medication were more lik.ely to give it 
or sell itto others (15). Although it isnot known whetherthis 
1S also the case for adults, practitioners may wish to exert par-
ticular caution in prescribing MPH to individuals with 
histories of substance abuse. 
Our results should be interpreted in light of several method-
ological limitations. First, because those who misused MPH 
were seIf-selected and the sample size was reIatively modest, 
it is possible that the resuIts do not represent MPH misuse in 
the university student population. In 2 previous studies of 
MPH mÎsuse among college students, 25% and 16% of par-
ticipants, respectively, reported inappropriate MPH use, and 
the respective response rates of those invited to participate 
were 64% and 20% (8, JO). Thus obtaining a comparable num-
ber ofMPH misnsers by sampling an entire studentpopulation 
could be expected to require several thousand subjects, with-
out any additionaI assurance of a representative sample. Nev-
ertheJess, only a true random sample of subjects who misuse 
... Can J Psychialry, Vol 50, No 8, July 2005 
MPH would ensure the generalizability of the findings . .sec-
ond, our investigation did not distinguisb between 
immediate-release MPH and the newer extended-release for-
mulation that is believed to be less Iiable to be abused 
intranasally. Altbougb the high levels of oral MPH abuse 
reported may be due in part to misuse of extended-release 
MPH, wecannot determine the respective misuse patterns of 
immediate- and extended-release MPH formulations with the 
present data, and this issue needs to be addressed in future 
investigations. 
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Résumé: Caractéristiques de l'abus de méthylphénidate dans un échantillon 
d'ehidiants d'université 
Qbjectif: Le mélhylpbénidate (MPH) est un stimulant d'ordonnance dont le potentiel d'abùs. est 
connu; cependant, on cohnaît peu les modèles dtmjauvais usage du médicament oules caràCtéli~il<jiic;s . 
dé ceux qui en abusent. .. . .. : 
Méthodes: Un échantillon de 50 étudiants d'université déClarant un at;us de MPH et 50 smets t@Qilis;: 
assortis selon l'âge, le sexe et l'ethnicitéontparticipéà des entrevnes structûréesenpers0lÎIie.àJ>r6P.Os 
de leur utilisation du MPH et d'autres drogues. Pour chaque sù»stariéedéjàritHisée, ils. oliif&ûij'iid€s .... , 
renseignements sur les modes. d'administration et l~ alltres substimcesdêjà~o-admiliistiées,airi~iqye . 
des détails sur l'administration la plus récen~e. Les utilisateurs de M1>Hont fourni des renseighefui:iits .. 
additionnels sur les raisons de leur utilisation et, dans 36 cas, sùt la façon d' obtenir le·mêdièaiIl~nt, 
Résultats: Relativement aux sujetstémolrlS, ceuxqlÛ abusaient ilhèMPH étaient plus Stisè~plibl'ê$' ....•. 
d'avoir utilisé d'autres stimulants d'ordonnaiicéou en vente libreaùcow:s deléurvie, etlà'ptiipaIt'dès 
utilisateurs de MPH déclaraient mêler IemMicament aVeC d'aulressûbstancespsyéhoactiv~s,;,Î)aiis . 
l'échantillon d'utilisateurs de MPII, 70 % d6ciaraieIit un usageéfécréatif du tIlédicru:i;iert4 tlipd!sgtle; 
30% déclaraient utiliser le MPHexclnsivementpoui étudier; R~làtivemenf àceIÙ qlÛnel'uiHis'èrlt4'ùèë 
pour étudier, les utilisateurs récréatifs'étaientplus susceptibles de déclàreiun usage U;trrui'liSaFdliifl?ff;i 
ainsi qu'une co-administration avec d'autrés sub~tances. La plupart de Ceux qùi ont révéiêjeilr·s~urci· 
de MPH l'obtenaient d'une connaissance ayant une ordonnance. 
Conclusions: Ceux qui abusent du MPH sont plus susèeptibles que leurS pairs d~abuser de diverses 
autres substances, et l'abus de MPH se produit souvent dans le .contexte d'utilisation simultanêe de 
polymMicaments. Étant donné que les principaux fournisseurs de MPFl illicitement utilisé'semblënt 
être des utilisateurs ayant uné ordonnance, on doit tenter d'en prévenir le détournement. 
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Appendix 3: 
Oral methylphenidate-alcohol co-abuse 
1 
Oral Methylphenidate-AJcohoJ Co-abuse 
Editors: 
The use of methylphenidate among adults diagnosed 
wiIh attention deficit hyperactivity disorder (ADHD) has 
gCl1erat.ed sorne concem.' Methylphenidate is consid-
ered to be a drug ofhigh abuse potentiaF and adults with 
ADHD are known to have an elevated risk for substance 
use disorders.3 Although methylphenidate abuse is usu-
ally thought to be restricted to intravenous and/or in: 
tranasal4•5 modes of administration, we have recently 
documented several cases of oral methylphenidate abuse 
",hen it is used concomitantly with alcohol. The practice 
of aIcohol-methylphenidate co-administration is an issue 
that warrants increased attention. Evidence suggests 
that methylphenidate is sometimes prescribed to adults 
Vi'ÏÙ\ comorbid alcohol problems3 and methylphenidate-
alcohol coadministration bas recently been demonstra-
ted to result in the production of ethylphenidate,6 a 
metabolite ofunknown toxicity.' 
Poly-drug users with a reported history of concomi-
ta.TJt methylphenidate-alcohol use completed structured 
interviews about their experiences using these drugs in 
combination. These participants were recruited from 
the community using the snowball method of sampling, 
a technique that requires the researcher to make an ini-
tial set of contacts with members from a target popula-
tion and to ask these contacts to introduce himlher to 
other potential participants.sln the present study, three 
contacts whose drug histories were known a-priori 
"ere used to recruit participants. Of the 25 individuals 
contacted, eight declined to participate, leaving a final 
sarnple of 17. The methods used for this investigation 
received ethical approval from the Department of Psy-
chology Research Ethics Committee at McGill Univer-
sity. Fifteen male and two female, non-treatment seeking 
indhiduals were interviewed for study. 
Participants ranged in age from 20 to 31 years (mean= 
'26.2; sd =3.3). AlI cases reported the concurrent use of 
L'lese drugs on at least 10 separate occasions (range= 
1'),,-100; mean=30.5; sd=22). ln each case, it was re-
ported that the methylphenidate dose (range = 10-75 
mg; mean=41.5; sd=19.5) was typically consumed in 
several small doses throughout the course of a drinking 
session. ln 16 (94%) of these the primary route of 
rnethylphenidate administration was oral, while in the 
remaining case methylphenidate was usually consumed 
:ntranasally. Interestingly, only 12% of the cases re-
ported that they had a prescription for methylpheni-
date, indicating that the vast majority obtained it Hlic-
illy. In every case, an alteration in psychotropic effects 
"as cited as the primary reason for coadministration. 
Combined methylphenidate-alcohol use was described 
as producing a desirable effect characterized by in-
creased euphoria and energy as weil as a diminished 
sense of drunkenness. Four cases likened the experi-
ence to using alcohol with 'low grade cocaine' and 2.üf 
these referred to the combination as 'diet coke'. This is 
particularly interesting considering that alcohol is also 
known to he commonly co-abused with cocaine9 and 
methamphetamine,10 drugs that share a similar pharma-
cological profile with methylphenidate, Il raising the pos-
sibility that a common mechanism may mediate each of 
their propensities to be coadministered alcohol. ln addi-
tion to desirable subjective effects a minority of cases 
also reported occasionally experiencing unpleasant side 
effects: 3 cases reported increased nausea, 2 cases in-
somnia, and 1 case 'jaw clenching'. 
Methylphenidate-alcohol co-abuse in humans war-
rants further investigation. Evidence suggests that co-
administration of alcohol with other psychostimulants 
such as cocaine9 and methamphetamineJO often leads to 
increased morbidity and mortality. Although it remains 
Ururnown the tlegree to which this is the case for 
methylphenidate, evidence suggests that the co-adrninis-
tration ofhigh doses ofmethylphenidate and alcohol may 
produce toxic effects.4• ln addition, because methyl-
phenidate bas become increasingly available to adult 
populations through licit3 and illicitl2 means, alcohol-
methylphenidate coadministration may become an issue 
of growing clinical concern. Practitioners may wish to 
exert caution when prescribing methylphenidate to indi-
viduals prone to alcohol abuse as weil as provide explicit 
wamings to patients not to consume alcohol white using 
this prescription medication. 
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Heightened Heart Rate Response to A1cohol 
Intoxication Is Associated With a Reward-Seeking 
Personality Profile 
Caroline Brunelle, Jean-Marc Assaad, Sean P. Barrett, Cesar Avila, Patricia J. Conrod, 
Richard E. Tremblay, and Robert O. Pihl 
Background: The psychomotor stimulant theory of addiction posits that sensitivity to the positively 
rewarding properties of a1cohol puts certain individuals at higher risk for alcohol abuse. A valid and reliable 
index of overactivation in the reward system has been a heightened baseline heart rate (HR) inerease on the 
ascending limb of the blood a1cohol curve. The main goal of !bis study was to investigate tbe relationship 
between this HR response and a questionnaire measuring sensitivity to reward and sensitivity to punish-
ment. Additiona! goals included looking at (1) the association between a bigh HR respunse and v.rious 
personality traits (hopelessness/introversion, anxiety sensitivity, impulsivity, and sensation.seeking) and (2) 
the relationship between these personality traits and stimulant use. 
Methods: A total of 18 low· and 19 high·HR responders completed the Sensitivity to Punishment and 
Sensitivity to Reward Onestionnaire (SPSRQ), the Substance Use Risk Profile Scale (SURPS), and a 
modified version of the Addiction Severity Index. 
Results: High·HR responders obtained significantly higher scores than low-HR responders on the 
sensitivity to reward scale of the SPSRQ, as weil as iocreased sensation-seeking scores on the SURPS. 
High-HR responders wele not at significantly higher risk of baving used stimulants, but stimulant use was 
associated with higber impulsivity scores on the SURPS. 
Conclusions: Novelty/sensation·seeking is arnong the personality traits tbat have been linked 10 beavy 
alcobol use. This s\udy suggests tbat reward sensitivity might mediate tbe relationship between this per-
sonality profile and drinking behaviol. 
Key Wards: Alcohol, Heart Rate, Behavioral Activation System, Personality Traits, Stimulant Drugs. 
ALCOHOL DEPENDENCE IS one of the most preva-lent psychiatrie disorders (Kessler et al., 1994), yet 
individuals are not at equal risk of deveJoping alcoholism. It 
is known that sons of alcoholics are at significantly higher 
risk for problematic alcohoI use (Schuckit and Smith, 1996; 
Sher et al., 1991; Sigvardsson et al., 1996). The study of 
individuals genetically vulnerable to aJcohol dependence 
has led to the identification of various neurobiological 
characteristics that are beginning to eJucidate potential 
etiological pathways to aJcoholism (Hill et al., 1998; Peter-
son et al., 1993; Porjesz et al., 1998). One of these markers, 
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an increased heart rate (HR) response after alcohol intox-
ication, has been suggested as partially mediating the ge-
netic predisposition to alcohol dependence (Conrod et al., 
1998). 
Sorne aJcoholics and men at risk for alcoholism display 
an exaggerated HR increase aIter ingesting an intoxicating 
dose of alcohol (Conrod et al., 2001; Wilson and Nagoshi, 
1988), a response noticeable only on the ascending limb of 
the blood alcohol curve (AL-BAC). Indeed, men with mul-
tigenerational histories of aJcoholism have significantly 
higher HR increases on the AL-BAC than family history-
negative individuals, but there are no differences in HR 
between the groups on the descending limb (Conrod et al., 
1997). This finding may he explained by the fact that stim-
ulant effects of alcohol seem to be solely expressed on the 
AL-BAC (Friedman et al., 1980; Holdstock et al., 2000; 
Martin and Earleywine, 1990). It has been suggested that 
an exaggerated HR increase on the AL-BAC reflects acti-
vation of the behavioral activation system (BAS), a system 
that responds to signaIs of appetitive eues and reward by 
increasing approach behaviors and positive mood (Fowles, 
1980, 1983; Fowles et al., 1982; Gray, 1987). Stimulants, as 
weil as alcohol, are thought to activate this system by 
Alcoho/ Clin Exp Res, Vol 28, No 3, 2004: pp 394-401 
HEART RATE RESPONSE AND SENSlTlVrTY TO REWARD 
potentiating the availability of neurotransmÎtters associated 
with reward, such as dopamine (DA) (Di Chiara et al., 
1992; Gianoulakis, 1996; Koob et al., 1998). Haloperidol, a 
DA D2/D3 receptor antagonist, reduced the stimulant ef-
fects of alcohol in subjects who reported increased stimu-
lation after alcohol ingestion compared with those who 
reported none (Enggasser and de Wit, 2001). Recently, it 
was found in a human positron emission tomography study 
that alcohol reduced the raclopride binding potential, indi-
cating DA release in response to alcohol administration 
(Boileau et al., 2003). Moreover, this was correlated with 
alcohol-induced increases in HR on the AL-BAC, suggest-
ing that alcohol-induced eardiac reactivity may be a marker 
of the DA-mediated reinforcing effects of alcohol. lndivid-
uals who experience more stimulating effects from alcohol 
on the AL seem to drink more heavily and may be at a 
higher risk for developing alcohol problems (Holdstock et 
al., 2000; King et al., 2002). 
Individuals who display a heightened HR response to 
alcoholon the AL-BAC also tend to show a specifie per-
sonality profile characterized by high extraversion, novelty/ 
sensation-seeking (SS), and disinhibition (Assaad 2002), 
traits that have been described as refleeting interest in 
exploratory behavior. lnterestingly, animal and human 
studies have demonstrated that those with a high interest in 
exploring their environment tend to be more sensitive to 
drug-induced reward and to use more alcohol and stimu-
lant drugs (Dellu et al., 1996; Hooks and Kalivas, 1994; 
Sher et al., 2000; Zuckerman and Kuhlman, 2000). Height-
eiled HR has been associated with a higher risk for a variety 
of addictive and disinhibited behaviors, sueh as alcoholism 
(Peterson et al., 1996), aggression (Assaad et al., 2003), and 
gambIing (Brunelle et al., 2003). The previously reviewed 
fmdings offer ample support to the recent description of 
exaggerated HR on the AL-BAC increase as a reliable and 
valid index of sensitivity to alcohol-induced reward (Con-
rod et al., 2001). 
However, inereases in autonomie arousal may not only 
reflect input from BAS-related systems. The behavioral 
inhibition system (BIS; Gray and McNaughton, 2000) is a 
system that responds to punishment, novelty, and nonre-
ward. When it is activated, it produces inhibition of ongoing 
behavior, as weil as increases in arousal, attention, and 
anxiety. Therefore, activation of the BIS may result in 
increased physiologic reactivity. Alcohol has been found to 
possess anxiety-dampening properties through activation of 
the inhibitory GABAergic system (Lewis, 1996; Pihl and 
Peterson, 1995). Accumulated evidence seems to suggest 
that ethanol-induced HR reactivity on the AL-BAC is me-
diated solely by the BAS. Gray (1991) describes activation 
of the BAS as related to "emotional states of pleasurable . 
anticipation" and compares it to a drug-induced high. As 
such, in high-HR responders, alcohol intoxication is corre-
lated with feelings of energy and vigor but is unrelated to 
the anxiety-dampening properties of alcohol (Conrod et al., 
2oo1).lt is also associated with increased motoric reactivity 
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(Conrod et al., 1995) and predicts potentiated memory for 
elating but not depressing statements (Bruce et al., 1999), 
characteristics that are all theoretically associated with 
BAS activation. 
Nevertheless, although high-HR responders are helieved 
to he oversensitive to rewards, Ihis may be the result of 
reduced BIS activity rather than an overactive BAS. Re-
duced functioning of the BIS could make sorne individuals 
more sensitive to approaching potentially rewarding stimuli 
because Ihey would no longer be under the inbibiting in-
fluence of threat. As such, it has been found that low BIS 
activation is related to an ability to associate punitive events 
with delayed rewards on a counterconditioning computer 
task (Âvila et al., 1999). Therefore, the first goal of this 
study was to investigate the relationshipbetween a height-
ened HR response to alcohol and BAS/BIS activation. 
The previously reviewed literature suggests that a high 
HR response to aJcohol intoxication on the AL-BAC re-
f1ects sensitivity to the positively reinforcing properties of 
alcohol. Recently, an instrument was developed to measure 
personality and motivational risk factors for substance use 
(Woicik and Conrod, The Substance Use Profile scale 
(SURPS): an instrument for measuring personaIity risk for 
substance abuse, submitted), which included the traits of 
hopelessness/introversion (H/l), anxiety sensitivity (AS), 
impulsivity (IMP), and SS. Whereas the researchers found 
that H/l and AS were associated with negative reinforce-
ment motives for alcohol and drug use, SS was related to 
positive reinforcement sensitivity. IMP did not seem spe-
cifically related to any particular motive for abuse, except 
that it seemed to be characterized by a disorganized and 
severe pattern of drug use. Interestingly, the study found 
that personality profiles suggested differential drug sensi-
tivity. For example, an impulsive profile was related to 
stimulant drug dependence, whereas an SS profile seemed 
to indicate an increased risk for alcohol abuse. An investi-
gation into the relationship between this instrument and 
heightened HR response may help to confirm that a high 
HR response occurs in individuals with a personality profile 
associated with reward sensitivity, and considering the as-
sociation between these personality traits and stimulant use 
could offer partial confirmation to the differential drug 
sensitivity theory. 
The main goal of this study was to study the association 
between an ethanol-induced HR increase on the AL-BAC 
and sensitivity to reward (SR)/sensitivity to punishment 
(SP) by using a questionnaire that respectively measures 
BAS and BIS activation. An additional goal was to confirm 
that the relationship between a high HR response to aJco-
hol intoxication and various personality traits (H/l, AS, 
IMP, and SS) is theoretieally in accordance with positive 
reinforcement motives for abuse. Finally, the relationship 
between these personality traits and stimulant use will be 
examined to replicate the results of Woieik and Conrod 
(The Substance Use Profile scale (SURPS): an instrument 
for measuring personality risk for substance abuse, submit-
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ted). Specifically, given the previously reviewed findings, it 
was hypothesized that a high HR response to alcohol in-
toxication would be related to higher SR scores and would 
!Je unrelated to SP. Moreover, it was expected that SS and 
IMP scores would be increased in high-HR responders and 
that IMP would be associated with stimulant use. 
METHODS 
Participants 
The participants were part of a longitudinal cohort of 1037 men \hat 
have been followed up since kindergarten in low socioeconomic areas of 
Montréal, Canada (Tremblay et al., 1994). AlI participants were French-
speaking Caucasian men of low socioeconomic status, to control for 
cultural and social factors. A subsample of 177 were invited to the labo-
ratory at the age of 13 to 14 years, where the relationship belWeen 
cognitive functioning and the stability of aggressive behaviors was studied 
[an extensive description of this subsample is provided by Séguin el al. 
(1995)]. A total of 66 of these 177 individuals agreed to participale in an 
alcohol challenge study when they were at least 18 years of age (mean, 
19.15 years; SD, 0.36 years), which is the legal drinking age in Québec. 
This subsample of 66 participants was not significantly different from the 
entire longitudinal cohort on measures of verbal intelligence, childhood 
family income, or self-reported delinquency over a number of years. The 
66 participants were divided inlo 3 equal groups of 22, based on a tripartite 
split of the distribution of the percentage in HR change after alcohol 
administration. Between 50 and 62 months after the aliohol challenge, the 
groups of high- (n ; 22) and low-HR responders (n = 22) were asked to 
participale in a telephone interview in which personality and stimulant use 
were assessed. A total of 37 participants took part in the phone interview. 
One participant refused, one had died since the alcohol challenge, and the 
remaining [IVe were impossible to either retrace or reach by telephone. A 
total of 19 high-HR responders and 18 low-HR responders successfully 
completed tbe telephone inlerview. 
Materials 
Physiologie Apparatus. HR was measured witb a Conlact Precision, 
Cambridge, MA polygraph via IWo electrodes placed bilaterally on tbe 
chest and one on the lower left abdomen of each participant. 
Alcohol Challenge. Participants consumed 1 ml of 95% akohol USP per 
kilogram of body weight, which is equivalent to 0.75 g of etbanol per 
kilogram of body weight. The alcohol dose was presented in the form of 
three separate glasses containing a 1 part ethanol:6 parts orange juiee 
solution. Participants were instructed to empty each glass in exact/y 5 min 
to ensure a constant rate of ingestion. Ali participants complied with these 
instructions. Blood alcohol concentrations were determined by using an 
Alco-Sensor III (Thomas Electronic Security, Montréal, Canada), which 
bas a measurement error of :!:0.003. 
Subjective Effects of Alcohollntoxication. Subjective effects after alcobol 
intoxication were measured with a modified version (Schuckit et al., 1997) 
of the 15-item Subjective High Assessment Scale (SHAS; Judd et al., 
1977). The following subscales were derived from this measure: (1) sub-
jective effects subscale, including the [mt 13 items of the SHAS; (2) global 
negative feeling (item 14 of tbe SHAS: ~G/obally tbe worst 1 have ever 
felt"); and (3) global positive feeling (item 15 of the SHAS: "Globally, the 
best 1 have ever fel!"). Items 14 and 15 were analyzed separately on the 
basis of the suggestion that they should nol be included in the total SHAS 
score because Ibey related to separate alcohol effect dimensions (Conrod 
et al., 2001). 
Personality and Drug Use Assessment (Telephone Interview). The Sensi-
tivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ; 
Caseras et al., 2003; Torrubia et al., 2001), the Substance Use Risk Profile 
Scale (SURPS; Woicik and Conrod, The Substance Use Profile scale 
(SURPS): an instrument for measuring personality risk for substance 
BRUNt:LLt ~ 1 l"'\L~ 
abuse, submilled), and the Addiction Severity Index (McLeDan et a1., 
1980) were adminislered during a telephone interview. 
The SPSRQ is composed of the SP and the SR subscaJes, which each 
contain 24 items. Il was designed to measure the respective level of 
functioning of the BIS and the BAS. On the basis of a review of Grays 
model, the authors of the SPSRQ suggested that to adequately measure 
Gray's dimensions, the BAS should correlate positively with extraversion 
and neuroticism, whereas the BIS should correlate positively with neurot-
icism and negatively with extraversion on the Eysenck Personality Qnes-
tionnaire (Eysenck and Eysenck, 1975). These hypotbeseswere supporte</, 
because SR wasrelatedpositively to extraversinn (r; 0.37;p < 0.01) and 
neuroticism (r = 0.25; P < 0.01) and SP was associated negatively' with 
extraversion (r = -0.48; P < 0.01) and positively with neuroticism (r = 
053; P < 0.01). Recently, this Same group of researchers (Caseras et al? 
2003) compared a variety of anxiety and IMP measures to determine 
which were best suited 10 measure individua/ differences in BISIBAS 
functioning. ln addition to providing convergent and discriminant validity 
information on the SPSRQ, the aulhors also performed a factor analysis 
wilh ail scales. A IWo-factor solution emerged that included an BlS-related 
scales on factor 1, whereas the second factor included almost ail BAS 
scales. Because the SP and the SR subscales were respectively among the 
highest-Ioading scales on factor 1 and factor 2 and showed a pattern of 
correlations wilh the Eysenck Personality Questionnaire that was consis-
tent with Gray's expeclations, the aulhors concluded that the SPSRQ was 
among the best measures of Grays BIS and BAS dimensions. Additional 
construcl validity was obtained by using the SPSRQ scale 10 test predic-
lions based on Gray's model in laboratory settings (ÂVlla et al.,1999; Âvila 
and Parcet, 2000, 2001, 2002). Finally, internai consistency and test-retes! 
reliability seemed satisfactory for both the SP and SR subscaJes (a = 0.83 
and 0.77, respeetively; r at l-year interva) of 0.74 and 0.69). 
The SURPS' is a 28-ilem instrument that measures the following 
dimensions: H/l, AS, IMP, and SS. The items were derived from a larger 
item pool constituting a variety of personality tests that tap into those four 
personality dimensions. The " coefficients ranged from 0.68 to 0.87. 
Test-retest reliability (mean, 39.6 days; SD, 18.75 doys) was high for the 
H/l, IMP, and SS subscales (r = 0.74,0.76, and 0.86, respectively) but was 
lower for AS (r = 0.53). Convergent and discriminant validity information 
was obtained by correlaling the SURPS with the following personality 
measures: Beek Hopelessness Scale (Beek el al., 1974), Anxiety Sensitivity 
Index (Peterson and Reiss, 1992), Impulsiveness and Empathy Scale 
(Eysenck et al., 1985), Sensation Seeking Scale (Zuckerman et al., 1978), 
and NEO Five-Factor Inventory (NEO-FFl; Costa and MeCro., 1992). 
The SURPS subscales were shown 10 correlate besl with the expected 
persona/ity measures. For example, Ihe H/I subscale was positively asso-
cialed with the Beek Hopelessness Scale (r ; 0.74; P < 0.001), with 
neuroticism on the NEO-FFl (r = 054;p < 0.001), and, to a much lesser 
degree, with the Anxiety Sensitivity Index (r = 0.26;p < 0.001). The H/l 
subscale of Ihe SURPS also correlated negatively witb extraversion (r = 
-0.45; P < 0.001) and conscientiousness (r = -0.38; p < 0.001) on the 
NEO-FFl. H/l was not significantly related to Ihe Impulsiveness and 
Empathy Sca/e, the Sensation Seeking Scale, or the openness and agree-
ableness dimensions of the NEO-FFL AlI SURPS subscoles were shown to 
correspond differentially 10 the type of drugs abused (AS with anxiolytics/ 
sedatives, IMP with stimulants, SS wilh a!cohol, and H/l with opioids) and 
10 reinforcement-specifie motives of a!cohol and drug use (H/l and AS 
with negative reinforcement motives, SS with positive reinforcement mo-
tives, and IMP with a disorganized pattern of motives). Confirmatory 
factor analyses confirmed that the SURPS' four-factor structure provided 
a better fit to the data than a 1W00factllr model (positive versus negative 
reinforcement sensitivity) or a five-factor model (NEO-FFJ). 
An abbreviated version of the Addiction Severity Index was used to 
• Additional infonnalion regarding the psychometrie properties of the 
SURPS may be obtained by corresponding with Patricia J. Woicik, Depart-
ment of Psychology, Slate University of New York al Slony Brook, NY 
11794-2500; E-mail: pwoicik@ic.sunysb.edu. 
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assess stimulant use. Although it is based on self-report data. this method 
of assessing substance use bas been demonstrated to be bolh valid and 
reliable (Fals-Stewart et al~ 2000). 
Procedure 
Alcohol Challenge. Before tbe alcohol challenge, individuals were con-
tacted over the phone 10 determine interes! in and eligibility for partici-
pation. Extensive information regarding tbe procedures involved in tbe 
study was provided. Criteria Ieading to exclusion from the study included 
any factor conlraiodieating alcobol consumption, sucb as self-reported 
medical problems or conditions; prescription drug use; illicit drug abuse or 
dependenee; psycbiatric disorders; alcohol-Telated offenses; or lack of 
familiarity with tbe alcohol dose required for participation in tbe study. In 
addition, participants bad to be al least 18 years of age at the time of tbe 
study, wbicb Tepresents the legal drinking age in Québec. Participants 
were asked to refrain from drinking alcobol 24 br before and from using 
drugs for 7 days before the day of lesting. Also, tbey were told not to drive 
to and from tbe laboratory on tbe d.y of testing, and measures were taken 
10 solve any transportation problems. 
On tbe day of testing, participants were given a description of the 
procedures and were informed of their right to witbdraw at any time, but 
they were told that once inloxicated, they wou/d have to wait uDtil Iheir 
blood alcobol concentrations bad reacbed a levelless tban 0.04%. Sobriety 
was established by breatrung into tbe breathalyzer for 6 sec. Abstinence 
from drug use for 7 days before the appointrnent was determined by 
self-report. Participants were tben weigbed to assess tbe amount of alco-
bol to be administered and were offeTed a ligbt snack befoTe abslaining 
from food for the 4 br preceding alcobol consumption. During Ibis time, 
a variety of tests and tasks not relevant to this investigation were 
administered. 
Atter Ibe completion of these taskg, a sober baseline HR was obtained 
for ail participants wbiJe they were resting cnurfortably in a cbair. Ailer 
resting for 10 min ta allow adaplation to the device, the baseline sober HR 
was measured for 5 min, during wbicb the participant was instructed to 
remain as still as possible. Aleobol was administered in the form of three 
glasses that wele ingested at a constant rate of one drink per 5 mm. 
Participants relaxed for 15 min to allow alcohol absorption. The SHAS 
was tben administered to measure tbe subjective effects of alcohol intox-
ication. To ensure HR measurement on tbe AL-BAC (Conrod et al., 
1997), eacb participant's intoxicated baseline HR was taken for 5 min after 
only 30 min after the onset of a1cohol ingestion. Participants were not 
permitted to leave before their blood alcohol concentrations had reacbed 
a level less Ihan 0.04%. During tbis time, they were invited to read or 
walch television and were offered a rneal. 
Personality and Drug Use Interview. Participants from the high- and 
low-HR response group were administered tbe SPSRQ, the SURPS, and 
a modified version of the Addiction Severity Index during a telephone 
interview tbat look place 50 to 6Z months after Ibe alcohol cballenge. 
Telephone interviews have been shown 10 improve the quality of Ihe dala 
oblained when compared witb face-to-face interviews (Greenfield el al., 
ZOOO; Midanik et al., Zool). 
RESULTS 
Data Preparation and Derivation of Cardiovascular 
Variables 
The autonomie signals were stored in a computer for 
later processing. The reciprocal of the interbeat interval of 
the cardiac cycle was multiplied by 60,000 to obtain HR in 
beats per minute. Sober resting baseJine HR and alcohol 
intoxicated resting baseline HR were calculated by averag-
ing each respective 5-min baseline. The percentage of HR 
change after ethanol intoxication was obtained by subtract-
ing the sober resting baseline HR from tbe intoxicated 
resting baseline HR and dividing the difference by the 
sober baseline HR. The 66 participants were divided into 3 
groups, based on the distnbution of percentage change in 
HR after alcohoI intoxication. Low-HR responders in-
cluded all participants in the lower third of the distribution 
with increases less tban 955% (mean, 3_23%; SD,5.75%). 
High-HR responders obtained HR scores in the upper 
third of the distnbution and displayed increases more than 
17% (mean, 23.50%; SD, 4.86%). The middJe group of the 
distnbution was not of interest in this study, because its 
main goal was to find support for a link between high and 
low HR response and personality characteristics. As previ-
ously mentioned, 18 of the 2210w-HR responders and 19 of 
tbe 22 high-HR responders completed the telephone inter-
view in which personality and drug use were assessed_ 
AlI variables in the study were screened for nonnality 
and outliers. One outlier was found in the SS scores and 
was replaced by a score one unit larger than the nen 
extreme score_ This procedure is in accordance with 
Tabachnick and Fide)) (1996) for wben reduced sarnple 
sizes are a potential issue_ 
Demographies, Verbal Intelligence, and Blood Alcohol 
Concentrations 
Separate analyses of variance were perfonned to deter-
mine whether high- and low-HR responders were sirniJar 
on demographic variables, verbal intelligence scores, and 
blood alcohol concentrations_ Results indicated that the 
differences between high- and low-HR responders on age, 
years of education, childhood familial incorne, and verbal 
intelligence were not· significant. However, high-HR re-
sponders displayed higher blood alcohol concentrations 
after alcohol ingestion than low-HR responders (Table 1). 
HR Response to A/cohol and the Subjective Effects of 
Alcohol Intoxication 
No significant differences were found between high- and 
low-HR responders in the SHAS total (rnean of items 1-13) 
subjective effects score [F(1,35) = O.OO9;p = 0.923]. Because 
the global negative feeling subscale (item 14) was not nor-
rnally distributed, nonparametric analyses were perfonned on 
this subscale. No sig/lÜÏcant differences were found in nega-
tive feelings after intoxication between bigh- and low-HR 
responders [U(1, N = 3'1) = 133; p = 0.220}. However, 
bigh-HR responders obtained significantly higher scores on 
the global positive feeling subscaIe (item 15) than low-HR 
responders, indicating that they experienced more positive 
feelings after alcohol intoxication [F(l,35) = 5_812;p = 0.02). 
HR Response to Alcohol in Re/ation to the SPSRQ, the 
SURFS, and the Addiction Severity Index 
Multiple analyses of variance were perfonned to detenniue 
the relationships between the HR response to a1cobol intox-
ication and the various questionnaires administered (Table 2)_ 
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Table 1. Group Differences Belween Low- and High-HR Responders 10 AlcohoJ Intoxication on Demographies, Inlellectual Functioning, and BIood Alcohol 
Concentrations (BACs) 
Low High 
responders responders 
Baseline variables Mean SD Mean SD dt F pVaiue 
Age (years)" 19.18 0.39 19.06 0.24 33 1.10 0.30 
Years of educationb Il.56 1.50 Il.26 2.13 34 0.22 0.64 
Childhood househoJd incomec 6.54 3.33 5.82 2.72 29 0.42 0.52 
Verbaf intelligence scored 922 2.02 9.44 2.00 35 0.11 0.75 
BACs 0.064 0.016 0.081 0.018 31 7.89 0.01 
" Age at lime of alcohol challenge. 
b Years of education compleled at the lime of alcohol challenge. 
C Household income al age 10. Family income scale ranges !rom 1 to 13; 1 inotcates revenues less!han $5,000 (Canadlan dollars), wilh incnaments of $5,000 unlil 
13, which represents salaries more than $60,000. 
d Verbal intelligence was assessed al age 13 by using the Sentence Completion Test (Veroff et al., 1971). Scores can range /rom 0 10 13 on Ihls lest. 
Table 2. Group Differences Between Low- and High-HR Responders to A1cohollnloxication on the SPSRO, the SUIlPS, and the Addiction Severity Index 
Low responders High responders 
For 
Variable Mean SD Mean SD dl ;fa p Value 
SP 6.83 3.64 7.16 4.69 36 0.05 0.82 
SR 11.00 3.68 13.68 4.03 36 4.46 0.04 
H/I 13.78 3.46 Il.11 2.77 36 6.78 0.01 
AS 14.89 2.45 14.63 4.57 36 0.06 0.83 
IMP 15.22 3.00 17.26 3.78 36 3.28 0.08 
SS 18.00 2.11 19.74 2.55 36 5.04 0.03 
Camabis (%)b 88.89 94.74 0.42 0.48 
Cocaïne 16.67 26.32 0.51 D.38 
Amphetamine 16.67 15.79 0.94 0.64 
Ecstasy 16.67 10.53 0.30 0.47 
a Chi-square tests were performed on categorical data 
b Percentage of individuals thaï used cannabis. cocaïne. amphetamine. or Ecstasy more than five times. The response was scored as 0 (no) or 1 (yes). 
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On the SPSRQ, high-HR responders had significantly higher 
SR scores but were not significantly different from low-HR 
responders on SP (Fig. 1). On the SURPS, high-HR respond-
ers had significantly lower H/I and higher SS scores as com-
pared with low-HR responders, There was also a trend 
for high-HR responders to obtain higher IMP scores, but 
no differences in AS were obtained between groups 
(Table 2 and Fig. 2). One-tailed -;(- tests were performed 
to examine the relationship between HR response and 
stimulant use. No significant differences in drug use emerged 
between high- and low-HR responders (Table 2). 
Because a significant difference in blood alcohol concen-
trations was found between the two HR response groups, 
one-tailed partial correlations controlling for blood a1cohol 
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rI!!. 2, Mean group differences betwean low-HR responders (n = 18) and 
high-HR responders (n = 19) on lhe SURPS. 
concentrations were performed between the personality 
variables and HR response. Results were essentially un-
changed: SR (partial r = 0.39; p = 0.01) and SS (partial r = 
0.35; p = 0.03) were significantly associated with an 
alcohol-induced HR increase on the AL-BAC, whereas 
there was a trend for a positive relationship between IMP 
and cardiac reactivity (partial r = 0.28; P = 0.06), The 
negative relationship between H/I and HR response be-
came a nonsignificant trend (partial r = -0.29; P = 0.06) 
when blood alcohol concentrations were controlled for. 
The SURPS in Relation to the Addiction Severity Index 
Participants who had used cocaine more than five times 
obtained significantly higher scores on the IMP dimension 
HEART RATE RESPONSE AND SENSrTMIY TO REWARD 
of the SURPS [F(1,36) = 5.68; p = 0.02}. Those who had 
used amphetamines more than five times also obtained 
higher IMP scores [F(1,36) = 6.98; p = 0.01] on the 
SURPS. Individuals who had used Ecstasy more than five 
times had a tendency to obtain higher IMP scores, although 
the difference did not reach significance [F(1,36) = 3.14;p 
= 0.09}. No other significant reJationships were found be-
tween the remaining subseaJes of the SURPS and stimulant 
use. 
DISCUSSION 
This study looked at the relationship between heightened 
HR responses to alcohol intoxication on the AL-BAC and 
personality. We found that high-HR responders obtained 
significantly higher SR scores when compared with low-HR 
responders. These results suggest that individuals with a 
heightened HR response are more sensitive to reward, 
which may refleet overactivation of the BAS. High-HR 
responders did not seem to differ from low-HR responders 
on the SP seale, which is thought to measure activation of 
the BIS. 
We also found that an increased HR response to alcohol 
was associated with increased SS scores and positive feel-
ings after aIcohoJ intoxication. Many studies involving both 
human and animal subjects have associated SS/novelty-
seeking with aleohol use (Daderman, 1999; Fernândez-
Teruel et al., 2002; Galen et al., 1997; Johansson and 
Hansen, 2002). Recent research seems to indicate that the 
meehanism through which this personality profile and 
drinking may be related involves the dopaminergic system. 
Leyton et al. (2002) found that individuals high in novelty-
seeking had greater amphetamine-induced DA release and 
responded to the drug challenge by desiring more of the 
drug. Similarly, rats high in exploratory behaviors drink 
more ethanol and show increased ethanol-indueed DA ac-
tivation and enhanced place preference for ethanol 
(Fernândez-Teruel et al., 2002).1t has also been found that 
high SS predicts drinking for its capacity to increase posi-
tive affect (Comeau et al., 2001). The previously reviewed 
evidence suggests that reward sensitivity might mediate the 
relationship between this personality profile and drinking 
behavior. Therefore, the possibility that a high HR re-
sponse may be a neurobiological marker for a pathway that 
leads to alcohol problems through seeking highly pleasur-
able experiences should be further investigated. 
We had hypothesized that high-HR responders would 
obtain higher IMP scores than low-HR responders on the 
SURPS. Although we observed a trend in this direction, the 
difference between groups was not significant. It is possible 
that with a larger sample size, the hypothesis would have 
been confirmed. However, sorne evidenee suggests that SS 
and IMP might be risk factors that underlie separate etio-
logical mechanisms. Finn et al. (2000) found that social 
deviance and excitement/pleasure-seeking were two sepa-
rate biopsychosocial pathways that Ied to alcohol problems 
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in individuals \vith a family history of alcoholism. The 
former includes self-regnlatory deficits and lack of consid-
eration for social norms and may involve frontal region or 
septohippocampal deficits. The excitement-seeking path-
way was descn1Jed as involving SS traits that were associ-
ated \vith BAS functioning, sensitivity to pleasurable activ-
ities, and mesolimbic DA influences. Furthermore, it has 
been suggested that these two separate pathways have in-
dependent genetic influences (Mustanski et al., 2003). 
Sensation-seekers seem to drink to benefit from ethanol's 
positively reinforcing qualities, as demonstrated in studies 
involving both adults (Conrod et al., Anxiety sensitivity, 
introversion/hopelessness, sensation seeking and impulsiv-
ity: different patterns of reinforcement sensitivity and drug 
abuse susceptibility, unpublished data) ànd adolescents 
(Comeau et al., 2001). IMP seems not to be associated \vith 
specifie motives as such, except for a disorganized and 
severe pattern of drug abuse (Woicik and Conrod, The 
Substance Use ProfIle scale (SURPS): an instrument for 
measuring personality risk for substance abuse, submitted). 
Moreover, an impulsive profùe was found to co-occur \vith 
antisocial personality disorder, whereas SS did not (Conrod 
et al., 2000). 1t is thought that IMP is associated \vith 
vulnerability to alcoholism through a pathway that includes 
antisocial personality disorder and deficits in executive cog-
nitive function (Finn et al., 2002). Therefore, preliminary 
evidence suggests that a high HR response on the AL-BAC 
may be more c10sely related to the risk factor of SS than 
IMP. 
An additional goal was to investigate HR response and 
personality traits in relation to stimulant use. It was found 
that high-HR responders did not use stimulants signifi-
eantly more often than low-HR responders but that stim-
ulant users had higher IMP scores. Our findings are similar 
to those of another study that found IMP, but not SS, to be 
associated with stimulant use (Conrod et al., 2000). This 
may offer additional support to the idea that IMP and SS 
are associated with distinct motivational reasons for abuse, 
as weil as \vith different drug use patterns. 
This study expands our understanding of the relationship 
between personality and drinking behavior. A high-HR 
response seemed to be associated with a reward-seeking 
personality profile, as demonstrated by increased SR and 
SS scores. This study and others suggest that further work 
is needed to fulJy disentangle the different mechanisms that 
underlie the personality risk for alcoholism. Work in this 
area may have been impeded by using broad terminology 
that may obscure distinct mechanisms of etiological risk 
(Finn et aI., 2000). Additional research might foeus on 
finding characteristics that separate sensation-seekers from 
impulsive individuals. Moreover, to further expand on the 
differential sensitivity theory, the question of whether in-
ereased scores on the SP scale (reflecting BIS activation) 
could indicate negative reinforcement motives of abuse 
Should be investigated. This may be possible because aux-
iety is associated \vith using alcohol for its capacity to 
400 
reduce negative affective states (Stewart et al., 1997) and 
because BIS activation represents individual vulnerability 
to anxiety (Torrubia et aJ., 2001). 
There are, nevertbeless, limitations to our study. A small 
bomogenous sample composed of young Frencb-speaking 
men from a low socioeconomic status Canadian neigbbor-
bood limits tbe generalizability of the findings to other 
populations. Furthermore, no placebo control group was 
included in the study. No differences seem to occur in HR 
responses to placebo in subjects with or witbout a family 
history of alcobolism (Newlin and Thomson, 1999), sug-
gesting the Jack of expectancy effects in the aicohol-HR 
relationship. Finally, althougb our results may suggest that 
a beigbtened HR response to alcohol intoxication is asso-
ciated with a pathway tbat leads to alcohoJ probJems 
througb reward-seeking personality traits, the study design 
does not aIlow us to conclude that this is indeed the case. A 
prospective study will be necessary to offer more support to 
the idea that the HR response to aicohol mediates the 
relationship between personality and aicohol problems. 
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The hedonic response to cigarette smoking is proportion al to dopamine 
release in the human striatum as measured by positron emission 
tomographyand [lIe] raclopride 
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ABSTRACT Positron emiss:ion tomography and (llClraclopride were used to assess 
the dopaminergic response to cigarette smoking in ten smokers. Nicotine-deprived 
smokers were scanned twice on separate days. In one condition, participants smoked 
their usual brand of cigarettes while in the scanner and in the other condition they 
remained nicotine abstinent. On each day, subjects monitored the hedonic properties of 
their experience as weIl as their levels of craving. Initial analyses revealed no significant 
differences between the conditions in 1'1Clraclopride binding potential (BP) in the 
cau date, putamen, or ventral striatum. Because previous research suggested that drug-
induced dopamine transmission i8 related to Jevels of craving and/or hedonic drug 
effects, the relationship between these variables and (llCJraclopride BP was examined. 
Craving levels were reduced by smoking but were not systematically related to BP 
change. However, the hedonic response to smoking was correlated with BP reduction in 
the caudate (P < 0.001) and posterior putamen (P < 0.05) but not in the ventral 
striatum. Post hoc analyses revealed that only five of the ten smokers reported mood-
elevating effects in response to the smoking procedure. In these subjects, smoking was 
associated with decreased [llClraclopride BP in the caudate. On the other hand, among 
subjects that reported a diminished mood response to smoking there was an increase in 
BP in the caudate and putamen. These results suggest that pleasurable drug experi-
ences are associated with increased dopamine transmission in the dorsal striatum while 
unpleasant experiences may be related to decreased dopamine release in this region. 
Synapse 54:65-71, 2004. " 2004 Wiley·Liss, Ine. 
INTRODUCTION 
Cigarette smoking has been identified as the leading 
cause of preventable death in industrialized nations 
(Polin, 1984). While cigarette smoke contains several 
thousand compounds (Schmeltz and Hoffmann, 1976), 
tobacco dependence appears to be predominantly asso-
ciated with the addictive properties of a solitary alka-
loid, nicotine (e.g., Domino, 1998). Evidence in rodents 
suggests that important aspects of nicotine addiction 
may be mediated by central dopamine (DA) systems. 
For example, nicotine administration leads to in-
creased DA cell firing in the ventral tegmental area 
(Corrigall et al., 1994) and increased DA release in the 
nucleus accumbens (pontieri et al., 1996), actions 
thought to be critical to the reinforcing properties of 
© 2004 W!LEY·L1SS, lNe. 
several addictive substances (Wise 1996; Di Chiara and 
Imperato 1988). In addition, disruption of DA function 
in rats has been shown to attenuate nicotine self-ad-
ministration (Corrigall et al., 1994), nicotine-induced 
locomotor stimulation (Clarke et al., 1988), as weIl as 
the acquisition ofnicotine·related place preference (Di 
Chiara, 2000). Despite evidence linking nicotine's ad-
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dictive properties with its central DA actions, nicotine's 
DA stimulating properties are relatively weak com-
pared to other addictive substances sucb. as amphet-
amine or cocaine (Yanagita et al., 1995; Tsukada et al., 
2002; Marenco et al., 2004; see Cumming et al., 2003) 
and appear more akin to those produced by "natural" 
reinforcers such as food (Di Charia, 2000). Evidence 
linking nicotine administration to DA release in hu-
mans and in non-human primates is currently limited. 
In a PET study using anesthetized babooDS, intrave-
nous nicotine reduced the mean distribution volume 
ratio of the D2 tracer IllCJraclopride, an action thought 
to refiect increased DA release (Dewey et al., 1999). 
While similar results have been reported in anesthe-
tized pigs (Cumming et al., 2003) and anesthetized 
rhesus monkeys (Marenco et al., 2004) these findings 
have not heen consistently replicated in fully conscious 
monkeys (Tsukada et al., 2002) and it is possible that 
the initial findings resulted from an interaction be-
tween nicotine and isofiurane anesthesia (Tsukada et 
al., 2002). In a functional magnetic resonance imaging 
siudy in humans, smokers that passively received in-
travenous nicotine displayed an increase in the blood 
oxygen level dependent signal in several DA rich re-
gions including the nucleus accumbens (Stein et al., 
1999). However, these findings should he interpreted 
with caution because the route of nicotine administra-
tion differed from that used by smokers and the meth-
odology did not directly measure DA release. 
The present investigation used PET and [l1Clraclo-
pride to assess the dopaminergic response to acute 
cigarette smoking in humans. Experimental evidence 
indicates that drug-induced DA release in the striatum 
causes a reduction in [llClraclopride binding potential 
(BP) that is proportional to the increase in extracellu-
lar DA (Endres et al., 1997). Although the exact mech-
anism by which enhanced DA transmission leads to a 
reduction in I11C]raclopride BP is likely more complex 
than what could he explained by a simple competition 
model (Tsukada et al., 2000), this technique has been 
successfully used to delineate the dopaminergic effects 
of several abused substances in hum ans, including co-
caine (Schlaepfer et al., 1997), amphetamine (Drevets 
et al., 2001; Martinez et al., 2003; Leyton et al., 2002), 
methylphenidate (Volkow et al., 2003), and alcohoI 
(Boileau et al., 2003). Previous PET data suggest that 
DA release in the striatum is related to various moti-
vational and rewarding processes in humans. For ex-
ample, decreased (llClraclopride BP in the ventral stri-
atum (including the nucleus accumbens) is associated 
with the appetitive (Leyton et al., 2002) and euphorie 
(Martinez et al., 2003; Drevets et al., 2001) effects of 
amphetamine, while the pleasurable effects of food 
(Small et al., 2003) have been associated with de-
creased 1' 1Clraclopride BP in the dorsal striatum (cau-
date and putamen). Thus, a goal of this study was to 
examine the DA properties of nicotine craving and the 
hedonic effects of smoking. 
METIIODS 
Subjects 
Ten right-handed, non-medicated smokers (5 males) 
with a mean age of 28.1 years (SD = 9.45) were re-
cruited from the community using word of mouth and 
advertisement. AIl were regu1ar smokers, smoking an 
average of 18 (SD = 7.6) cigarettes daily for an average 
of 11.2 years (SD = 10.5) and all were free from current 
or previous neurological or mental illness, including 
past or present substance use disorders other than 
nicotine dependence. None reported use of ilIegal drugs 
in the previous 30 days and all met a lninimum of two 
DSM IV criteria for nicotine dependence. Following a 
complete description ofthe study, ail participants pro-
vided written informed consent. The study was con-
ducted in accordance with the Declaration of Helsinki 
and was approved by the Research Ethics Committee of 
the Montreal Neurological Institute. 
Procedure 
Each participant was scanned twice. In ·one condi-
tion, subjects smoked their usual brand of cigarettes 
while in the scanner, and in the second condition par-
ticipants did not smoke. In OOth conditions, partici-
pants remained abstinent from cigarettes for a lnini-
mum of 12 hours, alcohol for a minimum of 24 hOUTS, 
and from food and caffeine for a minimum of 4 hours 
prior to their scans. AlI scans were performed at the 
same time of day (mid-afternoon) following overnight 
cigarette abstinence. The sequence of scans was coun-
terbalanced across subjects to avoid order effects. Ab-
stinence from smoking was confirmed with a breath 
carbon monoxide analyzer (Vitalograph Breath CO, Le-
nexa, KS), using a maximum cutoff of 10 parts per 
lnillion. Every 15 minutes while in the scanner, sub-
jects were asked to verbally rate the hedonic value of 
their experience as weIl as their level of craving by 
numerically indicating their agreement with the fol-
lowing statements: "1 feel elated or euphoric" and "I am 
craving a cigarette right DOW" (on a scale from 1 = 
strongly disagree, to 10 = strongly agree). 
In the smoking condition, cigarette consumption he-
gan 15 minutes prior to (llCJrac1opride delivery. The 
average nicotine yield of each cigarette smoked by the 
subjects ranged from 1.9-2.4 mg (mean = 2.1; SD = 
0.1). Subjects were asked to smoke at a rate of one 
cigarette every 12 minutes to a maximum of six ciga-
rettes. In two cases, only five cigarettes were smoked 
due to complaints of adverse effects. In order to avoid 
additional unpleasant responses, the smoking regimen 
was altered for the final two subjects so that only three 
cigarettes were smoked. ln each case, smoking was 
carefully monitored to ensure a steady pace of smoking 
CIGARETI'E SMOKING AND ["C]RACLOPRIDE BINDING 67 
as weIl as minimal movement in the scanner. Head 
position was verified throughout the scans using a la-
ser mounted on the camera. 
PET image acquisition and analysis 
Dynamic PET (63 slices, 26 time frames of 60 min-
utes total duration) was perfonned using the CTl/Sie-
mens ECAT HR+ camera with lead septa removed, 
with à theoretical spatial reoolution of 4.2 mm full 
width at half maximum. A transmission scan for atten-
uation correction was first perfonned using a ~e 
source. Then, ("Clraclopride (10 mCi in 10 ml of sa-
line) was injected over 120 seconds into the antecubital 
. vein and dynamic acquisition was begun. High-resolu-
tion 1.5 T Tl-weighted MRI scans were obtained at a 
separate time for each subjeet for the purpose of ana-
tomical co-registration. 
PET frames were summed and co-registered with the 
MRI, and both images were transfonned linearly into 
standardized stereotaxie space using the Montreal 
Neurological Institute template (Collins et al., 1994). 
Parametric maps of (llClraclopride BP were generated 
using a simplified referenee region method (Lam-
mertsma and Hume, 1996; Gunn et al., 1997). Regions 
of interest (ROI) were drawn in a two-step process 
using automated fol1owed by manual anatomieal seg-
mentation. First, each subject's MRI was automatically 
segmented into predefined anatomical regions using 
the program ANIMAL (Collins et al., 1995). Then, the 
ROI for caudate, putamen (divided into an anterior and 
posterior part by the anterior commissural !ine), and 
ventral striatum were manually revised on the co-reg-
istered MRI following the anatomical segmentation 
suggested by Martinez et al. (2003), which is based on 
the known subdivision of the striatum in primates 
(Parent, 1990). BP values were extracted from each 
ROI and corrected for partial volume effects using a 
method that takes into account the noise and resolu-
tion characteristics of the scanner (Aston et al., 2002). 
It is feasible to perform the partial volume correction 
on the BP images rather than on the original radioac-
tivity images since the simplified compartmental 
model is !inear. Finally, the segmented MRI was used 
to generate a 4-dimensional template that was used for 
head motion detection and correction, using a previ-
ously described method (Zald et al., 2004). Only five of 
the scans exhibited head motion greater than 2 mm 
(range: 2.5 to 4 mm), and these were motion-corrected. 
Because previous research has linked both craving 
and hedonic drug-related effects to changes in ("Clra-
clopride BP (Drevets et al., 2001; Leyton et al., 2002; 
Martinez et al., 2003), analyses were also perfonned to 
examine the relationship between these variables and 
BP change. For the two behavioral variables, baseline 
and overall differences between the two scans were 
evaluated using paired-samples t-tests, and Pearson's 
correlations were used to examine the relationship 00-
tween the average smoking-induced change in the vari-
able and the percent change in [llClraclopride BP for 
each ROI. 
In addition to ROI analysis, voxelwise estimation of 
the change in BP was also carried out to generate 
statistical parametric images as previously descriOOd 
(Aston et al., 2000). Two types of statistical maps were 
generated: a subtraction between smoking and non-
smoking, and a regression map to assess the relation-
ship of BP change to craving and hedonic measures. 
For the latter, a !inear regression was performed at 
. each voxel OOtween the nicotine-induced increase in 
euphoria rating and the difference in [llClraclopride 
BP OOtween the smoking and control scans . 
RESULTS 
Paired samples t-tests revealed no overall significant 
differences in [llClraclopride BP OOtween the smoking 
and control conditions in any of the ROI (all P > 0.05) 
and this was conflrmed by the statistical parametric 
subtraction map. The mean change in BP between the 
smoking and abstinence scans was 3.12% for the ven-
tral striatum, -1.9 % for the cau date, 2.9% for the 
anterior putamen, and -1.59% for the posterior 
putamen. 
Smoking-induced changes in elationleuphoria were 
found to be significantly correlated with changes in 
(llClraclopride BP in the caudate (r = -0.859; P < 
0.001) and posterior putamen (r = -0.679; P < 0.05), 
but not in the ventral striatum (r = -0.015; P = 0.967) 
(Fig. 1). No significant relationships between BP and 
smoking-induced changes in craving were revealed by 
correlation analysis. 
In order to detennine if various demographic and 
smoking-related variables were associated with re-
gional smoking-induced changes in [llClraclopride BP, 
stepwise linear regressions were prefonned using age, 
gender, number of cigarettes smoked daily, number of 
cigarettes smoked during the scan, duration oflifetime 
smoking, nicotine content of cigarettes, smoking-in-
duced changes in elation/euphoria, and level of craving 
as potential predictor variables. In both the caudate 
and posteriorputamen, smoking-related elationleupho-
ria was retained as the sole predictor of (llCJraclopride 
BP change. No associations were found between any of 
the variables and change in [llClracJopride BP in the 
ventral striatum. 
A post hoc inspection of the data revealed that in five 
subjects smoking produced an increase in elated/eu-
phorie ratings, in foùr subjects it produced a decrease, 
and in the remaining subject there was no change 
(Table I, Fig. 2). Paired samples t-tests demonstrated 
that among subjects experiencing an inerease in ela-
tionleuphoria in response to smoking, there was a sig-
nificant 21.3% decrease in [llClraclopride BP in the 
caudate (t (4) = -2.92; P = 0.043) as weil as a nonsig-
nificant trend towards decreased BP in the posterior 
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putamen (P > 0.05). In those experiencing a decrease 
in elationleuphoria, there was a significant 11.3% in-
crease in BP in the posterior putamen (t (3) = 3.30; 
P = 0.046) and trends toward increased BP in the cau-
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date (P > 0.05) and anterior putamen (P > 0.05). The 
statistical parametric correlation map confirms the as-
sociation between reduced [llCJraclopride BP and eu-
phoria (Fig. 3). 
Additional analyses were preformed to determine if 
there were systematic differences within or hetween 
the scans in levels of craving or elationleuphoria. Crav-
ing levels prior to the start of the scan did not signifi-
cantly differ hetween the control and smoking condi-
tions. Craving was reduced in the experimental 
condition following the initiation of smoking (t (9) = 
-2.88; P = 0.018) and overall greater levels of craving 
were reported during the control scan (t (9) = 2.76; P = . 
0.022). There were no significant baseline or overall 
differences hetween the smoking and control scans in 
reported levels of elationleuphoria (P > 0.05). 
DISCUSSION 
In this study, the effects of cigarette smoking on DA 
neurotransmission were dependent on and propor-
tional to the hedonic response of each subject. Partici-
pants were required to smoke multiple cigarettes lying 
on their backs in the scanner. For some subjects, this 
was an enjoyable experience while others found it un-
pleasant. The participants' level of enjoyment ap-
peared to he reflected in changes in DA neurotransmis-
sion in the dorsal striatum (Fig. 2). 
However, we failed to detect a purèly pharmacologi-
cal effect of nicotine on DA transmission. Looking at 
the group of subjects as a whole, there was no overall 
reduction in [llClraclopride BP in any subdivision of 
the striatum in response to acute repeated cigarette 
smoking. These findings suggest that the pharmacolog-
ical actions of cigarette smoking may not be in and of 
themselves sufficient to reduce (llCJraclopride BP in 
human smokers. Although abundant animal reséarch 
suggests that various aspects of nicotine addiction are 
mediated by DA systems (e.g., Di Charia, 2000), the 
present findings are consistent with observations that, 
relative to other abused substances, nicotine may only 
have relatively weak DA actions (e.g., Yan agita et al., 
1995, Marenco et al., 2004). Alternatively, our failure 
to observe a significant overall reduction in [llCJraclo-
pride BP may have resulted from nicotinic receptor 
desensitization resulting from repeated administra-
tion. In rodents, nicotine increases DA transmission 
through stimulation of the nicotinic receptors on DA-
containing neurons (Pontieri et al., 1996) and repeated 
nicotine administration results in a desensitization of 
these receptors (Pidoplichko et al., 1997). Thus, while 
Fig. 1. Relationship between euphoria and dopamine re)ease. Plots 
of the percent difference in [llCJraclopride BP between the smoking 
and non-smoking scans versus the change in self-reporled euphoria 
after smoking. A reduction in BP indicates an increase in dopamine 
transmission. In the caudate nucleus and posterior putamen. there 
was a statistically significant correlation between euphoria and dopa-
mine release (see text for details) but not in the ventral striatum. 
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TABLE 1. Tobacco-induced changes in euplwria and [Ilc]roclopride BP for each participant' 
Posterior Anterior Ventral 
Baseline Post-sInoking Caudate putamen putamen striatum 
Subject euphona euphoria (%) (%) (%) (%) 
9 1 +4.8 -30 -19 -16 -26 
8 3 +1_7 -38 -41 -26 -57 
7 2 +1.5 -6 0 6 25 
2 3 +1.2 -18 -2 16 31 
10 4 +.33 -14 11 13 70 
6 1 0 0 -11 -7 -45 
1 2 -.33 6 13 21 33 
4 3 -1.5 1 4 12 41 
5 4.5 -2 13 5 6 11 
3 5 -4 67 .22 4 -51 
Euphoria was measured using a lo..~int sca1e (1-10). The post-smoking euphoria value represents tlbe change frOID 
baseline. The change in [llC]radopride BP represents the percent difference between the smoking and non-smoking 
ScaDS. 
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Fig. 2. Change in ["C)raclopride BP in the striatum. Sul!iects who 
experienced the smokingIPET session as pleasant demonstrated in-
creased dopamine re]ease in the dorsal sb"Iatum. However,. subjects 
who experienced decreased euphoria from smoking demonstrated ev-
idence of reduced dopamine retease in al) striata1 areas. 
an initial cigarette may stimulate DA transmission, 
subsequent cigarettes may not cause further DA re-
lease unless there is an adequate refractory period 
(Pidoplichko et al., 1997). The cigarette smoking pro-
cedure utilized in thls study required participants to 
smoke 3-6 cigarettes in 12-minute intervals, begin-
ning 15 minutes prior to (llClraclopride administra-
tion. Although this smoking regimen was selected in 
order to maximize the nicotine response, it may have in 
fact resulted in desensitization, thereby reducing any 
nicotine-induced DA effects. 
Another consideration concerns the possible effect of 
nicotine craving on DA transmission. Although there is 
currently no rurect human evidence for a DA mediation 
of nicotine craving, animal models suggest that DA 
transmission in the ventral striatum mediates cravings 
for addictive substances that possess DA agonist ac-
tions (e.g., Robinson and Berridge, 1993; Wise, 1988). 
In the present study, levels of craving were not related 
to [llCJraclopride BP change in either the ventral or 
dorsal striatum. However, El ceilingeffect may have 
been reached because all subjects were nicotine-de-
prived and rusplayed hlgh lèvels of craving prior to 
each scan. Moreover, while craving levels significantly 
decreased following smoking in the experimental con-
dition, they remained· elevated throughout the control 
scan. Thus, if nicotine cravings are indeed associated 
with increased DA transmission, it is possible the per-
sistently e}evated level of craving during the control 
scan mayhave negated our ability to detect a nicotine-
specifie DA response in the experimental condition. 
Nonetheless, a possible explanation for the absence 
of a detectable effect of smoking on DA release in the 
group as a whole may be that DA release is the result 
of an interaction between the pharmacological effects 
of nicotine and the hedonic response to the cigarette. 
lndeed, among those who found the smoking procedure 
pleasurable, there was evidence for DA release in the 
neostriatum, and in those who found it aversive there 
was decreased DA transmission in this region (Fig. 2). 
These findings are consistent with animal data that 
show increased DA cell firing in response to rewarding 
. events but decreased DA neuronal activity in response 
to events that are less rewarding than expected (e.g., 
Schultz et al., 1997). 
The relationship between DA activity and the hedo-
nie effects of smoking was only apparent in the dorsal 
striatum, and not in the limbic ventral striatum 
(Figs. 1-3). A growing body of evidence has implicated 
the dorsal striatum as a key site for differentiating the 
hedonic value of rewarding and punishing events in 
humans. For example, in a recent fMRI study the dor-
sal striatum exhibited a differential response to mon-
etary gains and losses (Delgado et al., 2003). Similarly, 
Small et al. (2001) reported that the pleasurable effects 
of eating chocolate correlated with regional cerebral 
blood flow increases in the dorsal caudate and putamen 
but not the ventral striatum. Finally, in two recent 
[llCJraclopride PET studies, we showed that the plea-
surable effects of eating a meal correlated with DA 
release in the dorsal but not ventral striatum (Small et 
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Fig. 3. Correlation between the reduction in l''CJraelopride BP 
and euphoria. Statistica1 parametrie map of the t-statistie of the 
linear regression of the reduction in ("C)raclopride BP between 
smoking and non-smoking scans and the increase in euphoria ~esult­
ing from smoking. The statistical map is overlaid on an average MRl 
al., 2003), and thatmonetary reward led to DA release 
in dorsal parts of the striatum (Zald et al., 2004). Hu-
man drug administration studies have produced Jess 
consistent results. The euphorie effects of amphet-
amine have heen repOrted to correJate with the level of 
. DA release in the ventral striatum (Drevets et al., 
2001; Martinez et al., 2003) but this finding has not 
heen consistently reported (Leyton et al., 2002). It 
should be noted, however, that while the present inves-
tigation examined the effects of tobacco self-adminis-
tration in nicotine-dependent smokers, each of the am-
phetamine studies cited used drug-naive participants 
who passively received the drug. Thus, disparities in 
the expression ofhedonic drug effects hetween studies 
may reflect differences in the type of drug adminis-
tered, the route and method of administration, or the 
previous drug-taking experiences of the participants. 
For example, there is evidence that expectation of a 
positive drug effect in humans is associated with DA 
release in the striatum (de la Fuente-Fernandez et al., 
2001). 
The present results should be interpreted in light of 
the following considerations. First, while participants 
were permitted to smoke their usual brand of ciga-
rettes during the scan, the experimenters determined 
the frequency and rate of cigarette administration and 
this likely affected their hedonic value. An alternative 
design where participants were permitted to smoke ad 
lib might provide a superior index of how cigarette 
smoking affects DA transmission under "typical" smok-
ing conditions. Second, variability in nicotine concen-
trations of the different brands of cigarettes smoked as 
weil as potential individual differences in nicotine me-
tabolism may have led to differences in plasma nicotine 
concentrations. Although plasma nicotine levels were 
not directly measured in this study, this is an unlikely 
explanation for our findings. Numerous cigarette-
smoking parameters were found to he unassociated 
with changes in ['lC)racIopride binding including nic-
otine content of the cigarettes smoked, number of cig-
arettes smoked during the scan, and daily cigarette 
consumption, suggesting that the effect of differences 
image of ail subjects in stereotaxie spaœ. Axial sections from z = - 5 
mm to z = + 15 mm at 5-mm interva]s are shown (relative to the 
anterior commissure). The correlation is greatest in the dorsal and 
posterior parts of the neostriatuID. The left side of each image repre-
sents the left side of the brain. 
in plasma nicotine on our results was likely minimal. 
Finally, the sample size in this study was modest (n = 
10), but was weIl within the norms for assessingwithin 
subject drug effects, and the overall associations he-
tween the hedonic effeets of smoking and change in 
[llCJraclopride BP in the caudate (P < 0.001) and pos-
terior putamen (P < 0.05) were robust. 'Even when 
participants were divided into those experiencing eu-
phorie and· dysphorie effeets, the reported [llClracIo-
pride BP changes still exceeded P < 0.05 and smaII 
sample size is typieally associated with increased inci-
dence of type 1 but not type II error, 
In conclusion, although cigarette smoking failed to 
consistently alter DA transmission in the group as a 
whole, a relationship was observed between smoking-
indueed hedonie effects and DA release in the dorsal 
striatum. In subjeets experiencing a positive mood re-
sponse to smoking, there was evidence for increased 
DA release, while decreased DA activity was associated 
with a negative mood response. 
These findings suggest that changes in DA transmis-
sion in the dorsal striatum are related to the valence of 
affective responses to abused substances. However he-
cause of the correlational nature ofthe data, it is eur-
rently not possible to determine if changes in DA re-
lease are a cause or a consequence of drug-induced 
hedonie change. 
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Abstract 
The acute phenylalanine/tyrosine depletion (APTD) method was recently developed 
as a new tool to transiently decrease catecholamine transmission in humans. Initial 
studies indicate that the treatment iS sare, weil tolerated, and effective. Studies in 
primates suggest that both dopamine and norepinephrine syntheses are decreased, 
and that it might be possible to separate the effects of dopamine and norepinephrine 
using 3,4-dihydroxy-l-phenylalanine (L-DOPA). Behavioral effects appear to develop 
rapidly after treatment, within 3 hours in some studies. Furthermore, preliminary 
findings in healthy individualS suggest that APTD can lead to a miU mood-Iowering 
effect associated with decreased interest in both natural anddrug rewards. In bipo-
lar patients, more pronounced effects may be elicited, and manic symptoms might 
be reduced. A variant of this technique is being developed that would be suitable for 
extended administration, and an initial study suggests that it could have clinical 
utility as a treatment augmentation strategy for hyper-dopaminergic diSorders. 
Introduction 
The catecholaIlÙne neurotransmit-
ters dopamine (DA) and norepineph-
rine (NE) are thought to contribute 
to the regulation of attention, arouse 
al, mood, and motivational states.' 
Disturbances to this catecholaminergic 
regulation might increase vulnerability 
to various forms of psychopathology, 
including attention-deficitJhyperactiv-
ity disorder (ADHD),2 mood disorders,l 
and substance abuse.4 However, most 
of the evidence supporting these asso-
ciations cornes from indirect sources, 
such as correlations between symp-
toms and peripheral markers, and pre-
c1inical evidence that effective med-
ications affect catecholamine trans-
mission. Direct evidence for causal 
associations is generally sparse. One 
of the primary obstacles to a more 
direct assessment, of the roles of DA 
and NE in psychiatrie disorders has 
been the lack of an effective tool that 
safely, rapidly, and selectively decreas-
es catecholamine function in humans. 
This article describes recent efforts to 
develop acute phenylalanine/tyrosine 
depletioll (APTD) as a tool that might 
fulfill these needs. 
The Catecholamine 
Metabolic Pathway 
The synthesis of catecholamines 
in the brain occurs in se:veral steps 
(Figure). The amino acid precursors 
of DA and NE, phenylalanine and 
tyrosine, are derived from dietary pro-
tein. Neither crosses the blood-brain 
barrier passively. Instead, competition 
for active transport into the brain 
occurs via a saturable system that 
is a1so used by other large neutral 
amino acids. Once phenylalanine and 
tyrosine are in the brain and taken 
up into catecholamine neurons, there 
are three enzymatic steps. First, phe-
nylalanine hydroxylase converts the 
essential ami no acid phenylalanine 
into tyrosine, thereby providing an 
endogenous source of the latter amino 
acid. Second, tyrosine hydroxylase 
adds a hydroxyl group to tyrosine 
to produce 3,4-dihydroxy-l-phenylala-
nine (L-DOPA). L-DOPA is then rapidly 
converted into DA by aromatic amino 
acid decarboxylase and moved into 
storage vesicles by the vesicular mono-
amine transporter.' In noradrenergic 
neurons, these vesicles contain DA-B-
hydroxylase, the enzyme that converts 
DAintoNE. 
The conversion of tyrosine to L-
DOPA is considered the rate-limit-
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ing step in catecholamine synthesis. 
Tyrosine hydroxylase is the slowest of 
themetabolic pathway's three enzymes, 
and under normal physiological condi-
tions il is incomplelely saturated. As a 
consequence, reducing tyrosine avail-
ability should reduce catecholamine 
synthesis. A growing body of evidence 
indicates that APTD is a safe, rapid, 
and effective means for accomplish-
ing this. 
APTD Validation Studies 
Ingestion of an amino acid load can 
induce protein synthesis. Since the 
APTD mixture lacks phenylalanine and 
tyrosine, Ihese amino acids must be 
deiived from the body's stores, result-
ing in a reduction in their plasma 
concentrations. Moreover, since APTD 
mixtures contain other large neutral 
amino acids, the competition for trans-
port across the blood-brain barrier is 
also increased,' further reducing the 
amount of phenylalanine and tyrosine 
in the brain.6.? 
Recent studies provide compelling 
Figure 
The Catecholamine Metabolic Pathway 
evidence that depletion of phenylala-
nine and tyrosine in the brain leads to 
decreased DA synthesis. In research 
animals, APTD decreases postmortem 
tissue concentrations of DA,' amphet-
amine-induced DA release,' cerebro-
spinal f1uid (CSF) concentrations 
of the DA metabolite homovanillic 
acid! and amphetamine- and cocaine-
induced behavioral activation. IO In 
humans, APTD increases circulating 
levels of prolactin,1I a neuroendocrine 
index of decreased DA transmission, 
as weil as [11 C]raclopride binding, a 
more direct functional neuroimaging 
measure of decreased DA levels in 
striatal synaptic clefts. 12.13 In the Iwo 
positron emission tomography (PET) 
studies,I2·13 the APTD-induced change 
in [l1C]raclopride binding correlated 
with the reductions in phenylalanine 
and tyrosine, suggesting a direct asso-
ciation between DA release and pre-
cursor availability. 
Less is known about the effects of 
APTD on NE. In nonhuman primates, 
APTD has been reported to decrease 
~~'>'tl~ ~.~:)~~.. . . 
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by tyrosine hydroxylose. 10 produce 3.4·dihydroxy-l-phenylalanlne (L-DOPA). L-DOPA is rapldly 
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CSF concentrations of the NE metabo-
lite, 3-methoxy-4-hydroxyphenethyl-
eneglycol, to the same degree that it 
reduces homovanillic acid.~ In com-
parison, studies in rats suggest a more 
selective effect on DA." Il remains 
unclear whether this reflects a differ-
ence between rodents and primates, 
a failure as yet to identify the locus 
of effect on NE, or differences in 
theAPTD mixtures used by the Iwo 
research groups. Very preliminary evi-
dence suggests that, in humans, it may 
be possible to distinguish between 
effects of APTD that are DA versus 
NE mediated based on whether they 
are prevented by the immediate DA 
precursor, L-DOPA. Considering that 
L-DOPA may selectively increase DA 
synthesis,'4.lS it may reverse DA-related 
effects of APTD while leaving NE-
reIated effects intact. 
There are currently Iwo different 
versions of the APTD mixture in use; 
one containing 14 amino acids,' and 
the other only 7.' AIthough these meth-
ods have yet to be directly compared, 
each has been successfully used to 
examine aspects of catecholamine 
functioning in humans.'2,13 Both mix-
tures are believed tn transiently reduce 
catecholamine synthesis via the same 
mechanisms and over a similar time 
course.'6.17 Effects of the APTD mix-
tures have been observed within 3 
hours of administration, and their 
total duration of action is Ihoughl to 
be <8 hours. They can therefore be 
used on an outpatient basis and do not 
require prolonged monitoring. 
In addition, APTD has been dem-
onstrated to be weil tolerated in both 
clinical and normal human popula-
tions,s,16 and it appears to he devoid 
of any serious side effects, such as the 
motor dyskinesia often associated with 
other treatments that reduce catechol-
amine transmission, Moreover, while 
numerous medications are available 
that bind to one or more of the mul-
tiple DA and NE receptor subtypes, 
these compounds tend to be nonspe-
cific, also binding 10 the receptors 
of noncatecholaminergic transmitter 
systems.'" In comparison, with the 
possible exception of effects on the 
trace amines, APTD is thought to act 
specifically on catecholamine synthe-
sis and reduce transmitter binding al 
all DA and NE receptor subtypes. 
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Behavioral Effecfs of APlD in 
Humons 
Behavioral effects of APTD are now 
being examined in both healthy and 
c1inical populations (Table).s.II.16.17.l9-23 
Although tbis is still a relatively new 
area of investigation, preliminary evi-
dence suggests that APTD can affect 
motivation, reinforcement, and mood. 
Motivalion and Reinforcemenf 
The catecholamines, particularly 
DA, have been implicated in various 
motivational processes. For example, 
in varions laboratory animal species, 
DA-specifie lesions interfere with appe-
titive behaviors directed toward nor-
mally reinforcing stimuli, including 
food," sexual partners,25 and abused 
. drugS.26 Sueh findings were initially 
interpreted as implicating DA in the 
pleasure associated with reward.21 
However, due largely to evidence that 
DA transmission is also increased dur-
ing stress," explora tory behavior,29 and 
expectation of reward, '" a revised view 
Table 
is that DA is more closely related to 
the motivation to interaet with biologi-
cally-relevant environmental stimuli}! 
This possibility has been explored in 
recent APTD studies. 
In healthy men and women, APTD 
has been reported to increaSe feelings 
of boredoms and apathy," possibly 
reflecting a generalized indifference 
to otherwise interesting or important 
environmental stimuli. Consistent with 
this interpretation, APTD decreased 
the salience of rewarding eues in a 
decision-making task19 and diminished 
the ability of the ADHD medication d-
amphetamine to enhance responding 
for monetary reward.20 The effeet of 
APTD on reinforced learning was pre-
vented by L-DOPA, suggesting further 
that it is a DA-mediated effect.'o 
Drug-Related MoUvatfon 
Animal models of addiction have 
long implicated DA in the addictive 
properties of numerous abused sub-
stances, including cocaine, amphet-
amine, alcohol, and nicotine!.>6.31 Each 
of these substances promotes mid-
brain DA neurotransmission, and dis-
ruption of this action interferes with 
drug self··administration.26.3' Moreover, 
following repeated drug exposure, 
environmental cues that predict drug 
availability gain the ability to increase 
DA release.32 Preventing eue-induced 
DA transmission decreases drug-seek-
ing behavior.33 In comparison, dis-
rupting DA transmission does not 
appear to diminish the hedonic effect 
of rewards!' Based on this and other 
evidence, it has been proposed that, 
in laboratory animaIs, DA is associ-
ated with motivational aspects of drug 
taking.31 
Recent APTD findings support a mIe 
for DA in the motivational aspects of 
human drug-taking behavior as weiL 
For example, APTD has been shown 
to decrease alcohol consumption in 
social drinkers21 and cigarette craving 
in nicotine-dependent smokers. 17 In 
both cases, APTD left varions aspects 
of drug liking unaltered, suggesting 
Effects of APTD on Mood and Motivafionol Stafes"·n.16.11.1 •. 23 
Reference 
Leyton, et al" 
Harmer, et ai" 
McTavish, et 0116 
Casey. et 0117 
McLean, et 01'9 
Leyton, et 01'" 
Leyton. et af21 
McTavish, et aJ22 
Coupland, et aj23 
Motlvation/Reinforcement 
Increased levels of boredom 
Not tested 
Nottested 
Decreased cigarette craving but not 
cigarette IIking; craving effect was 
reversed by L-DOPA 
Increased apathy, decreased sallence of 
rewording cues ln a decision-maklng task 
Decreased d-amphetamine enhanced 
respondlng for rewardlng cues; effecf 
was reversed by L-DOPA 
Decrease alcohol Ingestion, 
but not alcoholliklng 
Nottested 
Not tested 
Mood 
Increased depressed mood following the completion 
of a stressful task; no slgnificant effect prior to challenge 
Decreased nfeel good' scores; no significant effect 
on 'depressed' scores 
Decreased 'mind race' and 'buzz' feelings following 
methamphetamlne ln healthy indlvlduals; decreased 
manic symptoms in patients with bipolor dlsorder 
No significant mood effects reported 
Decreased "feel good" scores; increased blas for 
negatlve affect related stimuli. 
Decreased subjective etfects of d-amphetamlne; 
effect not reversed by L·DOPA 
Nottested 
Decreased 'mlnd race" effect of d-amphetamlne; 
no effect was evident prlor to amphetamine challenge 
No slgnlficant mood effects 
APTD=acute phenylalanine/tyrosine depletion: L -oOPA=3,4-dlhydroxy+phenylolanine. 
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that the diminished motivation for 
drug use was independent of the enjoy-
ment of the drug effects. The effect of 
APTD on nicotine craving was prevent-
ed by L-DOPA." Although preliminary, 
these findings raise the possibility that 
the neurobiological substrates of drug 
wanting versus JilOng can be demar-
cated using the APTD method, and 
that DA is more closely reJated to the 
former. 
Mood 
In addition to their motivational 
effects, catecholamines have a1so been 
hypothesized to be involved in the 
regulation of mood. This is primarily 
based on observations that drugs that 
enhance catecholamine function tend 
to e1evate mood, drugs that inhibit 
catecholamines tend to lower mood, 
and abnormal peripheral markers of 
catecholamine function are evident 
in patients with affective disorders.' 
A1though most evidence linking cate-
cholamines to mood remains indirect, 
recent APTD studies support a role for 
catecholamines in the mediation of 
positive and negative affective states. 
In sorne studies.'·I1·31 though not in ail 
studies,22,23 APTD has been reported to 
produce mild mood-lowering effects 
in healthy individuals. In one study,'9 
subjects reported feeling less "content" 
and displayed a greater negative word 
bias in a word-response task following 
the ingestion of the APTD mixture, 
while in a second study,lI APTD sig-
nificanÙY decreased ratings of "feeling 
good." 
Evidence suggests that effects of 
APTD on mood may be greater when 
there is increased demand on cat-
echolamine function. In the one studyS 
meant to expliciÙy assess this possibil-
ity, a depressogenie effect of APTD was 
seen following a stressful psychologieal 
challenge but not before it. Similarly, 
studies22 suggest that APTD diminishes 
subjective effects of psychostimulant 
drugs without altering mood before 
drug administration. 
The evidence that various "challenge" 
conditions might augment mood-Iow-
ering effects associated with APTD is 
consistent with the neurobiologieal 
data. Mierodialysis studies in rodentsS 
and· both PET studies in humansJ2•t3 
indicated that APTD has greater effects 
on DA transmission relative to rest-
ing baseline, following amphetamine 
Acute PhenylalaninelTyrosine Depletion 
administration. These findings sug-
gest that APTD may be particularly 
weil suited for examining psychiatrie 
disorders characterized by hyperactive 
catecholamine activity while leaving 
normal function unaltered. 
Bipolar Disorder 
Indirect evidence has linked bipolar 
disorder with abnormalities in cat-
echolamine functioning. For example, 
peripheral markers for NE functioning 
are increased during mania" and have 
been shown to correlate with Iithium-
induced changes in mood.J4 In addi-
tion, several variations of genes that 
code for different DA receptors have 
been identified as potential mark ers 
for bipolar disorder's and medieations 
with known D2 receptor antagonist 
actions are efficacious in treating bipo-
lar symptoms.3S 
A recent investigation examined the 
effect of APTD on manic symptoms in 
an inpatient group of bipolar patients 
being treated with DA D2 medieations.16 
In this study, APTD reduced manic 
symptoms by approximately 35%. 
Because APTD effects on DA and NE 
were not differentiated, it is not cIear 
if the observed effect resulted from an 
augmentation of the medication's D2 
effècts or from a reduction in function 
at other DA or NE receptor subtypes. 
A1though further work is requîred to 
deJineate the precise mechanism of 
therapeutic action, these findings pro-
vide the first evidence that APTD can 
exert clinically significant effects in a 
psychiatric population. 
Theropeutic Potential of 
Catecholamine Depletion 
Given the evidence that APTD can 
acutely reduce manic symptoms and 
drug craving. there has been interest 
in developing the method for lon-
ger term administration. The original 
method, though, is not appropriate 
for long-term use. APTD requîres that 
patients follow a strict low-protein diet 
so that other sources of phenylalanine 
and tyrosine do not become avail-
able. Moreover, because APTD induces 
protein synthesis and this requires 
phenylalanine and tyrosine from the 
body's remaining stores, repeated 
APTD administration over proJonged 
periods could result in malnutrition or 
tissue damage. 
A recently developed variant of the 
APTD technique that is not believed 
to induce protein synthesis may be 
appropriate for long-term use.J • Il con-
sists of an amino acid mixture con-
taining three branched-chain amino 
acids (BCAAs)-leucine, isoleucine, 
and valine--which compete with phe-
nylalanine and tyrosine for transport 
into the brain. Preliminary evidence 
using this technique suggests that 
ingestion of a BCAA mixture may exert 
observable effects on catecholamine 
transmission. For example, BCAA 
administration has been demonstrated 
to produce cognitive and endocrine 
effects consistent with diminished DA 
function in healthy humans,3. as weil 
as to acutely reduce manie symptoms 
in patients with bipolar disorder by 
approximately 20"Al.31 This latter effect, 
albeit weaker than that associated with 
APTD, demonstrates that BeAA mix-
tures can exert c1inically significant 
effects, and they may have utility for 
the treatment of psychiatric disorders 
characterized by hyperactive catechol-
amine activity.J6,J7 
Conclusion 
APTD appears to be a safe, effective, 
and welJ-tolerated method for rapidly 
decreasing catecholamine transmission 
and investigating their role in the regu-
lation of various normal and abnormal 
behaviors. Preliminary APTD studies 
in healthy individuals support the role 
of catecholamines in motivational, 
reinforcement, and affective processes. 
Studies in nieotine-dependent smok-
ers and bipolar patients suggest that 
APTD can decrease drug craving and 
manic symptoms. A1though APTD does 
not appear to be suitable for long-term 
psychiatrie treatment, a variation of 
the method does show sorne promise 
for extended therapeutic use. Potential 
applications of APTD and related 
methods include investigating the role 
of catecholamines in the pathogen-
esis and symptom expression of vari-
ous psychiatrie disorders, delineating 
the mechanisms of therapeutie drug 
action, augmenting treatment response 
in hyper-catecholamine disorders, and 
identifying individuals at risk. pp 
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Ecstasy and Drug Consumption Patterns: A Canadian 
Rave Population Study 
Samantha R Gross, PhD(c)l, Sean P Barrett, PhD(ci, John S Shestowsky, PhD(ci, 
Robert 0 Pihl, PbD3 
Objective: This study investigates the drug consumption patterns of a sample of rave at-
tendees in the city of Montreal, Quebec, and seeks to identify the prevaJence of3,4-
methylendioxymethamphetamine (MDMA) and other drug use in this population. 
Metbod: We administered a self-report questionnaire to 210 respondents. For various /icit 
and iIIicit substances, participants reported their age of first use, number oflifetime uses, 
and usage in the previous 30 days. 
Remlts: We found a significant rank order for the sequence of first use: 1) alcohol, 
2) nicotine, 3) cannabis, 4) LSD, 5) psilocybin, 6) amphetamine, 7) cocaine, 8) MDMA, 
9) ganuna-hydroxybutyrate (GHB), 10) ephedrine, Il) ketamine. AIcohol and cannabis 
were the most commonly used substances, both in cumulative number of lifetime uses and 
in usage in the preceding 30 days. MDMA and amphetamine were also notable as the next 
2 most popular drugs for use in the preceding 30 days and in terms of those who had tried 
the drugs at least once. We identified a progressive rank order of experimentation, with 
early a\cohol or cannabis use (or both) associated with the early use of ail other drugs tried 
bymore than 25% of the sample. We found MDMA and amphetamine use to be prevalent, 
as was general experimentation with aIl drugs studied, other than heroin. 
Conclusion: Drug consumption levels were substantial in this "rave" population, parti cu-
lady with respect to recent use of MDMA, amphetamine, cannabis, and alcohol. Results 
also indicate that the sequence of drug experimentation in Ihis population follows an 
identifiable pattern. 
(Can J Psychiatry 2002;47:546--551) 
See page 550 for research fimding and support and page 551 for author affiliatious. 
Key Words: ecstasy, 3,4-methylendioxymethamphetamine, MDMA, polydrug use, rave, 
alcohol, cannabis, amphetamine 
B eginning in the late 1980s, a new "rave" subculture emerged. It was characterized by all-night technodance 
parties and the use of ilIicit drugs, particulariy 3,4-
methylendioxymethamphetamine (MDMA; also known as 
"ecstasy," "E," "X," and "XTC"). Originating in Great Brit-
ain, the trend for youth to attend these parties became strong in 
Canada around 1991 and has reportedly been growing expo-
nentially ever since, as has an overall increase in MDMA use 
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(1,2). Despite these increases, very little is known about the 
overall drug-use patterns of individuals who attend raves and 
how these patterns relate to MDMA use. 
MDMA is c1assified as an ernpathogen or enactogen (3) he-
cause the subjective experience has been described as in-
tensely emotional and as creating the perception that one can 
experience the emotions of others (4). Users typically report 
the impression offeeling clear-headed, serene, euphoric, and 
sensual; significant visual illusions common to LSD and other 
psychedelics gènerally do not occur (4-6). 
As recentlyas 1986, some physicians believed ecstasy to be a 
safe drug (7). However, recent research has revealed many 
negative effects associated with ecstasy use. Acute adverse ef-
fects include restlessness, ataxia, tremol, myoclonus, diar-
rhea, and the most severe si de effect, hyperthermia (8). 
MDMA use has been associated with sudden death and car-
diovascular collapse (9), witb the most common cause of 
death being hyperthermia (10). The behavioural and environ-
mental factors that often coexist witb MDMA consumption 
(for example, concomitant ingestion of other iIlicit drugs and 
higb ambient temperature) may increase the risk for severe ad-
verse effects, particularly cardiovascular complications and 
hyperthermia. Prolonged exercise (for example, dancing), 
high ambient temperatures, and high humidity are typical in 
rave and club environments and are believed to potentiate the 
neurologic toxicity of MDMA (11,12). lndeed, in the US 
emergency room visits related to MDMA consumption have 
increased from 637 in 1997 to 1143 in 1998 (13). 
The possible long-term consequences of MDMA use have 
also generated concern. It bas been reported that repeated ad-
ministration ofMDMA in laboratory animais diminishes se-
rotonin and dopamine levels and damages the nerve terminais 
from which serotonin is released, in a dose-related manner 
and with incomplete recovery (14-17). With some contro-
versy, many researchers nonetheless regard animal studies on 
MDMA to be relevant to human use. For example, the finding 
that the loss of serotonergic (5-H1') axons in monkeys is 
greater than in rats given a fourfold greater dosage ofMDMA 
has led some to conclude that MDMA is potentially far more 
neurotoxic in primates than in nonprimate mammals (18). 
According to the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), recent use is higher for ecstasy 
than for amphetamines and LSD (19). Although similar re-
sults have been reported in the US (20), very little is known 
about the patterns ofMDMA consumption in Canada. While 
some general surveys have identified ilIicit drug-use patterns 
ofhigh school students (21-24), university students (25,26), 
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and university athletes (27), none have targeted individuals 
who attend rave parties-individuals thought to be at greater 
risk for MDMA use. 
The Centre for Addiction and Mental Health (CAMH) pro-
duced a study that surveyed 7800 university students across 
Canada (25). This study identified 10.2% ofthepopulation as 
using iIlicit drugs other than cannabis. Alcohol was noted as 
the drug of choice among university students, with 92% of the 
population having tried it at least once. Quebec students had 
the highest rate ofboth cannabis and alcohol use in the previ-
ous 12 months (28.7% and 88.3%, respectively); MDMA was 
reportedly used by 4% of the entire sample; in accordance 
with the EMCDDA study (19), tbis reveals the greatest preva-
lence for lifetime use, compared with drugs other than ciga-
rettes, cannabis, or alcohol. A1though the prevalence of 
ecstasy use IDight not appear to be salient, it comprises a sub-
stantial proportion of the 10.2% trying any drug other than al-
cohol or cannabis. Another series of surveys was conducted 
by Parent Resources Institute for Drug Education (pruDE) 
every other year between 1987 and 1992. These studies sur-
veyed students in grades 6 through 12 and found that 14.1 % of 
the population used cannabis in 1991-1992, while 5.7% ofthe 
population used hallucinogens (21,22). While such surveys 
indicate the usage of an age group similar to that assumed to 
attend rave parties, a sequence of experimentation bas yet to 
be identified in Canada. Australian and European studies 
have, however, identified the progression or patterns of drug 
use. The following drug-use sequence was found in a survey 
ofl0812 students inNorway (aged 14 to 17years): I)alcohol, 
2) cigarettes, 3) cannabis, 4) amphetamines, 5) ecstasy, and 6) 
heroin (28). This study suggested that adolescents with a pat-
tern of polydrug use have used ecstasy and that ecstasy is sig-
nificantly associated with attendance at house parties and with 
subcultural music preferences. In Australia, studies of rave 
populations found that 90% of attendees had tried LSD, 76% 
had tried ecstasy, and 69% bad tried ampbetamine (29). The 
researchers noted that LSD is a possible sequential gateway 
drug to other substances and indicated the popularity ofboth 
ecstasy and amphetamines among rave attendees. 
Our study aimed to delineate the drug consumption histories 
of those attending raves in Montreal, Canada, and to deter-
mine whether these are similar to the histories found else-
where. In addition, we attempted to determine the popularity 
ofMDMA in this group and to identify potential specific se-
quences of drug experimentation within samples of rave-
attending individuals. 
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Method 
Participants (n = 210) were recruited from 3 different raves in 
Montreal, a bilingual metropolitan Canadian city (n = 48, n = 
64, n = 98, respectively). The 3 events were ail large-scale 
(3000 to 10000 people) and held indoors at private venues. 
Events similar in size and type are frequently beld in otber 
large Canadian metropolitan areas. Subjects were randomly 
approacbed by 3 research assocîates and asked to complete an 
anonymous self-report questionnaire for a scientific investi-
gation. Participants were informed that their responses would 
remain strictly confidential and that their participation was 
strictly voluntary. The questionnaire, conducted in both Eng-
Iish and French, was based on an abbreviated version of the 
Addiction Severity Index (ASI) (30), modified to incorporate 
drug classes not included on the original index. At the first 2 
events, participants were asked to identify age of fust use, 
number oflifetime uses, and number ofuses in the past 30 
days for 1 1 different substances. Information was collected on 
aJcobol, heroin, marijuana, ampbetamine, ephedrine, cocaine, 
LSD, psilocybin, ketamine, gamma-hydroxybutyrate (GHB), 
and MDMA use. At the third rave, a question regarding the 
age offirst use of nicotine was added to the survey. 
Results 
Questionnaires were completed by 80 women (38.8%) and 
126 men (61.2%), with 4 participants not indicating their sex. 
Statistical analyses were based on 11 of the drugs surveyed; 
we omitted heroin because only 8 respondents had used it. 
Participant ages ranged from 16 to 32 years (mean 21.4 years, 
SD 3.18). ln ail analyses, we considered sex and event at-
tended; however, no significant interaction effects were 
found. Drug histories are summarized in Table 1. 
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Progression of Drug Use 
Average age offirstuse for aleohol was 14.05 years (SD 2.18, 
n= 188), for cannabis 15.13 years(SD2.59,n= 192,) and for 
nicotine 14.21 years (SD 2.34, n = 63), which identified these 
drugs as potentially tbe first 3 steps in drug experimentation 
(see Table 1). 
To accommodate the data tha! fit a block design with missing 
values, we used a univariate analysis of variance to calculate 
significant differences between the means of age of first use. 
We treated subjects independently to account forvariability in 
the number of different drugs used by each participant. We 
found an overall significant difference between mean age of 
firstuse and theparticular drug used (F= 60.125,P< 0.001). 
We than applied Bonferroni and Tukey honestly significant 
difference (HSD) contrasts to identify specific significant 
mean differences. We found significant mean differences 
with the following subsets, defined using harmonie mean 
sample sizes and an alpha level of 0.05: 1) aJcohol, nicotine, 
and cannabis; 2) cannabis, LSD, and psilocybin; 3) ampheta-
mine, cocaine, MDMA, GHB, ephedrine, and ketamine. 
Based on overall significance, a rank order for progression 
can be inferred, which indicates the following linear trend in 
progression offirst use: 1) alcohol, 2) nicotine, 3) caunabis, 4) 
LSD, 5) psilocybin, 6) amphetamine, 7) cocaine, 8) MDMA, 
9) GHB, 10) ephedrine, and 11) ketamine. 
To test for !inear and quadratic trends, we also applied a 
repeated-measures analysis of variance (ANOVA) to the data 
on drugs used by more than 25% of the sample. While Ihis 
analysis yields results only for those subjects who used ail the 
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listed substances (n =44), we found a similarly significant lin-
ear trend for the experimentation order: 1) alcohol, 2) canna-
bis, 3) LSD, 4) psiJocybin, 5) arnphetarnine, 6) cocaine, 7) 
MDMA (F = 304.8, P < 0.001). To further delineate these 
trends, we employed a correJational analysis using the non-
parametric Spearman's mo to account formonotoruc relations 
between variables. We found significant positive correlations 
at the 0.01 level between the age of ftrSt use of alcohol and 
cannabis, cocaine, amphetamines, ephedrine, GHB, psilocy-
bill, MDMA, nicotine, and LSD. As well, we found signifi-
cant positive correlations between age offust use of cannabis 
and age of fust use of all drugs except ketamine. After we ap-
plied a Bonferroni correction, significant relations were main-
tained for ail except the alcohol-to-amphetamine, -ephedrine 
and -GHB correlations and the cannabis-to-GHB and -ephe-
drine relations. 
Total Number of Lifetime Uses 
Table 1 indicates the percentage of the subjects who had used 
each drug. 
Although mean computations suggest the highestuse for can-
nabis (mean 1088.4) and alcohol (mean 361.2), it is important 
to note that we did not collect lifetime estimates of tobacco 
consumption. When median scores are calcnlated to account 
for outliers in the data, alcohol (median 100) and cannabis 
(median 150) remain the most frequently used substances. 
We conducted bivariate correlations using the nonparametric 
Spearman's rho to determine relations among the number of 
lifetime uses for different drug types. Afterwe applied a Bon-
ferroni statistical correction, we found significant relations (P 
< 0.01) for the following groupings: alcohollifetime use cor-
related with cannabis lifetime use; amphetamine lifetime use 
with MDMA lifetime use; cannabis Iifetime use with psilocy-
bin Iifetimeuse; andLSD lifetimeuse with psilocybin lifetime 
use. 
Number of Uses in Preceding 30 Days 
Table 1 reports what percentage of subjects who had reported 
at least 1 use of a particular drug had used that drug in the pre-
ceding 30 days, as weil as the mean number ofuses for each 
dmg during this time period. Listed in descending order ac-
cording to percentageof recent recnrrent users, the drugs rank 
as follows: alcohol, cannabis, amphetamine, MDMA, keta-
mine, ephedrine, GHB, psilocybin, and LSD. 
Median scores were also considered, to account for extreme 
users. With these scores, cannabis is notable as the most fre-
quently consumed drug during the preceding 30 days (median 
15), followed by alcohol (median 5) . 
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Discussion 
Onr study sought to clarifY the drug-consumption patterns of 
Montreal youth who attend raves. Research on this population 
suggests that rave attendees represent a significant proportion 
ofillicit drug users. Our findings confirm that members of this 
group take greater quantities and experiment with a greater 
variety of substances than do their peers who do not attend 
raves (21-27). 
To determine whether there was a general pattern of stepwise 
drug experimentation, we applied 2 different statistical analy-
ses to the data. We identified the following progressive pat-
tern: 1) alcohol, 2) nicotine, 3) cannabis, 4) LSD, 5) 
psilocybin, 6) amphetamine, 7) cocaïne, 8) MDMA, 9) GHB, 
10) ephedrine, and Il) ketamine. It is notable that the sub-
stances used by more than 10% but less than 25% ofthis popu-
lation appeared as the last 3 in the sequence of 
experimentation. A similar study in Norway determined the 
following best-fit for the progression pattern: 1) alcohol, 2) 
cigarettes, 3) cannabis, 4) amphetamines 5) ecstasy, and 6) 
heroin (28). Despite the fact that this was a normal population 
sinvey, and questions on ha/lucinogen use were not incorpo-
rated, the overall similarities with our findings are striking. 
Thesample used alcohol and cannabis substantially. Overall, 
89.5% of the subjects reported prior intoxication with alcohol, 
69.7% ofthese in the past 30 days. Similarly, 91.4% ofthose 
surveyed reported having used cannabis, 67.7% ofthese in the 
previous 30 days. lnterestingly, the early use of either sub-
stance was associated with an early use of cocaine, psilocybin, 
LSD, and MDMA, suggesting their potential as possible 
"gateway" drugs. 
While MDMA was the third most commonlyused drug in this 
sample, the age offirst use appeared later (that is, 8th) in the 
drug experimentation sequence than had been anticipated. As 
weil, the lifetïme uses and uses in the preœding 30 days were 
also lower than had been expected. MDMA, however, is still 
among the most prevalent drugs consumed at raves. Indeed, 
the high preva/ence ofMDMA use found in this study is con-
sistent with research findings in rave samples surveyed in 
Australia (76%) (29). Since rave events typically occur on 
weekends, however, occasion to take MDMA may he re-
garded as less frequent than occasion for consuming snb-
stances such as alcohol or cannabis. 
The prevalence of amphetamine use, including both recent 
and overall consumption, was comparable to that ofMDMA. 
lt was the third most popular drug for use in the preceding 30 
days: 47.6% of those surveyed reported amphetamine use, 
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slightly exceeding the 40% reporting MDMA use during this 
period. Further, while 73.3% of the overall sample reported 
ever using amphetamine, a comparable 75.2% reported 
MDMA lifetime use. These findings suggest that, in addition 
to MDMA, amphetamine should be examined as a primary 
drug used by rave populations. 
The use of the hallucinogenic drugs LSD and psilocybin was 
also reported by a substantial portion of the sample (56.2% 
and 70%, respectively). Although participants reported ini-
tially experimenting with these drugs at a relatively earlyage, 
most users did not report consuming them in the preceding 30 
days (22% reported pilocybin use, and 12.7% reported LSD 
use). These findings suggest that while the use of hallucino-
genic drugs often precedes the consumption of drugs like 
MDMA and amphetamine, these drugs are seldom in active 
use by individuals attending raves.lt is interesting to note that 
while the level ofLSD use was positively associated with the 
level of psîlocybin consumption, using these drugs did notre-
liably predict the subsequentleveJ ofMDMA or amphetamine 
use, suggesting a limited IOle for hallucinogens as gateway 
drugs in a rave population. 
Several drugs, including ketamine, GHB, and ephedrine, did 
not surface as popular substances within this sample, each 
having been used by fewer than 25% of those surveyed. Nev-
ertheless, approximately one-third of those who had experi-
mented with these drugs had done 50 recently. lt seems 
plausible that the apparent infrequent use of these 3 drugs is 
related to their late introduction into the typical sequence of 
drug experimentation. 
Although Ihis study identifies the drug-consurnption patterns 
and histories ofindividuals who attend Montreal-arearaves, it 
is appropriate to address sorne of the investigation's possible 
limitations. Because this study relied on retrospective recall, 
the accuracy of such reports might be questioned. However, it 
should be noted that the research question precludes prospec-
tive data collection and that the methods used are in accord 
with abundant published reports that use a similar methodol-
ogy (for example, 27-29). ln addition there are several indica-
tions that substance use self-report data can be both reliable 
and valid (for example, 30,3 J). 
A second issue invotves the degree to which this moderate 
sample can accurately reflect the drug-taking patterns of 
Montreal rave attendees in general. BecaU5e the participants 
were self-seJected forthis investigation, it is possible thatthey 
do not represent the group as a who le. Although we attempted 
to minimize this by administering questionnaires at 3 separate 
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events and found no significant differences among these sub-
groups, only a random sample of rave attendees would ensure 
the generaJizability of these fmdings. NevertheJess, the pres-
ent results are consistent with findings obtained from other 
samples of drug users (for exarnple 2&,29). As weil, since an 
entire generation of ages was surveyed (range J 6 to 32 years), 
this study potentially captured both long-term and relatively 
new partygoers. 
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